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Abstract 
The use of nutritional supplements (NS) is common in able-bodied (AB) athletic 
populations and good evidence exists for a number of NS such as sports drinks, protein 
powder, creatine, caffeine and buffering agents. However, little evidence is available 
regarding the popularity and efficacy of NS in a population of athletes with physical 
impairments. 
Fifty-eight percent of athletes with a physical or visual impairment reported the use of 
one or more NS in the previous six months (Chapter three). The types of NS used were 
similar to AB athletes (most commonly protein, carbohydrate-electrolyte sports drinks, 
carbohydrate supplements and multivitamins) and were used for similar reasons (energy, 
recovery and immunity). A concerning finding was that 9% of athletes surveyed reported 
experiencing negative side-effects for the use of NS, which may in part be due to following 
AB dosage and timing guidelines. Approximately half the athletes wanted more information 
and education regarding anti-doping, NS and their efficacy. Further research on the 
effectiveness of different NS in a population of athletes with physical impairments is 
therefore warranted. The results indicated that caffeine was the most popular NS beyond any 
that provided only macronutrients. There is a large body of literature exploring its use as an 
ergogenic aid in AB athletes and yet the small amount of evidence remains equivocal in a 
population of athletes with physical impairments.  
Chapter four found that caffeine (4 mg∙kg-1) significantly improved cycling 
(2.0(2.0)%; 16:35 vs 16:56 min; p=0.033) but not handcycling (1.8(3.0)%; 24:10 vs 24:36 
min; p=0.153) 10 km time trial (TT) performance compared to placebo (PLA) in 
recreationally active AB participants. The improvement during cycling can be attributed to 
the increased power output (PO) during the first and last 2 km following caffeine. An 
increased PO for a given rating of perceived exertion (RPE) was also apparent during 
cycling. Participants with a handcycling peak oxygen uptake ( ·VO2 peak) above the mean 
improved their handcycling TT performance by 3.2% whereas those below the mean had a 
0.3% reduction, which suggests training status may have an influence on caffeine’s ability to 
improve upper-body exercise (UBE) performance. An individual’s training status may 
increase the amount of recruitable muscle mass during maximal exercise, improve 
consistency of performance and increase maximal effort due to motivation.  
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Further support for the influence of UBE-specific training status was provided in the 
form of 20 km TT performance improvements in an elite Paralympic triathlete following 
caffeine (2, 4 and 6 mg∙kg-1) (Chapter seven). Performance improvements were seen 
alongside increased PO and arousal scores, but not RPE.  The athlete experienced spasticity 
during two trials but attributed this to the maximal effort delivered not necessarily the 
ingestion of caffeine and he did not believe it influenced his performance.  
Caffeine has previously been shown as ergogenic during short-term, high-intensity 
exercise in AB athletes during lower- or whole-body exercise and now during UBE (Chapter 
five). Caffeine (4 mg∙kg-1) improved both 20 m sprint and a one-off bout of 4 min maximal 
push performance in club-level wheelchair sportsmen. Caffeine did however fail to improve 
repeated bouts of 4 min push. There were no apparent changes in arousal or RPE, but Feeling 
scores (a measure of the affective dimension of pleasure-displeasure) increased following 
caffeine. Salivary caffeine concentration results raised concerns over the absorption time in 
individuals with a physical impairment. Measurements of plasma caffeine concentration 
([CAF]) at rest (150 min) however, showed that the NS peaked at similar times in AB 
participants and participants with paraplegia and tetraplegia (80, 80 and 70 min, respectively) 
(Chapter six). The pattern of caffeine absorption did however differ. Peak [CAF] were higher 
in participants with tetraplegia, followed by a gradual decline. Caffeine curves did not 
significantly differ between AB participants and participants with paraplegia yet there was 
large inter-individual variance in both SCI groups.  
Findings suggest that caffeine does appear to positively influence UBE performance 
during short-term, high-intensity and endurance tests in certain individuals with and without 
physical impairments. Based on the data, the magnitude of caffeine’s ergogenic effects are 
likely to be influenced by training status and SCI level. 
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1  
General introduction 
The use of nutritional supplements (NS) is common among able-bodied (AB) athletes 
(Braun et al., 2009; Dascombe et al., 2010; Erdman et al., 2006; Heikkinen et al., 2011; 
Sundgot-Borgen et al., 2003) and there is a large body of evidence which has accumulated 
over recent years regarding the safety and effectiveness of many (Maughan et al., 2011). Elite 
athletes with a physical impairment experience the same pressure to succeed and improve 
their exercise performance as AB athletes. One may therefore predict that NS are also 
commonplace in the world of Paralympic and disability sport yet there is very little evidence 
to support this. There are currently 10 eligible impairment types for Paralympic athletes 
including impaired muscle power/range of movement, limb deficiency, short stature, ataxia, 
athetosis and visual impairment. Common physical impairments therefore include spinal cord 
injury (SCI), cerebral palsy, amputation and visual impairment. A SCI has major 
physiological consequences that can significantly impact upon sporting performance. Hence 
this area of research has received a great deal of interest in recent years. A SCI can also 
influence an individual’s nutritional requirements and the potential ergogenic effect of NS, 
which has received less attention in the literature. Tsitsimpikou et al. (2009) investigated the 
NS habits of Paralympic athletes (Athens 2004 Paralympic Games) and revealed that 
vitamins (43.5%), minerals/electrolytes (16.1%) and proteins/amino acids (10.5%) were most 
commonly consumed. This study was purely descriptive and therefore did not report the 
athletes’ reasons for NS use or the sources of information they consulted.  
There is growing evidence to suggest that certain NS such as caffeine, creatine and 
buffering agents are effective in the correct exercise setting in an AB population (Close et al., 
2016). On the other hand there is limited evidence that the reported ergogenic benefits can be 
translated to athletes with a physical impairment. Only a handful of studies have investigated 
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the use of NS in individuals with a physical impairment exploring the effects of caffeine 
(Flueck et al., 2014; 2015), carbohydrate sports drinks (Spendiff & Campbell, 2005), creatine 
(Jacobs et al., 2002; Perret et al., 2006) and sodium citrate (Flueck et al., 2014) (Table 2.1). 
Hence, it remains hard to make evidence-based recommendations for NS use in this 
population. The sports practitioner must currently rely on interpreting AB findings and 
athletes will often apply an element of trial and error.  
Inaccurate labelling of NS or insufficient knowledge regarding NS dosage may have 
more serious consequences on the health of individuals with a physical impairment due to 
unknown effects on their impairment. Furthermore, NS could have the potential to interact 
negatively with medication use for general health. Some athletes remain uneducated 
regarding their individual needs and the use of NS to complement their daily diet (Dascombe 
et al., 2010; Rastmanesh et al., 2007). A lack of evidence and knowledge in physically 
impaired populations raises concern given the potential for, or more acute sensitivity to side-
effects in some sportspeople with a physical impairment (Van de Vliet et al., 2011).  
Caffeine is a NS that has received a lot of attention in recent years since its removal 
from the World Anti-Doping Agency (WADA) prohibited list in 2004. There is evidence for 
caffeine’s positive impact on endurance exercise, intermittent sports and events involving 
sustained efforts lasting 1-60 min (for reviews see Burke, 2008; Graham, 2001). The 
evidence of a positive impact on single short-term events, strength and repeated high intensity 
efforts is less clear (for reviews see Astorino & Roberson, 2010; Burke, 2008; Keisler & 
Armsey, 2006).  The majority of research in AB individuals has employed whole- or lower-
body exercise (LBE) testing protocols such as cycling or running. In contrast, very few have 
assessed the impact of caffeine on upper-body exercise (UBE) performance and previous 
findings remain equivocal (Aedma et al., 2013, Black et al., 2015; Stadheim et al., 2013). 
There are a number of reasons why the results from UBE performance trials following the 
consumption of caffeine may differ to those from whole- or LBE. The arms possess a smaller 
active muscle mass and may display a different muscle fibre type distribution (Mizuno et al., 
1990; Mygind, 1995). The arms also appear to have a lower capillarisation and oxygen 
extraction capacity (Calbet et al., 2005; Pendergast, 1989) resulting in the earlier onset of 
anaerobic metabolism compared to LBE (Pimental et al., 1984).   
When discussing the use of caffeine by individuals with a physical impairment during 
UBE, one must consider the impact of the impairment. The impact of a SCI for example, on 
caffeine’s ergogenic potential may be related to autonomic dysfunction (Krassioukov, 2009), 
slowed gastrointestinal (GI) transit times (Fynne et al., 2012: Krogh et al., 2000) and changes 
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in muscle fibre type distribution (Castro et al., 1999; Schantz et al., 1997). It would therefore 
be unreasonable to directly translate the results from LBE studies to UBE scenarios and 
furthermore, AB findings to individuals with a physical impairment such as a SCI.  
1.1. Thesis aims and outline 
This thesis has two main aims: firstly to understand the habits and perceptions of athletes 
with a physical impairment towards nutritional supplements (NS), and secondly to provide 
evidence and practical recommendations for the use of caffeine during UBE, especially by 
individuals with a SCI. 
 
The main objectives were as follows: 
• To determine the NS habits and perceptions of athletes with a physical or visual 
impairment, and to establish whether caffeine is a popular NS in this population 
(Chapter three) 
• To examine the influence of caffeine on upper-body i) sprint, ii) short-term, high-
intensity and iii) endurance performance (Chapters four, five and seven) 
• To explore the acute effects of caffeine in individuals with a SCI to help determine the 
appropriate dose and timing recommendations for its use (Chapter six) 
 
A brief introduction to the chapters contained within this thesis is presented below and 
the thesis design can be seen in Figure 1.1. 
 
The following chapter (Chapter two) provides an overview of the current evidence 
relating to the use of NS by AB athletes and athletes with a physical impairment. The chapter 
also discusses the use of caffeine as a NS, the physiological consequences of a SCI and 
compares different modes of UBE.  
The first experimental chapter (Chapter three) investigates the NS habits and 
perceptions of athletes with a physical or visual impairment using an online questionnaire and 
establishes whether caffeine is a popular ergogenic aid in this population. Chapter four 
assesses the effects of caffeine (4 mg∙kg-1) on preloaded 10 km time trial (TT) cycling and 
handcycling performance in the same AB participants. Chapter five investigates the effects of 
caffeine (4 mg∙kg-1) on wheelchair propulsive exercise performance (4 min maximal push 
(PUSH) and 20 m sprint (SPR)) and subjective feelings in club level wheelchair sportsmen. 
Chapter six explores the caffeine absorption curves of AB individuals and individuals with 
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paraplegia and tetraplegia following the consumption of caffeine (3 mg∙kg-1) to assess the 
impact of SCI lesion level. Finally, Chapter seven investigates a real world scenario for an 
elite Paralympic triathlete whereby the effects of three different doses of caffeine (placebo, 2, 
4 and 6 mg∙kg-1) prior to a 20 km handcycling TT are assessed.  
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Figure 1.1. Schematic of thesis. AB=able-bodied, SCI=spinal cord injury and TT=time trial. 
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2 
Literature review 
2.1. The rise of disability sport 
The popularity of disability sport from grassroots up to elite level has been on the rise 
over recent years. This is evidenced by the increasing number of sports and nations 
competing at the Games since its first introduction at the Stoke Mandeville Games in 1948. 
The number of summer Paralympic sports for which medals are awarded has increased from 
six in 1952 to the 23 in Rio in 2016. The number of winter sports has also increased from two 
in 1976 to the five which were at the 2014 Sochi Paralympic Games. Since the 1988 
Paralympic Games it is notable that the Games have been hosted by the same city, in the 
same year and at the same venues as the Olympic competitions and hence a similar level of 
professionalism is expected. 
To match the rise of professionalism in disability and Paralympic sport, many 
Paralympians now train and access sport science and medicine services in the same manner 
as their AB and Olympic counterparts. This newfound professionalism and desire for 
optimising performance has seen an upsurge in research examining the physiological and 
biomechanical aspects of Paralympic sports that involve athletes with an impairment. 
However, given the heterogeneity of athletes’ impairments, impairment-specific information 
and research within sports nutrition is unknown. For this reason, disability sport practitioners 
often look to adapt findings from the AB literature to apply to their athletes, which is far from 
ideal when the majority of practitioners aim to deliver evidence-based practice.  
2.2. Nutritional supplements  
2.2.1. Dietary practices of individuals with a physical impairment 
The evaluation of nutritional intakes and requirements of healthy AB athletes are well 
versed in the scientific literature. The 2009 American College of Sports Medicine position 
stand on ‘Nutrition and Athletic Performance’ highlighted topics such as nutrient intake 
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recommendations, hydration and NS but impairment-specific guidelines are notable for their 
absence (Rodriguez et al., 2009). Numerous studies have documented the nutritional 
knowledge and practices of AB athletes (Dunn et al., 2007; Economos et al., 1993; Zawila et 
al., 2003). However, few have focused on athletes with a physical impairment reporting 
inadequate nutritional knowledge (Rastmanesh et al., 2007) and varying degrees of 
micronutrient adequacy (Goosey-Tolfrey & Crosland, 2010; Grams et al., 2016). The nature 
of a physical impairment may result in the individual having to face any number of practical 
issues regarding their dietary habits such as the sourcing and preparation of fresh meals due 
to accessibility, dexterity or visual impairment. The use of some macronutrient providing NS 
may therefore be increased to help meet nutritional needs due to their convenience. 
Moreover, the specific needs of different impairments could result in a greater prevalence of 
supplement use in this population such as the use of meal replacement or protein drinks in 
those with severe cerebral palsy to help prevent the risk of malnutrition (Dahl et al., 1996). 
Athletes’ perceptions regarding their use of NS may therefore differ from those of the AB 
athlete population, viewing them as essential for health and maintenance of their daily diet, 
rather than optional. Hence, there is a need for a greater understanding of the dietary practices 
of athletes with a physical impairment to provide evidence-based nutritional 
recommendations based on their impairment and exercise modality.  
It is widely accepted that diet can significantly influence both health and sporting 
performance and that many athletes adopt individualised nutrition strategies. However, even 
in the most popular AB sports such as football, some athletes have poor nutritional 
knowledge and do not meet the training and/or daily nutrition and hydration 
recommendations for their sport (Ruiz et al., 2005; Shirreffs et al., 2005). For example, Ruiz 
et al. (2005) reported lower than recommended carbohydrate intakes in adult club footballers 
and Shirreffs et al. (2005) highlighted inadequate rehydration strategies in elite professional 
footballers. An athlete’s nutritional needs are largely determined by daily energy expenditure 
(EE) (Rodriguez et al., 2009), which is influenced by two main factors; i) training load 
(intensity × frequency × duration of training sessions), and ii) body mass (Maughan & Burke, 
2002). These two factors will be considered in relation to athletes with a physical impairment 
in the following paragraphs. 
Athletes with a physical impairment often undertake similar training schedules to 
their AB counterparts, especially at an elite level, (Krempien & Barr, 2011) and should 
therefore also adopt specific nutritional strategies for their sport. It is often assumed that the 
EE of disability sports is lower than AB versions. Research to determine the energy demand 
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of such sports is scarce (for review see Price, 2010) yet necessary to help practitioners 
calculate athletes’ nutritional requirements. For select sports and impairment categories, the 
EE of training may not greatly differ (e.g. a visually impaired cyclist who trains with an AB 
guide). On the other hand, modes of exercise involving the upper-limbs result in much lower 
absolute EE than LBE. For example, the EE during wheelchair treadmill exercise was 43 and 
62.5% in individuals with tetraplegic and paraplegia compared to that of AB runners during a 
5 km TT (Lakomy et al., 1987; Ramsbottom et al., 1987). Abel et al. (2008) investigated the 
demands of the wheelchair court sports in training. The average exercise EE of the 
wheelchair athletes studied was 313.6(101.1) kcal·h-1 but the values from wheelchair rugby 
(249(70) kcal·h-1) were significantly lower than basketball and tennis (Abel et al., 2008). 
Data from AB rugby league match-play estimates EEs of ~876 kcal·h-1 (Cummins et al., 
2016), more than three times the wheelchair rugby training values. There remains limited EE 
data for the majority of disability sports and the aforementioned research shows that AB data 
is not transferable even when there appears to be a similar sport. The availability of this type 
of data would help to determine daily energy intake needs and which (if any) NS would aid 
performance in such sports. 
An athlete with a physical impairment may need to adapt their diet to suit a reduced 
active muscle mass due to their impairment. For example, an individual with a SCI who has 
full use of their trunk may use only 60-70% of their muscle mass during wheelchair 
propulsion (Goosey-Tolfrey & Crosland, 2010). This smaller active muscle mass will reduce 
the individual’s energy requirements and hence they will often reduce the total volume of 
food they consume to help prevent a concomitant increase in body mass. This reduced energy 
intake may result in an athlete not meeting nutritional recommendations, which may not be 
optimal for sporting performance (Goosey-Tolfrey & Crosland, 2010). This can also result in 
individuals not meeting their perceived macro- and micronutrient recommendations (Gomes 
et al., 2006; Krempien & Barr, 2011; Perret & Stoffel-Kurt, 2011) and could cause the use of 
NS to meet these needs. For example, despite the importance of the micronutrients involved 
in bone health such as calcium, vitamin D and magnesium, wheelchair basketball athletes 
reported inadequate intakes (Grams et al., 2016). The authors recommended a calcium 
supplement could be used to reach the recommended intakes if they could not be achieved 
through dietary intake alone (Grams et al., 2016). Importantly, there are no specific 
guidelines for individuals with physical impairments and hence the macro- and micronutrient 
recommendations are currently based on AB data, which may not be appropriate. 
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2.2.2. Safety of nutritional supplements 
Some athletes with a physical impairment may use NS to help them consume a 
healthy, well-balanced diet that meets the demands of their training schedule. Furthermore, 
the practical implications that occur due to visual impairment or cerebral palsy for example, 
can make it difficult to prepare fresh nutritious meals which may result in some individuals 
using convenient NS to meet their requirements. Consequently, athletes who regularly use or 
are prescribed supplements such as iron, calcium or protein/meal replacement shakes for their 
health may be more inclined to consume performance-enhancing supplements because it is 
the ‘norm’. Athletes with a physical impairment may, therefore be unwittingly engaging in 
behaviours that may have unknown health, performance and potential doping consequences. 
Athletes with a physical impairment experience the same pressure to succeed and improve 
their exercise performance as AB athletes. Doping in sport is forbidden by the Olympic and 
Paralympic movement, an environment in which being on the podium is the ultimate 
achievement. No matter what the motivation, athletes must remember that they are subject to 
drug testing and therefore must consider the pros and cons prior to using NS given the small 
yet real risk of an inadvertent positive doping test (Baylis et al., 2001). Inaccurate labelling 
has also been found to be a problem in that some NS have been shown not to contain the 
labelled amount or type of active ingredient, or they contain an unlabelled substance (Geyer 
et al., 2004; Kohler et al., 2010). This issue is prevalent due to a lack of regulatory laws 
regarding NS in some countries and the widespread purchase of NS over the internet. 
Consuming NS containing an incorrectly labelled ingredient may have more serious 
consequences on the health of an individual with a physical impairment as it may have an 
unknown effect on their impairment or it may interact with medication use.  
The International Olympic Committee discouraged the use of dietary supplements by 
athletes in its 2010 consensus statement, whilst encouraging them to meet their nutrient 
requirements from food. They do however recognise that NS such as carbohydrate-electrolyte 
sports drinks, bars and gels, and a few ergogenic aids such as creatine, caffeine and buffering 
agents may be of benefit to some individuals. Given the minimal amount of information 
regarding NS habits and perceptions in elite sportsmen and women with physical 
impairments, it is hard to currently deliver the same message to this population. It is thus 
essential that current NS habits and perceptions of athletes with a physical impairment are 
considered prior to the delivery of any such message. 
The number of NS available on the market continues to increase and yet many of 
these proposed ergogenic aids are unsupported by scientific evidence (Abel et al., 2005; 
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Jeukendrup & Randell, 2011). For example, fat burning NS continue to be popular and yet 
many lack the evidence to support any form of fat metabolism-enhancing properties 
(Jeukendrup & Randell, 2011). New supplements are also being used prior to a body of 
evidence regarding their effectiveness and long-term effects. Using creatine as an example, 
research in AB individuals shows an ergogenic effect during maximal power/strength, single-
effort and repetitive sprint performance, whilst also acting as a training tool to help increase 
strength, FFM and improve performance during high-intensity protocols (Kreider, 2003; 
Volek et al., 1999). On the other hand, the evidence is currently equivocal (and under-
researched) in athletes with a physical impairment (Jacobs et al., 2002; Perret et al., 2006). 
Both studies provided 20 g creatine monohydrate for 6-7 d with a 21 d washout period 
however, the performance tests differed; an peak arm ergometry test (Jacobs et al., 2002) and 
an 800 m wheelchair test on a training roller (Perret et al., 2006). Jacobs et al. (2002) reported 
improved peak PO and time to fatigue in individuals with tetraplegia whereas Perret et al. 
(2006) reported no change in performance in individuals with paraplegia and spina bifida. 
Despite a lack of evidence, creatine was reportedly used by more Paralympic than Olympic 
athletes (9.1% vs. 5.1%) during the Athens 2004 games (Tsitsimpikou et al., 2009). There is 
no evidence regarding the dosage recommendations for supplements such as creatine for 
individuals with a reduced active muscle mass such as individuals with a SCI, who may be 
inadvertently consuming more than they require when following AB guidelines. Even in AB 
athletes, supplements may cause detrimental effects when taken in large doses for prolonged 
periods (Maughan, 2005).  
There is currently insufficient scientific evidence regarding the effects of NS in a 
population of athletes with a physical impairment and the potential for unknown side-effects 
or more acute sensitivity to side-effects may exist (Van de Vliet et al., 2011). Some athletes 
remain uneducated regarding their individual needs and the use of NS to complement their 
daily diet and could, especially in a population of athletes with a physical impairment, 
therefore be threatening their health (Dascombe et al., 2010; Rastmanesh et al., 2007).  
2.2.3. Athletes’ sources of information 
Research from AB populations shows there is a need for athlete education regarding 
nutrition and NS (Dunn et al., 2007; Economos et al., 1993; Jacobson et al., 2001). Many 
individuals who consume NS on a regular basis are unaware of the proposed physiological 
mechanisms or the possible side-effects (Dascombe et al., 2010). Athlete populations also 
show a lack of understanding regarding NS and their associated effects (Petrόczi et al., 2008). 
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Hence athletes may be using NS without initially assessing the need for them or the 
associated risks.  
From an AB perspective, Froiland et al. (2004) reported that the three most common 
sources of information used by varsity athletes were family, other athletes and their athletic 
trainer. These were closely followed by their coach, strength coach, friends and a registered 
dietitian (Froiland et al., 2004). The use of these sources, except the registered dietitian, is a 
concern given the lack of professional knowledge likely in these individuals. Others have 
reported coaches and athletic trainers to be influential when deciding whether to use a NS 
(Jacobson et al., 2001; Juhn et al., 1999). However, working in the field of sport does not 
guarantee sufficient knowledge and understanding of NS. Considering the individual 
nutritional needs of athletes with a physical impairment there may be a heightened 
requirement for education in this population and it is imperative that athletes understand 
which sources of information are most knowledgeable and reliable e.g. registered 
nutritionists/dietitians. 
It has been shown that education can change attitudes and behaviours (Rastmanesh et 
al., 2007). For example, Rastmanesh et al. (2007) provided nutritional education (a booklet 
and four 3 h courses) to a group of athletes with a SCI or amputation. Following the 
education, 50% of the athletes reported that they would prefer to receive their nutritional 
information from a dietitian, compared to only 14% prior to the education.  An understanding 
of current sources of NS information for athletes with a physical impairment will help ensure 
educational practice is conducted at the correct level and therefore aid its effectiveness upon 
implementation.  
2.2.4. Nutritional supplement use by athletes with a physical impairment 
The majority of research suggests that the consumption of NS is common among AB 
athletes (51-88%) (Braun et al., 2009; Dascombe et al., 2010; Erdman et al., 2006; Sundgot-
Borgen et al., 2003) and there is a large body of evidence regarding their efficacy. On the 
other hand, there is a dearth of evidence regarding the use of NS by athletes with an 
impairment and further investigation is warranted. 
To the author’s knowledge the only study to determine food supplement use in 
Paralympic athletes was performed at the Athens 2004 Paralympic Games (Tsitsimpikou et 
al., 2009). The study revealed that food supplements made up 42.1% of the reported 
preparations. Interestingly, compared to their Olympic counterparts, fewer Paralympic 
athletes reported the use of food supplements and medications but they did display a similar 
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consumption pattern. Tsitsimpikou et al. (2009) revealed that vitamins (43.5%), 
minerals/electrolytes (16.1%) and proteins/amino acids (10.5%) were the most commonly 
consumed NS. Tsitsimpikou and colleagues (2009) provided important evidence that NS use 
is common among Paralympic athletes (27%) however; the data was purely descriptive and 
did not explore athlete’s habits or perceptions of NS and/or attitudes towards (anti-)doping. 
As stated earlier, many practitioners will utilise AB findings to make 
recommendations on NS use. Given the reliance on UBE within many disability and 
Paralympic sports it is important to assess this information with caution. Research on the 
impact of NS on (non-strength) UBE performance in individuals with a physical impairment 
is scarce and the evidence is currently equivocal. Studies include the exploration of caffeine 
(Flueck et al., 2015; 2014; see Table 2.4), carbohydrate (Spendiff & Campbell, 2002), 
creatine (Jacobs et al., 2002; Perret et al., 2006) and sodium citrate (Flueck et al., 2014) as 
ergogenic aids during short-term, high-intensity or endurance UBE protocols (Table 2.1). The 
former two caffeine studies resulted in no significant change in performance but individual 
responses were apparent (Table 2.4). Hence, further investigation is required. 
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Table 2.1. Studies investigating the use of nutritional supplementation (excluding caffeine) related to short-term high-intensity and endurance 
upper-body exercise performance in individuals with a physical impairment. 
Publication Participants Supplementation Exercise 
performance protocol 
Enhanced 
performance 
Other 
Carbohydrate supplementation  
Spendiff & 
Campbell, (2005) 
Participants with 
paraplegia (T5-T12) & 
spina bifida 
(8 males) 
4% (‘low’) or 11% 
(‘high’) carbohydrate 
drink 20 min prior to 
exercise 
1 h at 65% V̇O2peak & 
20 min performance 
test on a wheelchair 
ergometer 
Perhaps – tendency 
(p = 0.08) for greater 
performance distance 
& PO following 
‘high’ compared to 
‘low’  
Tendency for greater [GLU], 
RER & PO, & lower FFA 
concentrations following ‘high’ 
Creatine monohydrate 
Jacobs et al. (2002) 
(abstract only) 
Participants with 
cervical level SCI  
(C5-C7) 
(16 males) 
20 g·d-1 creatine 
monohydrate / PLA for 
7 d 
(21 d washout) 
Incremental peak arm 
ergometry test 
Yes - Improved peak 
PO & time to fatigue 
 
Perret et al. (2006) Competitive 
wheelchair athletes 
with paraplegia, spina 
bifida or hemiparesis 
(4 male & 2 female) 
4 x 5 g creatine 
monohydrate / PLA for 
6 d  
(21 d washout) 
All-out 800 m 
wheelchair test on a 
training roller 
No No difference in BM, RPE, 
peak/mean HR, maximum 
velocity or  [Bla] 
Sodium citrate 
Flueck et al. (2014) Elite wheelchair racing 
athletes with 
paraplegia & spina 
bifida (category 
T53/54) 
(9 males) 
0.5 g·kg-1 sodium citrate  
/ PLA in 700 ml water 
120 min prior to 
exercise 
1500 m  wheelchair 
racing TT 
No 5/9 participants suffered GI 
distress 
Tendency for higher [Bla] 
Note: [Bla]=blood lactate concentration, BM=body mass, C=cervical, FFA=free fatty acids, GI=gastrointestinal, GLU=glucose, PLA=placebo, PO=power output, RER=respiratory exchange ratio, RPE=ratings of 
perceived exertion, SCI=spinal cord injury, T=thoracic and TT=time trial  
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2.3. Caffeine 
2.3.1. What is caffeine? 
Caffeine is a member of a group of stimulants called methylxanthines, or xanthines, 
and occurs naturally in some plants.  Caffeine’s chemical name is 1, 3, 7-trimethylxanthine 
and its chemical structure can be seen in Figure 2.1. Caffeine is classed as a pharmaceutical 
compound or drug, rather than a nutrient, and is used in many commonly consumed foods 
and drinks. Caffeine is a naturally occurring plant alkaloid that is found in tea leaves, coffee 
beans, cocoa beans, guarana and kola nuts, and is often artificially added to over the counter 
products (e.g. weight loss products and cold preparations) and beverages (e.g. energy or 
sports products). The caffeine content of different types and brands of these foods and drinks 
(Table 2.2) vary greatly and can also depend on how they are prepared e.g. percolated 
contains more than instant coffee. Food and drink manufacturers are not legally required to 
list caffeine as an ingredient on their product label if it occurs naturally due to a plant source. 
However, it must be listed if it is an added ingredient in products such as sports drinks, gels, 
capsules and powders. This enables athletes to calculate caffeine dose more easily.  
 
 
 
 
 
 
 
Figure 2.1. Chemical structure of caffeine 
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Table 2.2. Caffeine content of common foods, drinks and nutritional supplements. (Table 
adapted from Burke, 2008). 
Food or drink Serving Caffeine (mg)* Range (mg) 
Instant coffee 250 ml (8 oz) 60  (12-169) 
Brewed coffee 250 ml (8 oz) 80  (40-110) 
Short black or espresso coffee 1 standard serving 107  (25-214) 
Tea 250 ml (8 oz) 27  (9-51) 
Hot chocolate 250 ml (8 oz) 5-10  
Milk chocolate 60 g 5-15  
Coca-cola 375 ml (12 oz)  49  
Red Bull energy drink 250 ml (8 oz) 80  
Powerbar caffeinated sports 
gel 
40 g sachet 25  
Spike Shotgun energy drink 500 ml (16 oz)  350  
Stay Alert Caffeine 
supplement chewing gum 
1 piece 100  
ProPlus tablets 1 tablet 50  
*These values were gathered from a variety of sources, including manufacturers’ information and nutrition databases (Centre for Science in 
the Public Interest (available at http://www.cspinet.org/new/cafchart.htm), and USDA National Nutrient Database (available at 
http://www.nal.usda.gov/fnic/foodcomp/search/). Note that commercial brands may vary slightly from country to country. 
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Caffeine is one of the most widely used drugs in the world and it has received recent 
attention as an ergogenic aid in sport since its removal from the WADA prohibited list in 
2004 (Del Coso et al., 2011). Caffeine has appeared on the WADA prohibited list 
intermittently for approximately 40 y; a common sign that it has been shown to have a 
positive effect on sporting performance. When banned, the urinary cut-off of 12-15 μg·mL–1 
did not allow distinction between social and performance-related consumption. Concerns 
regarding the abuse of caffeine as a performance aid mean that the substance remains on the 
WADA monitoring programme. These concerns may be unfounded given that the prevalence 
of caffeine consumption was similar during both the period it was banned and during the four 
years after it was removed from the prohibited list (2004-2008) (Del Coso et al., 2011).  
Caffeine is absorbed quickly in the GI tract and stomach (absorption reaches 99% in 
the GI tract) in both humans and animals, and it moves easily across cellular membranes 
including the blood-brain barrier due to its hydro- and lipophilic properties (Fredholm et al., 
1999). It can therefore potentially interact with every tissue in the body either via receptors or 
direct entry into cells, including all organs. The presence of food in the stomach slows the 
absorption of methyxanthines such as caffeine (McKim, 1996). Caffeine concentrations can 
be measured in urine, serum and saliva, and good correlations (r=0.93-0.98) have been 
reported between these methods in AB individuals (Birkett & Miners, 1991; Zylber-Katz et 
al., 1984). Salivary caffeine concentrations are ~80% of those measured in plasma (Zylber-
Katz et al., 1984). 
Caffeine is slowly metabolised by the liver and has a half-life of ~5-6 h (Smith, 
2002). Caffeine is distributed via the bloodstream with 10-30% being transported by proteins 
(McKim, 1996). Typical blood concentrations are elevated within 15-45 min and peak 45-60 
min post-ingestion in AB individuals (Goldstein et al., 2010b; Smith, 2002). Blanchard and 
Sawers (1983) reported rapid absorption of 5 mg·kg-1 caffeine in an oral solution in healthy 
adult males whereby the time to reach a peak plasma concentration (Cmax) was 30(8) min and 
a Cmax of 51(6) µM. There is no long-term accumulation of caffeine or it’s metabolites in the 
body.  
Caffeine is metabolised primarily by the cytochrome P450 enzyme system and is 
converted via demethylation reactions to three main dimethylxanthines (paraxanthine (~80%), 
theobromine (~11%) and theophylline (~5%)), which accounts for ~95% of metabolism. A 
small amount is excreted without being metabolized (Arnaud, 2011).  The cytochrome 1A2 
(CYP1A2) gene carries the instructions for building the cytochrome P450 enzyme and 
humans can express two variants. Individuals who are homozygous for the A variant are 
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rapid caffeine metabolisers, and individuals that possess the C allele (heterozygous) are slow 
metabolisers (McKim, 1996). Hence, individuals that metabolise caffeine slower may be 
more susceptible to adverse effects such as nervousness, jitters, restlessness, sleeplessness 
and irritability which may also negatively impact on sports performance. The increased 
potential for adverse effects may help explain why 16 of 19 participants with the C allele 
were voluntarily low caffeine users (Womack et al., 2012). Greater improvements in 40 km 
TT performance have been reported in individuals who possess the homozygous A allele 
compared to the C allele (4.9 vs. 1.8%, respectively) (Womack et al., 2012). The authors 
suggest this difference may be related to the earlier presence of caffeine’s metabolites, 
theophylline and paraxanthine that have higher binding affinities to adenosine receptors than 
caffeine and may therefore be more potent (Fredholm et al., 1999; Womack et al., 2012). This 
specific polymorphism may help to explain some of the large inter-individual variability in 
responses to caffeine ingestion that have been reported. Of these studies, Astorino et al. 
(2008) reported improvements in one repetition maximum bench press in 12 resistance 
trained participants following the ingestion of 6 mg∙kg-1 caffeine; while five improved 
following placebo and five performed the same following both treatments (n=22). Flueck et 
al. (2014) also reported faster 1500 m wheelchair race times in four out of nine participants 
following 6 mg∙kg-1 caffeine, while two were fastest following placebo and two were faster 
following an alternative NS. 
A number of other factors may influence the pharmacokinetics of caffeine including 
the presence of food and fluid in the stomach (Brachtel & Richter, 1988), genetics (McKim, 
1996), the use of oral contraceptives (Abernethy & Todd, 1985), diet and lifestyle, dosage 
and sleep deprivation (Kamimori et al., 1995). Obesity has been shown to prolong the 
elimination half-life of some drugs and therefore an individual’s body composition may also 
be another influencing factor (Kamimori et al., 1987). An increase in apparent volume of 
distribution (caffeine clearance divided by elimination rate constant) resulted in a trend 
towards a prolonged elimination half-life of caffeine in obese individuals (Abernethy et al., 
1985). Skinner et al. (2014) also suggested that individual rates of caffeine metabolism may 
be linked to body composition and training status. The pharmacokinetics of caffeine differs 
between species of animal and so the extrapolation of animal data to humans must be done 
with care (Arnaud et al., 2011). 
32 
 
2.3.2. Mechanisms of action 
Caffeine appears to have a variety of effects on the human body including as a smooth 
muscle relaxant, and as a stimulant for cardiac muscle and the central nervous system (CNS). 
Numerous mechanisms have been proposed to explain the beneficial effects of caffeine on 
exercise performance. The traditional theory was that caffeine increased the circulating levels 
of adrenaline, which subsequently stimulated an increase in lipolysis and fat metabolism, and 
therefore spared muscle glycogen stores (Graham, 2001). It was proposed that the increased 
availability of FFA (Graham et al., 2000; Van Soeren et al., 1996) led to a change in substrate 
utilisation following caffeine ingestion and was therefore thought to contribute to improved 
exercise capacity (Graham, 2001). However, Laurent et al. (2000) opposed this notion by 
reporting that 6 mg∙kg-1 caffeine ingested 90 min prior to 2 h cycling at 65% ·VO2 peak did not 
result in a muscle glycogen sparing effect in athletes with high muscle glycogen content 
despite increases in both adrenaline and FFA concentrations. Hence, the proposed traditional 
theory regarding changes in substrate utilisation during endurance exercise is unlikely to be 
the sole reason for caffeine’s ergogenic nature. Other studies have also revealed that caffeine 
can be advantageous during exercise protocols in which muscle glycogen stores are not 
compromised (Beck et al., 2006 (one repetition maximum bench press); Bruce et al., 2000 
(2000 m rowing performance); Collomp et al., 1992 (100 m swimming performance)). 
Further, despite individuals having an impaired catecholamine response (due to tetraplegia, 
see section 2.4.1), an increase in plasma FFA concentration and improvements in electrical 
cycling time to exhaustion have been observed following caffeine ingestion (Mohr et al., 
1998). Mohr and colleagues (1998) therefore provided support for the theory that caffeine 
may have a direct effect on adipocytes and various other tissues independent of the brain and 
circulating catecholamine concentrations (Mohr et al., 1998; Van Soeren et al., 1996).  
Caffeine’s influence on the CNS via adenosine receptor antagonism has been shown 
to influence mental and physical performance, improving attributes such as alertness, reaction 
time (Rogers et al., 2013) and exercise capacity (Van Soeren & Graham, 1998). Adenosine is 
a by-product of adenosine triphosphate (ATP) metabolism and hence concentrations rise 
when there is activity resulting in ATP metabolism e.g. exercise. Adenosine acts to reduce 
arousal, wakefulness and motor activity (Fredholm et al., 1999). It is also a potent 
vasodilator, and inhibits catecholamine release and lipolysis (Keisler & Armsey, 2006). The 
caffeine molecule (Figure 2.1) has a similar structure to adenosine and therefore acts as a 
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potent non-selective adenosine receptor antagonist, thereby reducing the inhibitory effect of 
adenosine on the body (Fredholm et al., 1999; Watson, 2008).     
There are four subtypes of adenosine receptor: A1, A2A, A2B and A3, and these can be 
found on cell surfaces throughout the human body. Importantly, caffeine, at plasma 
concentrations reached through dietary intake, acts mainly on adenosine A1 and A2A receptors 
which are found largely in the brain (McKim, 1996). Adenosine inhibits excitatory 
neurotransmitter release and hence antagonism may affect circulating levels of 
neurotransmitters such as dopamine (Davis et al., 2003). Therefore, the blockade of 
adenosine receptors, especially those in the brain can help delay fatigue (Goldstein et al., 
2010b).   
Caffeine has also been shown to lower the perception of effort experienced by an 
individual during exercise (Doherty & Smith, 2005). The reduction in pain perception may 
also be due to the analgesic effects of increased plasma endorphin concentrations. It has been 
suggested that caffeine may lower the threshold for exercise-induced ß-endorphin release, 
which can consequently reduce pain perception (Laurent et al., 2000). Caffeine consumption 
has been shown to reduce leg muscle pain during cycling exercise but more so at a 
submaximal, fixed intensity than during maximal exercise (Black et al., 2015; Motl et al., 
2006; O’Connor et al., 2004). 
It is likely that a combination of mechanisms is responsible for any improvements in 
performance and is likely to vary depending on the exercise protocol, caffeine dosage and the 
participants’ characteristics. Adenosine receptor antagonism appears to be the main 
mechanism via which caffeine improves performance at physiological concentrations. 
However, evidence does suggest that under certain conditions other biochemical mechanisms 
may be active but many have only been explored in vitro (Magkos & Kavouras, 2005). Other 
proposed mechanisms of action include the inhibition of phosphodiesterase enzymes, 
increased calcium mobilisation and stimulation of the sodium/potassium pump (Magkos & 
Kavouras, 2005). Caffeine’s ability to increase the release of calcium from the sarcoplasmic 
reticulum and therefore influence excitation-contraction coupling only occurs at supra-
physiological caffeine concentrations (minimum of 1-2 mM) (Luttgau & Oetliker, 1968). 
Hence, this is not a mechanism considered to improve exercise performance in humans 
however it cannot be discounted that some potentiation may occur via other pathways that 
increase the sensitivity of the calcium release system to caffeine (Mohr et al., 1998; Magkos 
& Kavouras, 2005). The inhibition of phosphodiesterase enzyme activity following caffeine 
administration leads to accumulation of cyclic adenosine monophosphate (cAMP), which is 
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involved in hormone regulation and importantly, increase adipose tissue lipolysis (Magkos & 
Kavouras, 2005). Once more, [CAF] needs to be greater than those reported with dietary 
intake or supplementation to induce this mechanism (0.1-6.0 mM) (Magkos & Kavouras, 
2005). Caffeine has also been shown to stimulate the sodium/potassium pump and ATPase 
activity by preventing the rise in potassium in the extracellular fluid and thereby maintaining 
an electrochemical gradient for optimal muscle contraction (Bittar et al., 1974). Once again 
this mechanism has only been reported at supra-physiological concentrations (>100 µM) 
(Bittar et al., 1974).   
2.3.3. Caffeine: side-effects, tolerance and withdrawal. 
Caffeine is generally well-tolerated in humans in doses up to 400 mg·d-1 with no 
adverse effects (Riddell et al., 2012). In those that are susceptible however, caffeine can 
cause adverse effects such as sleeplessness/disturbed sleep, trembling and increased anxiety. 
Caffeine also inconsistently causes other physiological effects such as an increased HR and 
breathing rate, and should therefore be avoided by pregnant or nursing women, babies and 
children, or those that are sensitive to the drug. 
Individuals can develop a tolerance and dependency for caffeine, which appears to be 
related to the up-regulation of adenosine activity and a decrease in adrenergic activity (Latini 
& Pedata, 2001) making withdrawal from the drug difficult. The removal of caffeine from the 
diet can cause withdrawal symptoms such as headache, irritability, lethargy and depressed 
mood (Riddell et al., 2012). Withdrawal has also been associated with sleepiness, lower 
mental alertness and can cause slower reaction times (Rogers et al., 2013). Upon a re-dose of 
caffeine, withdrawal symptoms are quickly reversed. Despite the occurrence of these 
symptoms, Van Soeren and Graham, (1998) published results that showed no effect of short-
term withdrawal from caffeine on endurance during high-intensity exercise, compared to no 
withdrawal. Despite this, it is common to ask research study participants to withdraw from 
the consumption of caffeine in the 24-48 h prior to trials to ensure all participants have a 
similar baseline and for their safety, to ensure no participant consumes dangerously high 
doses.  
 Caffeine can also act as a mild diuretic when consumed in high doses because it 
stimulates renal glomerular filtration and inhibits the reabsorption of sodium, which results in 
increased sodium and water excretion (Arnaud 1999). However, normal daily intakes of <240 
mg of caffeine, equivalent to approximately three cups of brewed coffee (Table 2.2), are 
unlikely to cause a significantly greater diuresis than a control fluid containing no caffeine 
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such as water (Armstrong et al., 2007). Any influence of mild diuresis would be minimal and 
there does not appear to be any basis for the common concern that caffeine will cause 
hypohydration (Graham, 2001). 
2.3.4. Caffeine and exercise performance 
2.3.4.1 Caffeine use during whole/lower-body exercise 
A substantial amount of evidence has accumulated on the effects of moderate doses 
(3-6 mg∙kg-1) of caffeine on both physiological and psychological performance in AB 
individuals during lower-body exercise modes such as running and cycling (see reviews 
Ganio et al., 2009; Graham, 2001; Keisler & Armsey, 2006; McLellan et al., 2016; 
Tarnopolsky, 1994). McLellan et al. (2016) suggested that 78%, 66% and 69% of the studies 
reviewed reported ergogenic effects of caffeine during endurance, high-intensity and 
muscular strength/endurance exercise protocols, respectively. Ganio et al. (2009) concluded 
that caffeine ingestion improved endurance TT (>5 min) performance by 3.2(4.3)% but this 
improvement was highly variable (-0.3-17.3%). Variability is likely dependent on a number 
of factors such as differences in timing and dosage of caffeine, route of delivery and 
participant characteristics. 
Small-moderate doses of caffeine (≤6 mg∙kg-1) have been shown to improve mental 
attributes such as reaction time, alertness and attention (Rogers et al., 2013; Smith et al., 
1999). Caffeine has been shown to be ergogenic during endurance exercise lasting ~60 min 
(Kovacs et al., 1998 (3-4 mg∙kg-1); McNaughton et al., 2008 (6 mg∙kg-1); Skinner et al., 2013 
(6 mg∙kg-1)). Both McNaughton et al. (2008) and Kovacs et al. (1998) reported improvements 
in performance during a 1 h cycling performance trial following caffeine ingestion. Skinner et 
al. (2013) was also able to report a 2% improvement in a more ecologically valid 40 km TT 
lasting ~1 h. Exercise protocols lasting longer than 60 min have also shown improvements in 
performance following caffeine (Cureton et al., 2007 (5.3 mg∙kg-1); Cox et al., (2002) (6 
mg∙kg-1)).  Both Cureton et al. (2007) and Cox et al. (2002) reported improved TT 
performance following a 120 min preload at 60-75% ·VO2 peak in addition to the improvements 
seen following carbohydrate ingestion.  
Caffeine may also be effective in exercise scenarios lasting less than 30 min where 
muscle glycogen depletion is unlikely to be the cause of fatigue (Jenkins et al., 2008; Bruce et 
al., 2000). Bruce et al., (2000) reported reduced times to complete a 2000 m rowing TT 
following moderate to large doses of caffeine (6 and 9 mg∙kg-1) whereas Jenkins et al., (2008) 
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described improvements in 15 min cycling TT performance following much lower and more 
practical doses (2-3 mg∙kg-1). Caffeine may therefore be useful during a variety of 
sports/events including endurance events, intermittent team sports and events involving high-
intensity activity lasting less than 60 min. However, the evidence for an ergogenic effect of 
caffeine during single events that require strength and power remains inconclusive (Keisler & 
Armsey, 2006). Caffeine supplementation has been shown to improve sport performance but 
the magnitude of the effect is dependent on various factors such as an athlete’s training status, 
and the intensity, duration and mode of exercise (McLellan et al., 2016). Caffeine appears to 
be effective in an AB population at doses between 3 and 6 mg∙kg-1 without any adverse 
effects. Caffeine does not appear to respond in a dose dependent manner, with higher doses 
not producing any further performance enhancement (Goldstein et al., 2010b) but may 
increase the likelihood of adverse effects (Burke, 2008; Graham & Spriet, 1991).  
2.3.4.2 Caffeine use during upper-body exercise and by individuals with a physical 
impairment 
There is a lack of evidence regarding the effects of caffeine on UBE performance, 
which is highlighted by the number of publications compared to whole/LBE in Table 2.3. 
There are even fewer studies investigating the effects of caffeine in individuals with a 
physical impairment/disability (Table 2.3). However, based on the mechanisms discussed in 
section 2.3.2 caffeine could theoretically be advantageous for those competing in disability 
sports requiring endurance or short-term, high-intensity exercise performance such as 
athletics, football, wheelchair sports, triathlon and cycling. The ergogenic benefit of a 
supplement such as caffeine can be influenced by a number of factors including individual 
variation and training status, which are two key differences between AB athletes and athletes 
with a physical impairment. For example, no individual with a SCI will display the exact 
same physical and neurological issues and hence each athlete needs to be considered as an 
individual. Furthermore, any athlete who uses a wheelchair for daily ambulation will display 
vastly different training loads and EEs compared to an AB individual. Individuals with 
neurological impairments such as CP or SCI must also consider the effects of caffeine on the 
occurrence of palpitations and tremor (Astrup et al., 1990; Shirlow & Mathers, 1985), and the 
possible effects it may have on spasticity (anecdotal evidence from athletes). This highlights 
the importance of considering the dose when using caffeine in an athletic population with 
physical impairments.   
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Table 2.3. Number of publications on caffeine and lower/whole-body exercise compared to upper-body exercise. 
Pubmed search terms Number 
of studies 
Lower/whole-body exercise studies  
Caffeine and exercise performance 494 
Caffeine and running 159 
Caffeine and running performance 99 
Caffeine and cycling 254 
Caffeine and cycling performance 115 
Upper-body exercise studies  
Caffeine and UBE 19 
Caffeine and wheelchair/wheelchair performance 2 
Caffeine and arm crank 2 
Caffeine and handcycling/handbiking 0 
Caffeine and disability sport 3 
Note: Searches performed on 05.08.16 and excluded any publications from this thesis. 
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Table 2.4. Studies of caffeine supplementation related to upper-body strength, short-term high-intensity and endurance exercise performance. 
Publication Participants Caffeine protocol Exercise 
performance 
protocol 
Enhanced 
performance  
Blood lactate 
concentration 
(mmol·L-1)  
Ratings of 
Perceived Exertion 
(RPE)  
Strength exercise performance 
Duncan & Oxford, 
(2011) 
Moderately trained  
(13 males) 
5 mg∙kg-1  
60 min prior to 
exercise 
Repetitions to failure 
at 60% 1RM 
Yes ↑ repetitions to 
failure & ↑ weight 
lifted 
↑ Unaffected 
(↑ scores for vigour) 
Duncan et al. 
(2013) 
Resistance trained 
(9 males & 2 
females) 
5 mg∙kg-1  
60 min prior to 
exercise 
Repetitions to failure 
at 60% 1RM 
Yes ↑ repetitions to 
failure 
Unaffected ↓ 
(↓ pain) 
Beck et al. (2006) Resistance trained  
(37 males) 
201 mg (mate, 
guarana, black tea 
extract) 
60 min prior to 
exercise 
1RM bench press 
Muscular endurance 
test (total volume of 
weight lifted with 
80% 1RM) 
Yes 2.1%↑ 1RM BP 
No change in muscular 
endurance 
n/a n/a 
Goldstein et al. 
(2010a) 
Resistance trained 
(15 females) 
6 mg∙kg-1 
60 min prior to 
exercise 
1RM bench bench & 
repetitions to failure 
at 60% 1RM 
Yes ↑ 1RM  
No change in 60% 
1RM 
n/a n/a 
Timmins & 
Saunders, (2014) 
Resistance trained  
(16 males) 
6 mg∙kg-1  
30 min prior to 
exercise 
MVC of elbow & 
wrist flexors 
Perhaps ↑ mean MVC  
As muscle size 
increased so too did the 
improvement in MVC 
n/a n/a 
Jacobs et al. (2003) Healthy, active 
(13 males) 
4 mg∙kg-1 
90 min prior to 
exercise 
3 supersets of 80% 
1RM bench press 
No n/a n/a 
Green et al. (2007) Physically active 
participants (≥8 wk 
strength training) 
(13 males & 4 
females) 
6 mg∙kg-1 
60 min prior to 
exercise 
3 sets of 10 RM 
bench press to failure 
No n/a Unaffected 
Bellar et al. (2011) Recreationally 
trained participants  
(5 male & 5 female) 
100 mg caffeine gum  
(delivered 85% 
effective dose) 
immediately prior to 
exercise 
Grip TTE at 30%max No n/a Unaffected 
(↓ pain) 
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Black et al. (2014) Recreationally active 
participants  
(6 male & 6 female) 
5 mg∙kg-1  
60 min prior to 
exercise 
MVC & motor unit 
recruitment of elbow 
flexors tested pre-
capsule, pre- & post-
40 min arm cycling 
No  
 
n/a n/a 
Short-term, high-intensity exercise performance 
Flueck et al. (2015) Healthy, trained 
participants 
(17 AB, 10 PARA & 
7 TETRA males) 
6 mg∙kg-1  
60 min prior to 
exercise 
3 min all-out arm 
crank test 
Yes ↑ average PO in 
PARA only 
Yes ↑ peak PO in 
AB/PARA only 
No TETRA (Large 
inter-individuality) 
Unaffected in 
AB/PARA  
↑ in TETRA post-
ex 
n/a 
Flueck et al. (2014) Elite wheelchair 
racing athletes  
(6 male & 3 female) 
6 mg∙kg-1  
60 min prior to 
exercise 
1500 m wheelchair 
racing TT 
No but 4 out of 9 
athletes improved  
↑ post-TT n/a 
Aedma et al. 
(2013) 
Trained wrestlers  
(14 males) 
 
5 mg∙kg-1  
30 min prior to 
exercise (1st test) 
4 x 6 min UBE 
intermittent sprint 
performance tests 
with 30 min recovery 
between tests 
No ↓peak PO in test 4 ↑ in tests 3 & 4  Unaffected 
Endurance exercise performance 
Stadheim et al. 
(2013) 
Highly trained CC 
skiers  
(10 males) 
6 mg∙kg-1 
~75 min prior to 
exercise 
Incremental warm-up  
8 km CC DP 
performance test 
Yes 4%↓ performance 
time 
↑  
 
↓ during sub-
maximal intensities 
Stadheim et al. 
(2014) 
Highly trained CC 
skiers 
(8 males) 
 
3 & 4.5 mg∙kg-1 
~75 min prior to 
exercise 
15 min submaximal 
exercise & a 10 min 
all-out CC DP 
ergometer test 
Yes 4%↑ distance on 
day 1 & ~5%↑ on day 
2 
Unaffected at 
rest/during warm-
up 
↑ post test 
 
↓ during sub-
maximal intensities 
Unaffected during 
test 
Black et al. (2014) Recreationally active 
participants  
(9 male & 5 female) 
5 mg∙kg-1 
60 min prior to 
exercise 
30 min arm cycling at 
60% V̇O2peak & 10 
min performance trial 
No but improved by 
2.1% (n.s) 
↑  
Unaffected post-
performance trial  
↓ 
(↓ pain during sub-
maximal but not 
maximal exercise) 
Note: AB=able-bodied, CC=cross-country, DP=double-poling, MVC=maximal voluntary contraction, PARA=individuals with paraplegia, PO=power output, 
RM=repetition maximum, TETRA=individuals with tetraplegia, TT=time trial and TTE=time to exhaustion 
40 
 
A summary of studies that have investigated caffeine supplementation during UBE can 
be seen in Table 2.4. As with the evidence in an AB population, it appears that caffeine is 
unlikely to consistently enhance UB strength. The evidence is equivocal for short-term, high-
intensity UBE but both studies by Flueck et al. (2014; 2015) show positive signs that caffeine 
may improve performance in some individuals with a physical impairment. The 2014 study 
investigated the effects of caffeine and sodium citrate on 1500 m wheelchair racing 
performance (~2:50 min) using elite athletes with a SCI or spina bifida (category T53/54) 
(Flueck et al., 2014). The authors concluded that caffeine supplementation, or its combination 
with sodium citrate, did not improve 1500 m race performance compared to placebo. 
However, individual variability was evident, with four athletes (n=9) producing their fastest 
time during the caffeine only trial. The differing muscle fibre type composition in the arms 
compared to the legs and the elite athlete participant pool were among the proposed reasons 
for the lack of an ergogenic effect. Flueck et al. (2015) suggested that the effects of 6 mg∙kg-1 
caffeine on 3-min all-out arm crank performance differed depending on an individual’s SCI 
lesion level in UBE trained participants. Improvements were seen in AB individuals (n=17) 
and individuals with paraplegia (n=10) but high inter-individuality remained evident in all 
groups (n=7, individuals with tetraplegia) (Flueck et al., 2015). The authors proposed that the 
lesser training status of the participants in the 2015 study was one of the reasons for the 
differing results. During short-term maximal exercise Flueck et al. (2015) suggested that elite 
athletes may benefit less from caffeine because they are already performing close to their 
maximum. This opposes Collomp et al. (1992) who suggested that the intra and/or 
extracellular adaptations resulting from specific swimming training were necessary to reap 
the benefits of caffeine during 2 x 100 m sprint performance. Both studies published by 
Flueck et al. (2014: 2015) are notable for their absence of subjective measures of perceived 
exertion, pain, mood and/or arousal, which are reported to be positively altered following 
caffeine (Doherty & Smith, 2005; Smit & Rogers, 2000). 
The third study to investigate short-term UBE performance employed an UB intermittent 
sprint performance test on an arm crank ergometer (Aedma et al., 2013). The test was 
developed specifically to assess anaerobic performance in wrestlers and involved four six min 
bouts of intermittent sprint arm cranking (repeated 15 s sprints and 40 s unloaded cranking) 
with 30 min recovery in-between. Aedma et al. (2013) are the only known study to report a 
negative effect of caffeine supplementation on UBE performance, whereby a significant 
reduction in peak PO was observed in the fourth intermittent sprint test compared to a smaller 
decline following placebo. The authors concluded this was due to the increased HR and blood 
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lactate concentrations [Bla] observed during the caffeine trial, which may have impaired the 
wrestlers’ recovery between consecutive bouts (Aedma et al., 2013). Increased [Bla] in the 
absence of performance improvements has been reported previously (Black et al., 2014; 
Flueck et al., 2014) but the reasons for this are currently unknown. 
Three further studies have investigated the effects of caffeine supplementation on UBE 
endurance performance in AB participants. Stadheim et al. (2013) reported caffeine              
(6 mg∙kg-1) to enhance endurance performance during an 8 km double-poling  performance 
test lasting ~33-34 min. Stadheim et al. (2014) also reported improvements during a 10 min 
all-out double-poling TT following a 15 min preload and a lower caffeine dose (3 and 4.5 
mg∙kg-1). These results must be assessed with caution given that the double-poling technique 
used in cross-country skiing also involves the muscles of the trunk and upper-leg, but the 
arms provide the speed generating force (van Hall et al., 2003). To the author’s knowledge, 
Black et al. (2015) is the only study that has investigated the influence of caffeine on UB-
only endurance performance. The authors compared participant’s performance in a 10 min 
performance trial during leg and arm cycling following a 30 min submaximal preload at 
60% ·VO2 peak. Caffeine (5 mg∙kg-1) ingestion 60 min prior to exercise improved leg but not 
arm cycling performance, which Black et al. (2015) suggested may have been due to a 
potential threshold intensity of pain/RPE above which caffeine cannot exert its ergogenic 
effects. Participants reported near maximal RPE scores of ~19 following both placebo and 
caffeine, following the 10 min performance trial. There are currently a limited number of 
studies employing different exercise and caffeine protocols, participant populations and 
measures of performance making it hard to form any clear conclusions on caffeine’s effects 
on individuals with physical impairments.  
2.4. Spinal cord injury 
2.4.1. Spinal cord anatomy and terminology 
The spine consists of 33 vertebrae: 24 pre-sacral vertebrae (7 cervical (C), 12 thoracic 
(T), and 5 lumbar (L)) followed by the sacrum (5 fused sacral (S) vertebrae) and the coccyx 
(4 fused coccygeal vertebrae) (see Figure 2.2). The spinal cord originates at the caudal end of 
the medulla oblongata and sits within the spinal vertebra before terminating above the 
foramen magnum to the level of L1/2. The spinal cord acts as a major conduit for motor, 
sensory and autonomic neural information. Injury to the spinal cord therefore results in a 
complex, lesion level dependent challenge to the cardiovascular, respiratory, digestive and 
42 
 
  
Figure 2.2. Schematic diagram of autonomic cardiovascular (CV) control in individuals with 
a spinal cord injury (SCI). Adapted from Krassioukov and West, (2014). 
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skeletal muscle systems. Evidently the higher the lesion level, the greater the loss of 
functional muscle mass and autonomic control (Haisma et al., 2006; Leicht et al., 2013a). 
Injury at a thoracic, lumbar or sacral level is commonly referred to as paraplegia and causes 
lesion level dependent damage to the neural elements within the spinal canal resulting in loss 
of motor and/or sensory function of the trunk, pelvic area and lower limbs (Maynard et al., 
1997). The upper limbs remain functional in individuals with paraplegia. Injury at a cervical 
level is commonly referred to as tetraplegia and results in the additional loss of motor and/or 
sensory function in the upper limbs. A SCI can be further classified as complete (no sensory 
or motor function below the lesion level), or incomplete (partial preservation of sensory 
and/or motor function below the lesion level and preserved function in the lowest sacral 
segments (S4 and S5) known as ‘sacral sparing’). 
2.4.2. Consequences of a SCI 
A SCI results in a range of dysfunctions that extend beyond muscle paralysis. 
Importantly, the autonomic dysfunction that occurs consequently leads to cardiovascular, 
respiratory, bladder and bowel, thermoregulatory and/or sexual dysfunction (Krassioukov & 
West, 2014). Discussion of the consequences of SCI in their entirety is beyond the scope of 
this thesis however, the reader is directed towards a number of detailed reviews on such 
topics (Hou & Rabchevsky, 2014; Krassioukov & West, 2014; Price, 2006; West et al., 2012). 
The current thesis will focus on the consequences most directly linked to the potential 
ergogenic effect of caffeine in individuals with a SCI; autonomic, cardiovascular and 
gastrointestinal dysfunction, and changes to skeletal muscle and body composition. 
2.4.3. Autonomic and cardiovascular function 
The autonomic nervous system (ANS) has two components: sympathetic and 
parasympathetic, both of which innervate the majority of visceral organs including the heart 
and bronchial pulmonary tree (Krassioukov & Weaver, 1996). Under normal conditions in 
AB individuals the sympathetic and parasympathetic systems interact to produce a balanced 
regulation of the innervated organs (Krassioukov, 2009).  The sympathetic component is 
commonly referred to as the ‘fight or flight’ and the parasympathetic component produces the 
‘rest and digest’ response. A complete SCI disrupts the pathways from the brain to the 
peripheral sympathetic nervous system and therefore disrupts cardiovascular, respiratory, 
metabolic, urinary, gastrointestinal, sexual and thermoregulatory function. 
The loss of sympathetic tone and subsequent blood pooling in the peripheral and 
splanchnic vasculature in individuals with cervical and high-thoracic SCI results in 
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bradycardia and low resting arterial blood pressure (Hou & Rabchevsky, 2014; Krassioukov, 
2009) (see Figure 2.2). These individuals will face the daily challenge of managing an 
unstable blood pressure which can result in two serious conditions: orthostatic hypotension 
(OH) and autonomic dysreflexia (AD). An episode of OH is observed as a sustained (3 min) 
decrease in systolic/diastolic blood pressure of greater than 20/10 mmHg, respectively upon 
the assumption of an upright posture from a supine position (Freeman Somers, 2010). 
Whereas an episode of AD is characterised as an increase in systolic blood pressure of at least 
20 mmHg (Krassioukov,  2009) and occurs following noxious or non-noxious stimuli below 
the SCI lesion level. The sudden uncontrolled increase in blood pressure can be caused by a 
variety of stimuli including bladder and bowel distention, spasms, pressure sores, urinary 
bladder catheterisation or something as trivial as a stone in the shoe or laces tied too tight 
(Krassioukov & Weaver, 1996). Self-induced AD, known as ‘boosting’, is unethical and 
deemed illegal by the International Paralympic Committee however; it has been reported that 
some wheelchair athletes induce AD voluntarily to enhance exercise performance 
(Bhambhani et al., 2010).  
The heart has dual innervation: parasympathetic from the vagal nerve and sympathetic 
from T1-5 (Krassioukov, 2009). Bradycardia therefore occurs in individuals with a SCI above 
T6 where there is a loss of direct sympathetic outflow to the heart (see Figure 2.2) (Wecht et 
al., 2015). The influence of lesion level is observed with peak HRs of 181(10) and 127(10) 
beats·min-1 in trained wheelchair athletes with motor complete paraplegia and tetraplegia, 
respectively (Paulson et al., 2013b). Innervation of the adrenal medulla (primary source of 
catecholamine release) derives from T5-9 and hence individuals with cervical and high-
thoracic SCIs show reduced adrenaline and noradrenaline responses at rest and during 
exercise compared to AB controls and individuals with lower SCI lesion levels (Paulson et al., 
2013b; Schmid et al., 1998; Van Soeren et al., 1996; see Table 2.5). Catecholamine 
concentrations have a wide-ranging impact on physiological responses such as HR, blood 
pressure and glycolytic flux. Reductions in blood volume, muscle pump action below the 
lesion level, and sympathetically mediated vasoconstriction limit both cardiac preload and 
ventricular filling (Krassioukov & West, 2014). The consequent volume unloading may be 
responsible for the cardiac decline observed in individuals with cervical or high-thoracic SCI 
(Wecht et al., 2015).  
Physical capacity can be described as ‘the capacity of the cardiovascular system, 
muscle groups and the respiratory system to provide a level of physical activity’ (Haisma et 
al., 2006). The physical capacity of individuals with a SCI is limited due to the loss of 
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functional muscle mass and diminished sympathetic control below the lesion level (Hoffman, 
1986). Unsurprisingly, peak oxygen consumption and other physiological parameters such as 
peak [Bla], HR and ventilation rates are inversely related to lesion level (Bhambhani, 2002). 
A review by Haisma et al. (2006) reported mean V̇O2peak values of 1.51 and 0.87 L·min-1 in 
individuals with paraplegia and tetraplegia, respectively during maximal arm crank 
ergometry. Anaerobic capacity and strength measures also show decreases which are lesion 
level dependent whereby trained individuals with low-level paraplegia can produce 
comparable upper-body muscle strength measures to those of AB individuals (Janssen et al., 
2002; Phillips et al., 2000). 
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Table 2.5. Studies related to the effects of caffeine supplementation on catecholamines, glucose, lactate, free fatty acids (FFA) and respiratory 
exchange ratio (RER). 
 
Note. AB=able-bodied, FES=functional electrical stimulation, PARA=individuals with paraplegia, TETRA, individuals with tetraplegia and TTE=time to exhaustion. 
Publication Participants Protocol Caffeine protocol Adrenaline Noradrenaline Blood glucose 
[GLU] & lactate 
[Bla] concentration 
FFA RER 
Van Soeren et 
al. (1996) 
6 TETRA 
2 PARA  
3 h rest 6 mg∙kg-1 
 
Unaffected ↑ in PARA only Unaffected ↑ Unaffected 
Mohr et al. 
(1998) 
7 TETRA  
2 PARA 
Rest & FES 
TTE 
6 mg∙kg-1 
60 min prior to 
exercise 
Unaffected Slight increase 
after 15 min FES 
Unaffected 
 
↑after 60 min 
rest & 15 min 
FES 
Unaffected 
Battram et al. 
(2007) 
14 TETRA 60 min rest  4 mg∙kg-1 
 
Unaffected n/a Unaffected 
 
↑ n.s n/a 
Flueck et al. 
(2015) 
17 AB 
10 PARA 
7 TETRA 
3 min all-out 
arm crank test 
6 mg∙kg-1  
60 min prior to 
exercise 
↑ in AB only ↑ in AB only [Bla] unaffected in 
AB/PARA  
↑ [Bla] in TETRA 
post-ex 
n/a n/a 
Graham & 
Spriet, (1991) 
7 AB trained 
runners 
2 x cycling TTE 
2 x running TTE  
9 mg∙kg-1 
60 min prior to 
exercise 
↑ at rest & 
during exercise 
Unaffected at rest 
or during exercise 
↑ [Bla] 
[GLU] unaffected 
Unaffected Unaffected 
Van Soeren et 
al. (1993) 
7 AB users 
7 AB non-
users 
1 h cycling at 
50% V̇O2max  
5 mg∙kg-1  
60 min prior to 
exercise 
 
Unaffected at 
rest.  
2-fold ↑ in users 
vs. non-users 
during exercise 
Unaffected  ↑ [Bla] during 
exercise in users 
[GLU] unaffected 
↑ at rest only  
 
Unaffected 
Jackman et al. 
(1996) 
14 AB rec. 
active 
2 x 2 min cycle 
V̇O2max with 
6 min rest & a 
TTE at V̇O2max 
6 mg∙kg-1  
60 min prior to 
exercise 
 
↑ at rest &  
during exercise 
Unaffected ↑ [Bla] (n.s)  
↑ muscle lactate 
concentration 
n/a n/a 
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2.4.4. Gastrointestinal function 
Cervical SCI above the level of sympathetic outflow to the GI tract disturbs normal 
interdigestive antral-duodenal motor coordination and delays postprandial GE of liquid meals 
(Fealey 1984; Segal 1995) (Figure 2.3). The impact of different SCI lesion levels on 
autonomic voluntary control of bladder and bowel function requires the sacral spinal cord 
(S2-4) to remain intact to allow communication with the brain. Hence, the majority of 
individuals with a SCI do not have spontaneous bladder and bowel movements. 
The alterations in physiological and metabolic functions in individuals with a SCI mean that 
the fundamental pharmacokinetics derived from AB individuals cannot be directly translated 
(Mestre et al., 2011). Consequently the standard dose and schedule for some drugs therefore 
do not achieve the required therapeutic effects or alternatively, they may produce drug 
concentrations that are toxic (Mestre et al., 2011). Treatment protocols for this heterogenic 
population must therefore be altered to help optimise absorption, distribution, metabolism 
and excretion.  Delayed GE and intestinal motility may influence the absorption of drugs 
and/or NS in individuals with a SCI (Mestre et al., 2011).  
Oral ingestion is a common drug administration method in a SCI population and yet it 
may not be the most effective due to impaired GI motility. Slower gastric, intestinal and 
colonic peristalsis may slow the rate at which the drug is transported to the site of absorption. 
The absorption of some drugs such as theophylline has been investigated (Segal 1986). 
Theophylline is a methylxanthine drug, which is structurally and pharmacologically similar to 
caffeine and is commonly used by individuals suffering from respiratory diseases to help 
relax the bronchial smooth muscle. When consumed orally by individuals with tetraplegia 
decreased bioavailability (fraction of dose of unchanged drug to reach the circulation) was 
apparent compared to individuals with paraplegia and a control group (Segal 1986). This 
reduced bioavailability could lead to incorrect dosage recommendations in individuals with 
tetraplegia and therefore patterns of absorption of specific drugs may need to be explored in 
this population. 
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Figure 2.3. The influence of spinal cord injury (SCI) lesion level on sympathetic and parasympathetic innervation related to the gastrointestinal 
and urinary system. Adapted from Tortora and Grabowski, (2003). Note: C=cervical, GE=gastric emptying, GI=gastrointestinal, S=sacral, 
T=thoracic
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2.4.5. Skeletal muscle and body composition 
A SCI causes inactivation and consequently results in unloading of skeletal muscle 
which causes a number of changes. There is a rapid decline in the cross-sectional area (CSA) 
of muscle in the paralysed lower limbs of individuals with a SCI (Castro et al., 1999; Olive et 
al., 2003). Intramuscular fat also increases after SCI (Gorgey et al., 2015), which has been 
linked to impaired glucose tolerance (Elder et al., 2004). Spungen et al. (2003) reported total 
body percent lean tissue losses of 2.4 and 3.0% per decade for males with paraplegia and 
tetraplegia, respectively compared to age, height, and ethnicity-matched AB controls in 
which a 1% loss was reported.  
Following the decline in leg muscle CSA, there is a change in the distribution of 
muscle fibre types (McCully et al., 2011). Within the first 6 months post-injury, it has been 
noted there are minimal changes to the relative CSA and myosin heavy chain (MHC) content 
of type I fibres but there is a transformation of type II fibres whereby type IIa decreased and 
type IIx increased (Castro et al., 1999; Talmadge et al., 2002). The muscle fibre type changes 
in the leg lead to a reduction in oxidative metabolism, evidenced by ~50% reduction in 
mitochondrial function in individuals with paraplegia compared to AB individuals (McCully 
et al., 2011). Reductions in capillary-to-fibre ratio have also been reported to be lower 
compared to AB controls (Martin et al., 1992). However, larger reductions in type I fibres are 
seen in individuals 1-9 y post-injury (Greve et al., 1993; Rochester et al., 1995; Round et al., 
1993). The utilisation of electrical stimulation of the lower limbs can help prevent the decline 
in type I muscle fibres and oxidative enzyme activity (Martin et al., 1992).  
In the arm however, the opposite appears to occur; increases in type I and reductions 
in type IIb muscle fibres have been reported (Schantz et al., 1997). Percentage of type I 
muscle fibres in the deltoid of individuals with paraplegia were 59 and 55% for untrained and 
trained participants, respectively (Schantz et al., 1997). The untrained and trained participants 
with tetraplegia had a substantially greater percentage of type I muscle fibres with 66 and 
82%, respectively (Schantz et al., 1997). Despite the acute impact of a SCI, adaptations to 
muscle fibre type distribution, capillarisation, and oxidative and glycolytic enzyme levels 
following training are similar to those reported in AB individuals (Biering-Søerensen et al., 
2009; Schantz et al. 1997). 
The consequence of a loss of lean body mass (LBM) is directly reflected in the resting 
metabolic rate of individuals with a SCI (Monroe et al., 2011). Hence, the higher the lesion 
level and the longer time since injury (TSI) (and presumably a reduction in lean mass / 
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increase in fat mass (FM)), the greater the reduction in basal EE (Mollinger et al., 1985). 
Reductions in metabolic rate, changes in diet and limited mobility in individuals with a SCI 
lead to changes in body composition. Lower total fat-free mass (FFM), greater upper-limb 
FFM and higher total FM are observed in individuals with a SCI (Beck et al., 2014; Maggioni 
et al., 2003) compared to AB participants. The greater FFM seen in the upper-limbs is likely 
due to the use of the arm musculature during daily wheelchair propulsion. These alterations 
in body composition below the lesion may be associated with carbohydrate intolerance, 
insulin resistance and lipid abnormalities (Bauman & Spungen, 2001; Elder et al., 2004). 
Paralysis and immobility, leading to the aforementioned adaptations in body composition 
leave individuals with a SCI at increased risk of the adverse consequences associated with 
reduced physical activity levels and obesity such as metabolic syndrome (Nelson et al., 2007). 
The assessment of body composition in individuals with a SCI is more difficult than in 
AB populations. A number of measurements use assumptions based on a cross section of the 
population that may not be valid for individuals with a SCI. For example, the equations used 
by Durnin and Womersley (1974), and Jackson and Pollock (1978) do not incorporate a 
lower limb measurement and therefore do not account for the increased regional adiposity in 
this area following a SCI. The use of dual-energy x-ray absorptiometry (DXA) offers greater 
accuracy when measuring body composition in individuals with a SCI compared to other 
field-based assessments such as bioelectrical impedance analysis, skinfolds and waist 
circumference (Goosey-Tolfrey et al., 2016; Willems et al., 2016). A DXA scan measures the 
soft tissue by the attenuation of FM to FFM, and the use of a meat calibration technique 
enables it to bypass traditional assumptions for fat content assessment (Spungen et al., 1995). 
A DXA scan does not provide three-dimensional imaging, as magnetic resonance and 
computed tomography techniques do, but it is more accessible, simpler, cheaper and produces 
lower radiation levels (Sutton et al., 2009). For this reason DXA has become the gold 
standard for body composition assessment in individuals with a SCI (Sutton et al., 2009). 
Additional methodologies independent of traditional assumptions, validation of existing 
methods and the development of specific population equations for individuals with a SCI 
have been a topic of interest recently (Goosey-Tolfrey et al., 2016; Willems et al., 2016) yet 
still require further exploration with larger sample sizes. 
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2.5. Modes of exercise 
2.5.1. Physiological responses to lower- and upper-body exercise 
Studies comparing LBE and UBE have reported different physiological responses 
during submaximal and maximal exercise (Bobbert, 1960; Sawka, 1986). Peak oxygen uptake 
responses during UBE (e.g. handcycling or arm cranking) are ~70% of those obtained during 
LBE (e.g. cycling) (Bottoms et al., 2015; Sawka & Pandolf, 1991). For example, Black et al. 
(2015) reported ·VO2 peak values of 3.1 and 2.3 l·min-1 in recreationally active AB participants 
during leg and arm cycling, respectively. These lower values for UBE are due to the lower 
oxygen extraction in the arms compared to the legs, which is attributed to the smaller 
diffusional surface area, less capillarisation and shorter oxygen transit time (Calbet et al., 
2005; Pendergast 1989; Volianitis et al., 2004). The arms also possess a smaller muscle CSA 
compared to the legs which results in a smaller oxidative capacity and a reduced muscle force 
potential (Pendergast 1989; Pimental et al., 1984). Improvements in V̇O2peak associated with 
UBE training are attributed to an increase in arm blood flow, a larger extraction of oxygen 
via a higher capillary surface area, and improved oxidative metabolism (Hooker et al., 1989; 
Pendergast et al., 1979; Volianitis et al., 2004).  
Cardiac output is similar during LBE and UBE but how this is achieved differs 
greatly; UBE results in a greater HR and lower stroke volume at any given absolute 
submaximal intensity (Bottoms et al., 2015; Davies & Sargeant, 1974; Pimental et al., 1984). 
This likely reflects a greater sympathetic outflow (increased HR) and a reduced lower-body 
skeletal muscle pump (reduced stroke volume) (Bevegard et al., 1966). The gross mechanical 
efficiency (GME: derived from the ratio between external PO and internal energy liberation) 
is lower during UBE compared to LBE (Sawka, 1986). The anaerobic threshold therefore 
occurs at a lower mode-specific oxygen uptake: 46.5% and 58.6% ·VO2 peak for arm cranking 
and leg cycling, respectively (Davis et al., 1976). Exercise at the same relative load results in 
higher carbohydrate and lower fat oxidation in the arms compared to the legs (Helge, 2008). 
Consequently, UBE is associated with larger lactate release than LBE at comparable exercise 
intensities (Jensen-Urstad & Ahlborg, 1992; Killerich et al., 2008; Mizuno et al., 1990). 
There also appear to be fewer type I muscle fibres in the arms (triceps brachii/deltoid = 32-
54%) compared to the legs (vastus lateralis/gastrocnemius = 52-69%) (Killerich et al., 2008; 
Mizuno et al., 1990; Mygind, 1995), and type II muscle fibre area is reported to be larger in 
the triceps brachii compared to the gastrocnemius (Mizuno et al., 1990). The distribution of 
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muscle fibre type in the arms may be dependent on training status and level of SCI (Gollnick 
et al., 1972; Schantz et al., 1997), which will in turn influence a person’s ability to perform 
UBE and the type of substrate utilised (Astorino & Harness, 2009; Knechtle et al., 2004). 
These aforementioned factors highlight that whole- or LBE research on the effects of NS 
cannot necessarily be directly translated to UBE.  
2.5.2. Wheelchair propulsion, arm crank ergometry and handcycling 
Individuals with lower limb impairments (e.g. SCI, cerebral palsy or lower limb 
amputations) are often dependent on manual wheelchair propulsion, which means a transfer 
from leg to arm work for daily ambulation (Woude et al., 2005). Participation in sports such 
as wheelchair basketball, rugby and tennis also require the use of a manually propelled 
wheelchair. Due to the discontinuous and complex movement patterns required during 
wheelchair propulsion, the GME is low and rarely exceeds 11% (Dallmeijer et al., 2004; 
Hintzy et al., 2002; Lenton et al., 2008). For reference, the GME of leg cycling is ~20% in 
trained and recreational cyclists (Hopker et al., 2007). Since wheelchair propulsion is 
inefficient and is of a repetitive nature it often leads to pain, discomfort and repetitive strain 
injury (Woude et al., 2001). An individual’s GME during wheelchair propulsion can however 
be improved with training (de Groot et al., 2002).  
Other less straining and more efficient modes of exercise used for fitness or for sports 
training include arm cranking (GME ~14-15%; Hopman et al., 1995) and recreational 
handcycling (GME ~13%; Hettinga et al., 2013). The latter is easily accessible using an 
attachment for the daily use handrim wheelchair to form a three-wheeled handcycle (see 
Figure 2.4). The use of asynchronous arm cranking has therefore been recommended as an 
alternative mode of ambulation to help reduce the risk of overuse injuries (Martel et al., 1991; 
Woude et al., 2001). The sport of handcycling also allows individuals to achieve higher 
speeds and therefore cover longer distances compared to wheelchair propulsion (Hettinga et 
al., 2010). The majority of modern handcycles now employ synchronous propulsion which 
produces constant application of force throughout the propulsion cycle. Consequently, due to 
athletes’ adopting this technique while in an aerodynamic supine position in the handcycle 
(Figure 2.5), GME in trained individuals has been reported as ~21% (Goosey-Tolfrey et al., 
2008). Handcycling is therefore an effective mode of exercise to improve an individual’s 
physical capacity; four months of handcycle training resulted in significant increases in      
POpeak (123 to 141 W; p<0.001) and ·EVO2E Apeak (1.98 to 2.11 l·min-1; p=0.002) in individuals 
53 
 
with a physical impairment (Hoekstra et al., 2016). Furthermore, A ·EVO2E Apeak values of ~2.3(0.5) 
l·min-1 have been reported in trained handcyclists (7.7(2.6) h·wk-1 handcycle training) with 
paraplegia (T2-8) (Fischer et al., 2015).  
The employment of untrained, AB participants has been used as a model of novice 
wheelchair users and handcyclists previously (Hettinga et al., 2016; Paulson et al., 2013a). 
Experienced manual wheelchair users display higher GME (8-11%) than novice users (4-
8%), which highlights the need to familiarise and habituate participants to allow 
improvements in co-ordination and force production prior to experimental trials (Brown et 
al., 1990; Dallmeijer et al., 2004; Lenton et al., 2008). Findings cannot be directly applied to 
the wheelchair user population, particularly for individuals with a high level SCI. Yet the 
application of novice, AB participants reduces confounding factors of UBE training, 
wheelchair propulsion experience and upper-limb pain within research design. Experimental 
findings from the study of AB individuals can, where appropriate be extended to novice and 
experienced wheelchair users and handcyclists for verification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Arm crank ergometer set-up in a laboratory (a) and an attachment for the daily 
use handrim wheelchair to form a three-wheeled handcycle (b). 
 
 
 
 
a. b. 
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Figure 2.5. Synchronous handcycle testing set-up on the Cyclus II ergometer. Photos 
courtesy of Phil Wilson. 
 
2.5.3. Assessment of upper-body exercise performance 
Assessment of UBE performance is important to enable the measurement of physical 
capacity of individuals taking part in UBE sports. Reliable and valid test protocols also allow 
the assessment of NS such as caffeine on exercise performance. Determination of UBE 
maximal aerobic responses during arm crank ergometry (ACE) and handcycling utilise 
similar protocols to LBE tests with adaptations to the initial and incremental PO values (Price 
& Campbell, 1997; Smith & Price, 2007). Maximal ACE tests have been reported to reliably 
determine A ·EVO2E Apeak (Price & Campbell, 1997). A crank rate of 60 or 70 rev·min-1 can reliably 
determine UBE A ·EVO2E Apeak in AB participants and a verification phase is not deemed necessary 
(Price & Campbell, 1997). Wheelchair propulsion testing (usually in a sport-specific 
wheelchair) can also be performed in the laboratory on an ergometer or a wide belt treadmill 
and will follow similar protocols whereby participants will complete constant load exercise 
bouts at ascending velocities or gradients (Goosey-Tolfrey et al., 2014b; Paulson et al., 
2013a; West et al., 2015).   
Given the smaller muscle mass involved during UBE, and due to some individuals not 
having UBE-specific training there is a tendency for peripheral fatigue and consequent early 
cessation of exercise during maximal UBE (Smith & Price, 2007). Traditional criteria 
for A ·EVO2E Amax attainment such as i) RER >1.00-1.15 or ii) 90-100% HRpeak are not necessarily 
appropriate during UBE (Leicht et al., 2013b). The maximal HR achieved during UBE is 
~10-20 beats·min-1 lower than during LBE because of the smaller active muscle mass (Hill & 
Price, 2016; Janssen & Hopman, 2005). The use of HR as a secondary criterion is also less 
useful in individuals with a high-level SCI (>T6) due to the interruption of sympathetic 
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pathways to the heart which limit cardioacceleration (Janssen & Hopman, 2005). Hence, in 
the absence of a plateau, A ·EVO2E A secondary criteria must be adjusted based on the participant 
pool.  
Other anaerobic and sport-specific UBE tests that have been used to assess the impact 
of NS on performance include ACE Wingate tests (Aedma et al., 2013) and maximal 
performance tests (Flueck et al., 2015 (3 min maximal test); Spendiff & Campbell, 2005 (20 
min performance trial)). There are also a number of validated field-based tests such as the 6 
or 4 min push tests (Cowan et al., 2012; West et al., 2014), multi-stage fitness tests 
(Vanderthommen et al., 2002), TTs (Flueck et al., 2014), and sprint, skill and agility tests 
(West et al., 2014; Yilla & Shirrel, 1998). For a review of field-based exercise testing see 
Goosey-Tolfrey & Leicht, (2013).  
2.6. Summary 
The use of NS is common in the AB athlete population and a large body of evidence 
exists exploring their potential ergogenic properties. One such NS is caffeine, which has been 
extensively researched during various short and long-term exercise protocols involving 
whole- or LBE in AB individuals. A recent review of nutritional strategies to increase 
exercise performance highlighted caffeine as a NS with considerable evidence behind its 
effectiveness (Close et al., 2016). The review however, did not include any insight into the 
effectiveness of caffeine during UBE. 
The physiological responses to whole- and LBE differ to those of UBE (Pendergast, 
1989), and it is therefore debatable whether the findings of caffeine studies during the 
different modes of exercise are transferable. The current research exploring the use of 
caffeine as an ergogenic aid during UBE is limited (Table 2.4) and has focused mainly on 
strength exercise. Hence, no conclusions can currently be drawn regarding caffeine’s 
effectiveness during short-term, high-intensity or endurance UBE protocols.  Further UBE-
specific investigations employing non-strength-related exercise protocols are therefore 
required.  
To the authors knowledge only two studies have previously explored the impact of 
caffeine on performance in individuals with a physical impairment (SCI and spina bifida) 
(Flueck et al., 2015; 2014). The findings indicate individual responses to the NS, which may 
be related to SCI lesion level (Flueck et al., 2015). The further complications of a SCI (e.g. 
reduced active muscle mass, slower GI transit times, changes in muscle fibre type distribution 
56 
 
and an impaired catecholamine response) highlight the need for impairment-specific 
investigations into the impact of caffeine on UBE performance.  
The proceeding experimental chapters therefore aim to answer the following questions: 
• What type of NS are used, how and why are they used, and who do athletes with a 
physical impairment consult for advice regarding NS use? (Chapter three) 
• Do the effects of caffeine differ between LBE and UBE performance in the same 
participants? (Chapter four) 
• Does caffeine improve short-term, high-intensity (Chapter five) and endurance 
(Chapter four and seven) UBE performance? 
• Does the rate of caffeine absorption in individuals with paraplegia and tetraplegia 
differ to AB individuals at rest? Do AB guidelines need to be adjusted for individuals 
with a SCI? (Chapter six)  
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3  
Study 1: Nutritional supplement habits of athletes 
with an impairment and their sources of 
information. 
 
 
This chapter has been published in a slightly modified form in International Journal of Sport 
Nutrition and Exercise Metabolism: 
 
Graham-Paulson, T.S., Perret, C., Smith, B., Crosland, J. & Goosey-Tolfrey, V.L. (2015). 
Nutritional supplement habits of athletes with an impairment and their sources of 
information. International Journal of Sport Nutrition and Exercise Metabolism, 25(4), 
387-395.  
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3.1. Abstract 
The consumption of NS is common among AB athletes yet little is known about NS 
use by athletes with an impairment. This study aimed to examine the: (i) prevalence of NS 
use by athletes with an impairment; (ii) reasons for use/ non-use; (iii) sources of information 
regarding NS; and (iv) whether age, gender, impairment, performance level and sport 
category influence NS use. The questionnaire was completed by 399 elite (n=255) and non-
elite (n=144) athletes (296 males, 103 females) online or at a sporting event/training camp. 
Data were evaluated using chi-square analyses. Fifty-eight percent (n=232) of athletes used 
NS in the previous 6-month period and 41% (n=102) of these followed the instructions on the 
label to determine dose. Adherence to these AB recommendations may partly explain why 
9% (n=37) experienced negative effects from NS use. As expected, the most popular NS 
were: protein, carbohydrate-electrolyte sports drinks, multivitamins and carbohydrate 
supplements, which were obtained from health food/sport shops, the internet and 
supermarkets (top 3) where evidence-based, impairment-specific advice is limited. The 
nutritionist/dietitian was the most used and trusted source of information, which is a 
promising finding. The most prevalent reasons for use were to support exercise recovery, 
support the immune system and provide energy. Elite athletes were more likely to use NS, 
which may reflect greater training hours and/or access to nutritionists. Fifty-two percent of 
athletes (n=209) requested more information and education regarding NS. NS use is prevalent 
in this population and therefore education on dosage and appropriate sources of information 
is required. 
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3.2. Introduction 
It is widely accepted that nutrition can influence exercise performance (Rodriguez et 
al., 2009) and that it should be integrated into an athlete’s programme to fully capitalise on 
their athletic potential (Broad, 2014). Likewise, the use of some NS, defined by the Dietary 
Supplement Health and Education Act of 1994 as ‘any product intended to supplement the 
diet’, may have the ability to improve sporting performance (Maughan et al., 2004). It is 
therefore unsurprising that the consumption of NS is common among AB athletes (Braun et 
al., 2009; Erdman et al., 2006; Sundgot-Borgen et al., 2003). With the increased popularity of 
disability and Paralympic sport in recent years there is a need to also understand the 
nutritional practices of athletes with an impairment. That said few studies have focused on 
the nutritional requirements and behaviours of athletes with a physical impairment (Bertoli et 
al., 2006; Goosey-Tolfrey & Crosland, 2010; Krempien & Barr, 2012; Rastmanesh et al., 
2007). The only study to investigate the NS habits of Paralympic athletes (Athens 2004 
Paralympic Games), revealed that vitamins (43.5%), minerals/electrolytes (16.1%) and 
proteins/amino acids (10.5%) were most commonly consumed (Tsitsimpikou et al., 2009). 
This study however failed to report the athletes’ reasons for NS use or the sources of 
information they consulted.  
The nutritional requirements for AB athletes are almost certainly not directly 
transferable to athletes with a physical impairment (Broad, 2014). For example, athletes who 
use a wheelchair utilise a smaller working muscle mass during movement, which will lead to 
lower energy requirements than those of AB athletes (Glaser, 1985). Furthermore, within this 
population there are likely to be a wide range of requirements based on individual impairment 
characteristics, including level and completeness of SCI (Goosey-Tolfrey et al., 2014a). In 
cases where a wheelchair is used for mobility, there may be considerable muscle atrophy in 
the lower limbs, leading to a lower resting metabolic rate, and in turn, a further reduction in 
daily energy expenditure (Goosey-Tolfrey & Sutton, 2012; Goosey-Tolfrey et al., 2014a). To 
prevent unwanted weight gain, energy intake must be correspondingly reduced. This lower 
total food intake could encourage a reliance on vitamin and mineral supplementation to meet 
micronutrient needs. In addition, there are practical issues to consider associated with food 
preparation. For example, individuals with an upper-limb amputation or visual impairment 
may have difficulties accessing, purchasing or preparing food (Meyer & Edwards, 2014), and 
some individuals with cerebral palsy may use NS to overcome feeding difficulties (Crosland 
& Boyd, 2014). Athletes’ reasons for NS use may therefore reflect a nutritional requirement 
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and hence some NS may be viewed as ‘essential’ rather than ‘optional’ in some 
circumstances.  
The number of NS available on the market continues to increase despite insufficient 
supporting scientific evidence (Abel et al., 2005; Jeukendrup & Randall, 2011) and many are 
ineffective despite their widespread use (Maughan et al., 2004). There is currently very little 
evidence regarding the effects of ergogenic aids and macronutrient-providing NS in athletes 
with a physical impairment (Tables 2.1 and 2.4). This raises concern given the potential for, 
or more acute sensitivity to, side-effects in some sportspeople with a physical impairment 
(Van de Vliet et al., 2011). The potential risks associated with NS use in AB athletes such as 
inadvertent doping and unknown concentrations of active ingredients have been well-
researched (Molinero & Márquez, 2009) and are acknowledged by the authors; however, this 
will not be the central theme of this study. 
The use of NS is often a personal choice made by the athlete and/or in conjunction 
with their dietitian/nutritionist, ideally following a full cost-benefit analysis. Previous AB 
research shows that athletes are often more likely to report the use of family members, 
themselves, coaches and fellow athletes than more informed sources such as registered 
dietitians/nutritionists (Dolan et al., 2011; Froiland et al., 2004; Krumbach et al., 1999). The 
sources of information used by athletes with an impairment are currently unknown despite 
the importance of impairment-specific advice. Therefore, the objectives of this study were to 
determine the: (i) prevalence of NS use by athletes with an impairment; (ii) reasons for use/ 
non-use; (iii) sources of information regarding NS; and (iv) whether age, gender, impairment, 
performance level and sport category influence NS use.  
3.3. Methods 
3.3.1. Participants 
A total of 399 athletes (74% male, 26% female) across five impairment categories 
(42% SCI, 19% amputation, 18% Les Autres, 11% CP and 10% VI), 28 sports and 21 
Nationalities (44% British, 17% American and Canadian, 13% Swiss, 11% other, 8% 
German, 6% Brazilian) completed the questionnaire. Athletes were aged 18-24 (24%), 25-30 
(24%), 31-35 (18%), 36-40 (12%), 41-45 (9%) and 46+ (13%) years, and reported weekly 
average training hours of 0-5 (17%), 6-10 (30%), 11-15 (23%), 16-20 (20%) and 21+ (10%) 
h. Sixty four percent (n=255) and 36% (n=144) of athletes reported playing at an elite 
(currently represent their country Nationally or Internationally) and non-elite (train and 
compete for a club, regional or development team) performance level, respectively. Seventy-
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nine percent of athletes completed the questionnaire online (n=317) and the remainder 
completed a paper version (n=82). 
3.3.2. Survey instrument and survey procedure 
A self-designed questionnaire which was developed by six professionals (a dietitian, a 
qualitative scientist and sport nutritionists/ scientists) and tested for reliability using 
McNemar and Cronbach’s Alpha tests in a representative sample (n=10; p(range)=0.582-
1.000, with the exception of one question where p=0.125).  It included; i) 12 closed and 9 
open-ended; ii) 10 multiple-choice; iii) 7 Likert-type rating scale; and iv) 2 ranking questions. 
The questionnaire captured data pertaining to individual characteristics (e.g. age, gender, 
sport participation, impairment etc.), NS habits, reasons for NS use/ non-use and sources of 
information. The questionnaire took approximately 20 minutes to complete electronically or 
on paper. A copy of the questionnaire can be viewed in Appendix A and was made available 
in English, French, German, Portuguese and Spanish. The study was approved by the 
University Research Ethics Committee and informed consent was provided prior to 
completion of the questionnaire.  
Participants were recruited during the 2012-13 athletic season at training 
camps/competitions across a variety of sports (e.g. Wheelchair Rugby/Tennis/Basketball, 
Sitting Volleyball and Athletics) in Great Britain, Canada, America, Switzerland and 
Germany following event organisers’ approval. Despite unsuccessful attempts to gather 
information from Powerlifting, Swimming and Boccia events, the investigators distributed 
links to the online questionnaire through their own network of coaches, sport scientists and at 
the International Paralympic Congress to widen the participant pool.  
Athletes with a VI were aided by one of the authors to complete the questionnaire 
where necessary. Since the questionnaire was developed without consideration of athletes 
with an intellectual impairment, only athletes with a physical or visual impairment, over 18 
years of age, who regularly took part in disability or Paralympic sport were included. Sighted 
guides were excluded. 
In order to maintain the accuracy of participant responses, a 6-month recall period 
was set. For the purpose of this questionnaire the term ‘nutritional supplement’ was defined 
as ‘any product intended to supplement the diet, provide nutrients and/or improve 
performance.’ Examples of health-related and performance-enhancing NS were provided, and 
reported NS were categorised prior to analysis (Table 3.1). Categories were based on the 
macro- and micro-nutrient components i.e., ‘carbohydrate supplements’ contained 
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predominantly carbohydrate for the purpose of providing energy, ‘protein’ contained 
predominantly protein for the purpose of power, strength, muscle building etc.; whereas 
‘recovery’ contained both carbohydrate and protein for the purpose of recovery. 
3.3.3. Statistical analysis 
The Statistical Package for the Social Sciences version 20 software (SPSS Inc., 
Chicago, IL) was used to analyse the data. All descriptive data are presented as frequencies 
(%, n). Data were evaluated by age, gender, impairment, performance level and sport 
category (intermittent, speed and power, endurance, skill-based) (Table 3.2)) using chi-square 
(χ2) analyses. Where appropriate, data were subsequently interpreted using odds ratios. 
Significance was determined at p<0.05.  
3.4. Results 
3.4.1. Nutritional supplement habits 
In total, 58% of athletes (n=232) used NS in the previous six months. The use of 
multiple NS was commonplace with 33%, 30%, 15%, 8%, 6% and 8% reporting the use of 1, 
2, 3, 4, 5 or 6 different types of NS, respectively. Forty percent (n=259) of NS consumed 
were used daily (at least 4-5 times per week), 36% (n=231) were used before/during/after 
training, 6% (n=38) were competition-specific, with only 2% (n=13) used rarely. Other 
options were ‘unknown’ (10%), ‘reason-specific’ (3%) and ‘weekly’ (2%). 
The most popular health-related NS were multivitamins, other health-related NS (e.g. 
aloe vera, coenzyme Q10, mushroom extract, evening primrose oil and chromium) and 
essential fatty acids; and the most popular performance-enhancing NS were protein, 
carbohydrate–electrolyte sports drinks and carbohydrate supplements (Figure 3.1). Caffeine 
was the most used NS (5%) beyond any macronutrient providing NS such as sports drinks 
and protein. The three most common outlets where athletes obtained NS were the 
supermarket (23%, n=71), internet (22%, n=67) and health food/sports shop (21%, n=65); 
others included pharmacy, sports nutritionist/dietitian and team sponsor. The most prevalent 
reasons reported for use/ non-use of NS are reported in Table 3.3.  
When NS users were asked ‘How do you decide how much of a supplement to take?’, 
102 (41%) followed the (AB) recommendations on the label/manufacturers website, 60 
(24%) were told by a sports nutritionist/dietitian, 35 (14%) calculated it based on their body 
mass, 22 (9%) were unsure and 32 (13%) indicated ‘other’ (e.g. ‘doctor’s advice’, ‘how I 
feel’, ‘a third of the recommended as I have roughly a third of body function’, ‘half the 
63 
 
instructions,’ and ‘trial and error’). Nine percent of all athletes (n=37) reported having 
experienced a negative effect from using NS such as GI/digestive problems (protein, 
carbohydrate–electrolyte sports drinks/gels, creatine, cherry juice, beetroot juice), itchiness 
(beta-alanine) and palpitations (caffeine).  
3.4.2. Comparisons by age, gender, impairment, performance level and sport category 
Whether an athlete used NS did not differ by age (p>0.05). However, when the two 
oldest categories were combined, those over 41 y were most likely to use multivitamins 
compared to the younger age categories (p<0.05). Whether an athlete used NS or which type 
they used did not differ between gender (p=0.661) or impairment (p=0.489). Of note 
however, 9% of athletes (14 of 152) with a SCI reported using cranberry.  
Elite athletes trained significantly more hours per week (p<0.05) and odds ratio 
analysis revealed they were 1.6 times more likely to use NS than non-elite athletes. Elite 
athletes were significantly more likely to use multivitamins, amino acids and carbohydrate–
electrolyte sports drinks compared to non-elite (p<0.05). There was a significant association 
(p<0.05) between sport category and whether an athlete used NS. Individuals who took part 
in predominantly endurance sports were most likely to use carbohydrate–electrolyte sports 
drinks, carbohydrate supplements, protein, multivitamins and NS in general, compared to 
those in skill-based, intermittent or speed/power sports (p<0.05). Figure 3.2 indicates the use 
of NS within the sport categories. Caffeine was used mostly by wheelchair court sports, 
cycling, athletics and goalball athletes. 
2.4.3. Sources of information 
Athletes ranked sports nutritionist/dietitian (18%, n=155), coach (14%, n=122) and 
training partner/athlete (13%, n=114) as their top three sources of information. When asked 
who provided the most trusted source (top 3), athletes chose the sports nutritionist/dietitian 
(24%, n=248), doctor/medical professional (21%, n=214) and coach (12%, n=128). Other 
sources included friends/family, physiotherapist, supplement/health food store, evidence-
based/scientific journals and books/magazines. Elite athletes had greater access to 
nutritionists/dietitians (60%, n=153) compared to non-elite (22%, n=31). Fifty-two percent of 
athletes (n=209) would like more information and education regarding NS. The type of 
information sought by athletes is shown in Figure 3.3.  
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Table 3.1. Nutritional supplement categories and frequency of use. 
Category Types of nutritional supplement included Frequency ((%) (n)) 
Carbohydrate–
electrolyte sports 
drinks 
Isotonic and hypotonic drinks/powders 20% (81) 
Carbohydrate Energy drinks (>10% carbohydrate), carbohydrate 
gels and energy bars 
13% (53) 
Protein Protein bars, powders and ready-to-drink shakes 
(<20 g carbohydrate per serve) 
26% (102) 
Recovery Products containing carbohydrate (>20 g 
carbohydrate per serve) and protein to aid recovery 
6% (25) 
Caffeine Any product containing caffeine/guarana as an 
active ingredient 
5% (20) 
Buffering agents Beta-alanine, sodium bicarbonate, sodium citrate 2% (7) 
Amino acids Any amino acids/BCAAs e.g. leucine, glutamine, l-
carnitine 
8% (31) 
Creatine Any pure creatine products 4% (16) 
Combination Products containing carbohydrate and/or protein, 
and other ingredients e.g. vitamins 
3% (13) 
Essential fatty 
acids 
Omega 3 and 6 fish oils/cod liver oil 8% (30) 
Joint care Glucosamine and chondroitin 4% (14) 
Multivitamin Multivitamins 14%(55) 
Probiotics Probiotics 2% (9) 
Vitamin C Vitamin C only 4% (17) 
Vitamin 
D/calcium 
Vitamin D and/or calcium only 5% (20) 
Iron  Iron 2% (7) 
Cranberry  Cranberry tablets/extract/capsules 4% (15) 
Herbal  Any product containing herbal ingredients e.g. 
Echinacea, turmeric, arnica 
3% (18) 
Unknown (health 
or performance) 
If a product’s content could not be identified it was 
recorded as unknown  
1% (2) health 
3% (10) performance 
Other (health or 
performance) 
Products which do not fit into the other categories 
were recorded as other  
10% (38) health 
3% (11) performance 
Note: Total number of supplements reported = 594. 
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Figure 3.1. Frequency distribution for the type of nutritional supplement used. 
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Table 3.2. Sport grouping according to the nature of the sport (n=399). 
Group Sports 
Intermittent Badminton (3), Football (16), Sitting Volleyball (26), Sledge Hockey (15), Wheelchair 
Basketball (48), Wheelchair Tennis (39), Wheelchair Rugby (80), Wheelchair Flag Football 
(1) 
Speed/power Athletics (Field/Sprint) (6), Goalball (20), Kickboxing (1), Paracanoeing (2), Paraclimbing 
(1), Rowing (4), Swimming (17), Powerlifting (2), Alpine Skiing (8) 
Endurance Biathlon (1), Cycling (24), Paratriathlon (23), Athletics (mid-long distance running) (26) 
Skill-based Archery (1), Boccia (4), Equestrian (3), Shooting (6), Table Tennis (7), Wheelchair Curling 
(7), Wheelchair  Dance (1), Wheelchair Fencing (7) 
Values reported as frequency (n). 
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Table 3.3. Reasons for use and non-use of nutritional supplements. 
Reasons for use of performance-
enhancing NS (%, n)) 
Reasons for use of health-related NS 
(%, n)) 
Reasons for non-use of NS (%, n)) 
Support exercise recovery (32%, 224) Support  immune system (32%, 114) I don’t know enough about them 
(30%, 77) 
Provide energy (28%, 200) Medical need/deficiency (22%, 80) I don’t need them (25%, 65) 
Increase strength/power (20%, 142)  Inadequate diet (11%, 40) I am concerned about a positive 
drugs test (18%, 47) 
Note: Athletes could select as many responses as were applicable. Reasons in the health-related ‘other’ category included anti-inflammatory, joint care, I thought I’d give it a go, heart health, to help promote lean 
body mass, and to support female reproduction. Total number of supplements reported = 594.  
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Figure 3.2. Frequency distribution of nutritional supplement use within sport categories.  
69 
 
 
Figure 3.3. Frequency distribution for the type of information sought by athletes who 
indicated they would like more information/education regarding nutritional supplements and 
anti-doping.  Note: Athletes were able to select multiple responses where applicable.  
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3.5. Discussion 
3.5.1. Nutritional supplement habits 
This study demonstrates that a wide-variety of NS are currently being used across a 
range of disability and Paralympic sports, and that 58% of athletes surveyed used NS in the 
previous six months. To our knowledge the only other study to investigate the use of NS by 
athletes with an impairment reported that 64% of athletes tested for doping control at the 
Athens 2004 Paralympic Games declared the use of medications and food supplements (58% 
and 42%, respectively) (Tsitsimpikou et al., 2009). Interpretation of these data would suggest 
that 27% of all athletes tested used at least one food supplement, which is less than half that 
reported in the current study. The higher reported NS use in the current study may reflect an 
increase in i) NS use over the previous decade, ii) the popularity and availability of NS, 
and/or iii) the training load/demand placed on the modern day athlete. 
The prevalence of NS use in the current study was at the lower end of that reported by 
elite and collegiate AB athletes where 51-88% reported the use of NS (Dascombe et al., 
2010; Erdman et al., 2006; Sundgot-Borgen et al., 2003). Thus, this supports the observations 
of Tsitsimpikou et al. (2009), who found Paralympians to use a more rational intake pattern 
compared to their Olympic counterparts. However, the lower reported use in the current study 
may also reflect a non-homogenous sample that included elite and non-elite athletes, which 
when separated suggests that more elite athletes used NS than non-elite. The lower reported 
use may also reflect a lack of knowledge regarding their effectiveness, side-effects and the 
dosage recommendations for this specific population given that 52% indicated they would 
like more information on these topics.  
The most common NS were similar to those reported by the Athens 2004 Paralympic 
athletes (vitamins, minerals/electrolytes and proteins/amino acids) (Tsitsimpikou et al., 2009) 
but also included carbohydrate–electrolyte sports drinks. Previous research has shown that 
some athletes do not consider calorie/fluid replacement products as NS (Froiland et al., 2004) 
and may therefore fail to report them as such. The addition of carbohydrate–electrolyte sports 
drinks in the current study may reflect its inclusion on the list of NS examples. The 
prevalence of some macro- and micronutrient-providing supplements such as carbohydrate–
electrolyte sports drinks, protein and multivitamins appears to be lower in this population of 
athletes with an impairment compared to AB athletes; used by 20%, 26% and 14% in the 
current study. Kristiansen et al. (2005) reported the use of sports drinks, protein and 
vitamins/minerals by 87%, 51% and 52% of male varsity athletes. Similarly, Froiland et al. 
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(2004) reported the use of energy drinks, protein and multivitamins by 73%, 48% and 47% of 
varsity athletes. Potential reasons for these differences may include; i) some athletes with an 
impairment may be more aware of eating a well-balanced diet for health reasons and 
therefore may not deem multivitamins and protein supplements necessary, ii) some 
individuals may be aware of their lower daily EE and therefore avoid sports drinks and 
protein supplements which provide additional energy to help prevent weight gain, iii) athletes 
may lack an understanding of the role that sports foods can play in improving performance/ 
training capability, and iv) some athletes with an impairment may not understand their 
training needs and how NS may support their training goals compared to weight management 
goals which are common in a rehabilitation setting. Caffeine was the most used NS beyond 
any that provided a macronutrient. The 5% of athletes with an impairment that reported using 
caffeine is very low compared to AB sports such as cycling (60%) and track and field 
athletics (33%) since its removal from the WADA prohibited list in 2004 (Chester & Wojek, 
2008). This low frequency of use may be related to a lack of knowledge of the benefits of 
caffeine for sports performance compared to daily use as a ‘stimulant’. 
Athletes used various methods to calculate NS dosage but 41% indicated that they 
follow the (AB) instructions on the label/manufacturers website. The NS dose for some 
individuals with a SCI, amputation or CP may need to be adjusted from the AB 
recommendations due to a reduced active muscle mass, or the potential side-effects that may 
occur. The use of AB guidelines may therefore have been a contributing factor to the 9% that 
experienced side-effects having consumed a NS. It is encouraging that a number of athletes 
did however indicate that they use a proportion of the recommended dose, or adapt the dose 
based on personal experience. Given the nature of a questionnaire we cannot be sure whether 
these adaptations are the athlete’s decision or those of a nutritionist/dietitian. Although there 
are no specific recommendations for NS dosage, some individuals may be aware of emerging 
evidence regarding the segmental body composition (obtained via DXA) of athletes with a 
SCI (Goosey-Tolfrey & Sutton, 2012) and also the energy requirements of some disability 
sports (Abel et al., 2008). This type of evidence provides some basic information on which to 
base NS dosage recommendations, however, further research is required.  
It may be concerning that the internet (22%) was a popular place to obtain NS. 
Previous research suggests that there are issues with NS being improperly tested, containing 
substances not declared on the label and/or not containing significant amounts of the active 
ingredients listed on the label (Geyer et al., 2004; Kohler et al., 2010; Maughan, 2005). A 
lack of regulatory controls on the internet may increase the likelihood of inadvertent doping 
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when purchasing products in this manner. Unfortunately in some countries, these problems 
also occur with products bought over-the-counter or in stores. The nature of the questionnaire 
means we cannot be sure if athletes checked whether the products they purchased were 
regularly tested for prohibited substances (e.g. via Informed-Sport) but it does suggest that 
‘where to obtain NS’ should be a topic of education for these athletes. This topic is usually 
included in National Anti-Doping education sessions for elite funded athletes.  
3.5.2. Reasons for nutritional supplement habits 
Athletes reported similar reasons for the use of performance-enhancing NS (support 
recovery, support the immune system, to improve strength/power and to provide energy) and 
non-use (I don’t know enough about them and I don’t need them) to those of AB athletes 
(Froiland et al., 2004; Neiper, 2005). The most popular health-related answer in the current 
study was ‘to support the immune system’ (32%). This is understandable given the depressed 
immune function experienced by individuals with a SCI (Leicht et al., 2013a), who formed a 
large proportion of the athletes (42%). The top reason for non-use was ‘I don’t know enough 
about them’ (30%), which suggests that NS information may be either unavailable, 
inaccessible or the athletes are not interested. One athlete’s reason for non-use was ‘I take 
enough medication as it is’. The use of medication by Paralympic athletes’, highlighted by 
Tsitsimpikou and colleagues (2009), may help to explain the lower reported use of NS by 
athletes with an impairment because they do not want to take anything beyond what they 
need to maintain health.  
3.5.3. Comparisons by age, gender, impairment, performance level and sport category 
There was no influence of age on whether an athlete used NS. However, individuals 
46+ y were more likely to use ‘other health supplements’ and when the upper two age 
categories were combined, individuals >41 y were more likely to use multivitamins. The 
increased use by older athletes has not been seen in previous AB literature because it is rare 
to find a group of athletes in this age category. Older athletes may feel the need to consume 
NS such as multivitamins to maintain health and this may be heightened in athletes with an 
impairment if their diet is restricted in some way. 
A number of AB studies show that female athletes tend to use more NS than males 
(Froiland et al., 2004; Krumbach et al., 1999; Neiper, 2005; Ziegler et al., 2003). This can 
partly be explained by the fact that females may be more aware of their nutritional needs and 
that their actual need for certain micronutrients may be heightened due to their gender 
(Neiper, 2005). In contrast there was no influence of gender on NS use in the current study 
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(59% male; 56% female). Zeigler et al. (2003) reported that female AB elite figure skaters 
were more likely to use multivitamin-minerals than their male counterparts. In aesthetic 
sports such as figure skating low energy intakes are common, especially in females, and 
multivitamins may be used to help maintain overall diet quality. This difference may not have 
been apparent in the current study because both male and female athletes may reduce their EI 
due to their impairment and therefore feel the need to consume a multivitamin to meet their 
micronutrient needs. 
There was no significant influence of impairment on NS use however, 9% of athletes 
with a SCI reported the use of cranberry supplements which is likely due to the perceived 
prevention of urinary tract infections which are common in this population (Dermen et al., 
2014). The limited evidence available however, shows that cranberry supplements are 
ineffective at preventing and/or treating urinary tract infections (Opperman, 2010).  
It is well-documented that AB athletes report the use of more NS than the general population 
(Erdman et al., 2006, Sobal & Marquart, 1994). The current study supports ‘level of 
performance’ as a key indicator of NS use because elite athletes were 1.6 times more likely to 
use them. The significant positive association between training hours and performance level 
may help to explain the greater use by elite athletes. The energy requirements of greater 
training hours may influence an athlete’s (perceived) need for NS. Elite athletes also had 
greater access to nutritionists/dietitians and may thus have more knowledge regarding NS for 
performance or enhanced training capacity, and therefore the confidence to use them. 
The energy requirements of an endurance athlete may also influence their use of NS. 
Heikkinen et al. (2011) found that endurance and speed/power athletes reported the use of NS 
significantly more often than team sport athletes. This partly agrees with the finding that 
athletes who took part in endurance sports in the current study were most likely to use 
carbohydrate–electrolyte sports drinks, carbohydrate supplements, protein, multivitamins and 
NS in general.  
3.5.4. Sources of information 
Knowledge of where athletes seek advice regarding NS is essential to devise and 
implement educational strategies (Erdman et al., 2006). Athletes in the current study reported 
the use of similar sources of information as AB athletes (Erdman et al., 2006; Froiland et al., 
2004; Krumbach et al., 1999) and the top three were sports nutritionist/dietitian, coach and 
training partner/athlete. Registered nutritionists/dietitians should be knowledgeable and 
trustworthy sources; however, athletes and even coaches may lack the desired level of NS 
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knowledge. The coach-athlete relationship however, puts the coach in a unique position to 
influence his/her athlete’s diet, which emphasises the need to educate coaches regarding 
issues pertaining to the use of NS. It also highlights that there may be a need to educate 
athletes themselves on who is a knowledgeable source. It is clear that impairment-specific 
information and education regarding NS for this population is required, with 52% of all 
athletes indicating they would like more.  
When the question was rephrased to ask ‘who the most trusted sources of information 
are’ the athletes’ replaced training partner/athlete with doctor/medical professional (top 3). 
This change may be due to regular consultations/visits regarding their impairment, 
medication or secondary complications, and the on-going relationship that may develop as a 
result. Despite being trustworthy, doctors/medical professionals do not necessarily possess 
the area-specific expertise to advise athletes on their use of NS for sport and should therefore 
be educated on how to deal with these questions should they arise. 
Direct athlete education should be provided through sources of information that they 
trust and already use e.g. sports nutritionists/dietitians and coaches. Education regarding 
impairment-specific advice should therefore be directed at these professions. This type of 
information could be included within the coach education curriculum to make future 
disability sport coaches more aware of potential questions that may arise and who to contact 
for advice. Any impairment specific advice and information on NS for athletes should also be 
made available to a wider audience online through organisations such as WADA, National 
governing bodies and sport science/nutrition/medicine providers. 
3.5.5. Limitations 
As with all questionnaire-based data, the results of the current study rely on the 
honesty, recall, and self-report accuracies of athletes. An alternative to using an open-ended 
approach would be to prompt athletes with a list of common NS to choose from (Erdman et 
al., 2006), which may help reduce recall error. We appreciate the limitations of a 6-month 
recall period and that a longer survey period (i.e. 12 months) or biannual reporting may 
provide a more accurate representation of seasonal NS usage. However, the accuracy of recall 
and/or participant adherence may be reduced.  
3.6. Conclusion 
This study provides previously unknown information regarding NS habits and sources 
of information used by athletes with an impairment. Fifty-eight percent of those surveyed 
used NS. Athletes with an impairment appear to require and more importantly want more 
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information and advice regarding NS. Ultimately, further impairment-specific NS 
investigations are required in order to provide evidence-based recommendations. 
The current chapter confirms the use of caffeine as an ergogenic aid in athletes with 
an impairment. Caffeine was the most used NS beyond any macronutrient providing NS such 
as sports drinks and protein, and hence it warrants further investigation in the following 
experimental chapters. 
3.7. Practical applications 
For the sports practitioner working with athletes with a physical or visual impairment 
it is important to understand that NS use is common in this population and that they may face 
questions on this topic. It is therefore vital to ensure athletes and practitioners are well 
educated on their use of NS to ensure practices are safe and effective. The current study 
indicated that education should be delivered directly to athletes and/or through those they 
trust e.g. sports nutritionists/dietitians and coaches. Education topics should include 
impairment-specific information (where available) regarding effective and safe NS and doses, 
where to buy NS and who to use as a source of information.  
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4  
Study 2: Improvements in cycling but not 
handcycling preloaded 10 km time trial performance 
in habitual caffeine users 
 
 
This chapter has been published in a slightly modified form in Nutrients: 
 
Graham-Paulson, T.S., Perret, C. & Goosey-Tolfrey, V.L. (2016). Improvements in cycling 
but not handcycling 10 km time trial performance in habitual caffeine users. 
Nutrients, 8(7), E393.  
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4.1 Abstract 
Caffeine supplementation during whole-/lower-body exercise is well-researched, yet 
evidence of its effect during UBE is equivocal. The current study explored the effects of 
caffeine on cycling/handcycling 10 km TT performance in habitual caffeine users. Eleven 
recreationally trained males (mean(SD) age 24(4) y, body mass 85.1(14.6) kg, 
cycling/handcycling A ·EVO2E Apeak 42.9(7.27)/27.6(5.1) ml∙kg∙min-1, 160(168) mg·d-1 caffeine 
consumption) completed two maximal incremental tests and two familiarisation sessions. 
During four subsequent visits, participants cycled/handcycled for 30 min at 65% mode-
specific A ·EVO2E Apeak (preload) followed by a 10 km TT following the ingestion of 4 mg∙kg-1 
caffeine (CAF) or placebo (PLA). Caffeine significantly improved cycling (2.0(2.0)%; 16:35 
vs 16:56 min; p=0.033) but not handcycling (1.8(3.0)%; 24:10 vs 24:36 min; p=0.153) TT 
performance compared to PLA. The improvement during cycling can be attributed to the 
increased power output during the first and last 2 km during CAF. Higher [Bla] was reported 
during CAF compared to PLA (p<0.007) and was evident 5 min post-TT during cycling 
(11.2(2.6) and 8.8(3.2) mmol·L-1; p=0.001) and handcycling (10.6(2.5) and 9.2(2.9) mmol·L-
1; p=0.006). Lower overall RPE were seen following CAF during the preload (p<0.05) but 
not post-TT. Lower peripheral RPE were reported at 20 min during cycling and at 30 min 
during handcycling, and lower central RPE was seen at 30 min during cycling (p<0.05). 
Caffeine improved cycling but not handcycling TT performance. The lack of improvement 
during handcycling may be due to the smaller active muscle mass, elevated [Bla] and/or 
participants’ training status. 
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4.2. Introduction 
Low-moderate doses of caffeine (3-6 mg∙kg-1) have been shown to positively 
influence cycling TT performance (Astorino et al., 2012; Santo et al., 2014). During cycling 
the leg musculature provides the speed-generating force. However, there are numerous sports 
and activities such as kayaking, handcycling, double-poling and wheelchair sports during 
which the arms produce this force. It is apparent that NS such as caffeine are commonly used 
in both AB (Braun et al., 2009; Erdman et al., 2006) and disability sports (Chapter three), 
including many that involve UBE. The physiological responses to whole- and lower-body 
exercise (LBE) differ to those of UBE (Pendergast, 1989), and it is therefore debatable 
whether the findings from the aforementioned cycling studies are transferable to an UBE 
sport such as handcycling.   
Caffeine is proposed to influence central nervous system (CNS) function by acting as 
an adenosine receptor (most likely A1 and A2A) antagonist (Davis et al., 2002; Fredholm et 
al., 1999). Antagonism reduces the influence of adenosine and produces motor-activating and 
arousing effects. Caffeine can therefore have a positive influence on subjective feelings such 
as RPE, mood and cognitive performance (Doherty & Smith, 2005; Smit & Rogers, 2000). 
Lower RPE during submaximal exercise have been reported following caffeine ingestion, 
and/or similar RPE when a higher workload has been achieved (Cureton et al., 2007; 
Stadheim et al., 2013). Caffeine has also been shown to produce hypoalgesic effects during 
submaximal cycling in male and female participants (Motl et al., 2006; O’Connor et al., 
2004). It has been suggested that the inhibition of adenosine receptors following caffeine 
ingestion could also influence neuromuscular function (Kalmar, 2005; 1999). It is likely that 
a combination of factors contribute to improved endurance performance but with caffeine’s 
influence on the CNS in mind, a similar ergogenic benefit could be expected during UBE as 
has been reported during LBE. However, the evidence for a positive influence of caffeine 
during UBE remains equivocal. 
An 8 km double-poling TT performance lasting ~34 min was enhanced following the 
consumption of 6 mg∙kg-1 caffeine in regular caffeine users (Stadheim et al., 2013). Double-
poling is considered primarily to be an UBE however; the trunk and legs also play a role in 
the performance of this technique. On the other hand, when LBE and asynchronous UBE 
were directly compared in very low caffeine users (<40 mg/d) during a preloaded 10 min all-
out performance trial (40 min total exercise time), caffeine (5 mg∙kg-1) improved LBE but 
failed to statistically impact UBE in a mixed AB group (Black et al., 2015). The opposing 
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results may be linked to differences in the exercise testing protocols, caffeine dose, training 
status of the participants’, or the participants’ level of habitual caffeine consumption. The 
contrasting responses may also be due to a number of factors related to the physiology of the 
leg and arm muscles. Firstly, the arms possess a smaller muscle CSA and hence a reduced 
absolute muscle force. Arm muscles may possess a higher percentage of fast-twitch muscle 
fibres (Mizuno et al., 1990; Mygind, 1995) and have a lower oxygen extraction capacity 
compared to the legs (Calbet et al., 2005; Pendergast, 1989). The onset of anaerobic 
metabolism during UBE therefore occurs at a lower level of oxygen uptake, and lactate 
concentrations are reported to be higher than during a comparable bout of LBE (Cerretelli et 
al., 1979; Pendergast, 1989). These factors can be altered with training however (Gollnick et 
al., 1972) and may help explain differences between performance outcomes in recreationally 
active participants (Black et al., 2015) and those that are specifically UBE trained (Stadheim 
et al., 2013). 
It has been previously reported that caffeine increases muscular strength (maximal 
voluntary contraction) and motor unit recruitment in the knee extensors but not in the elbow 
flexors (Black et al., 2015; Warren et al., 2010). These observations may help to explain the 
lack of performance improvement during short-term UBE in AB participants (Aedma et al., 
2013). The influence of caffeine on longer UBE endurance performance however, requires 
further investigation given the protocols of Stadheim et al. (2013) and Black et al. (2015) 
both allowed involvement of the trunk to some extent to produce force yet report opposing 
effects. Black et al. (2015) also used a mixed male and female participant pool of very low 
caffeine users (<40 mg·d-1), which makes their findings less applicable to the many 
competitive athletes who consume caffeine regularly. Therefore, the purpose of the current 
study was to explore the effects of caffeine on both LBE and UBE endurance performance. 
The study will employ an ecologically valid LBE and UBE endurance protocol whereby male 
habitual caffeine users will complete preloaded (30 min at 65% A ·EVO2E Apeak)  10 km TTs 
following the ingestion of caffeine and placebo. Importantly they will adopt a synchronous 
handcycling modality for the UBE aspect, which is akin to the sports of handcycling and the 
cycling discipline of Paralympic triathlon. 
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4.3 Methods 
4.3.1. Participants 
Eleven recreationally active, healthy males (age 24(4) y, body mass 85.1(14.6) kg, 
lower and upper body relative A ·EVO2E Apeak 42.9(7.3 and 27.6(5.1) ml∙kg∙min-1) participated in the 
current study. Caffeine users, with average daily caffeine intake 160(168) mg.d-1 were 
recruited to represent the usual dietary habits of athletes. All procedures were approved by 
the University’s Ethical Advisory Committee and performed in accordance with the 
Declaration of Helsinki. All participants provided written informed consent and none 
revealed contraindications for participating in the study. 
4.3.2. Experimental design 
The study employed a double-blind, placebo-controlled, repeated measures design. 
Participants attended the laboratory on eight separate occasions which consisted of a A ·EVO2E Apeak 
test, a familiarisation and two (caffeine and placebo) experimental trials (Figure 4.1) for both 
cycling and handcycling. Familiarisation sessions aimed to limit a potential learning effect. 
Familiarisation procedures were the same as the experimental procedures described in Figure 
4.1 with the exception of capsule consumption and blood sampling. Experimental trials were 
separated by ≥48 h and were conducted at the same time of day within participants (07:30-
09:30) to avoid any influence of circadian rhythm (Drust et al., 2005). 
4.3.3. Equipment 
The cycling trials were performed on a Viking Jetstream 14 road bike and the 
handcycling trials were performed on a Draft handbike (operating in synchronous crank 
mode). Both pieces of equipment were mounted on a Cyclus II ergometer (Avantronic 
Richter, Leipzig, Germany). Bike settings were individually adjusted and standardised for 
each participant across trials (Figure 2.5). The differentiated Borg 6-20 RPE scale (Borg, 
1998) was explained to participants prior to the commencement of preliminary trial testing. 
4.3.4. Preliminary testing 
On separate occasions, participants performed incremental cycling and handcycling 
tests until exhaustion to determine mode-specific A ·EVO2E Apeak. The ergometer was set in power 
control mode, which ensured a pre-set power output (PO) was automatically regulated 
independent of cadence or gear selection by continuous adjustment of the degree of 
electromagnetic braking. The participants’ performed a 5-min warm-up at a self-selected 
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pace. The continuous step tests consisted of 3-min submaximal stages with an initial load of 
70 W for the cycling and 20 W for the handcycling test. Increments of 30 W for the cycling 
and 10 W for the handcycling test were then applied. Participants reported differentiated RPE 
scores at the end of each stage and upon completion. [Bla] were determined using a Biosen 
C-Line (EKF Diagnostic GmbH, Barleben, Germany) at the end of each stage from earlobe 
capillary blood samples. When the participant’s [Bla] increased beyond 4 mmol·L-1 the 
resistance was increased by 5 W every 15 s until volitional exhaustion (failure to maintain a 
cadence of ≥50 rpm following 2 warnings and an overall RPE=19-20). Secondary criteria 
included RER >1.15 and/or a HRpeak > (220-age)-20. Online respiratory gas analysis was 
carried out via a breath by breath system (MetaLyzer 3B, Cortex Biophysik GmbH, Leipzig, 
Germany). Prior to each test, gases were calibrated according to the manufacturer’s 
recommendations. The highest 30 s rolling average A ·EVO2E Avalue was used as the 
participant’s A ·EVO2E Apeak and HR was monitored continuously (Polar RS400, Polar, Kempele, 
Finland).  
4.3.5. Experimental trials 
Participants refrained from exercise, caffeine and alcohol consumption in the 24 h 
preceding each trial, as previously utilised [23]. They completed 24 h dietary diaries prior to 
the first experimental trial and were asked to replicate their diet for all subsequent trials. 
Participants were asked to consume a self-selected standardised meal 1.5 h prior to arriving at 
the laboratory, which was noted upon arrival (62(10)% carbohydrate, 18(9)% protein, 20(9)% 
fat) and replicated prior to all subsequent trials.  
The experimental trials involved the consumption of either 4 mg∙kg-1 caffeine 
anhydrous (CAF) (My Protein, Northwich, UK) or dextrose placebo (PLA) capsules (Bulk 
Powders, Colchester, UK) 45 min prior to the warm-up. A 4 mg∙kg-1 caffeine dose has 
previously increased [CAF] to 14.6 µM, 50 min post-ingestion (Skinner et al., 2010) and was 
therefore deemed suitable for the current study. The protocol can be seen in Figure 4.1 and is 
based on that used previously to assess the effects of glucose ingestion on UBE performance 
(Spendiff & Campbell, 2002). The preload and TT provide information on the effect of 
caffeine on physiological parameters and performance, respectively. Previous data show 
preloaded and unloaded TTs to be highly reproducible with CVs of 3.5 and 3.4%, 
respectively (Jeukendrup et al., 1996). Participants were instructed to complete the 10 km TT 
in the shortest time possible, during which they could change gear at any time. Cycling 10 km 
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TTs have been shown to be reproducible in active and endurance-trained participants with a 
coefficient of variation of 1.5% for performance time (Astorino et al., 2012). No motivation 
was provided during the TT and to avoid test-retest influence the only feedback provided was 
cumulative distance covered. Experimental trial conditions were temperature 19.7(1.1)°C, 
pressure 1004(11) hPa and humidity 52(12)%.  
The 6-20 RPE scale (Borg, 1998) was used as a measure of perceived exertion during 
exercise at 10, 20 and 30 min during the preload, and post-TT. Participants were asked for 
three RPE scores: peripheral (muscle and joint exertion) (RPEP), central (ventilatory and 
circulatory exertion) (RPEC) and overall (integrated) (RPEO).  
4.3.6. Statistical analysis 
Statistical Package for the Social Sciences version 20 software (SPSS Inc., Chicago, 
IL) was used to analyse the data. Normal distribution was confirmed using the Shapiro-Wilk 
test and consequently [Bla], performance times, HR, PO, respiratory exchange ratio (RER) 
and A ·EVO2E A data are reported as mean(standard deviation) (SD). Repeated measures analysis of 
variance (ANOVA) was used to examine differences in [Bla], and preload HR, RER and PO. 
Post-hoc paired samples t-tests using the Bonferroni correction were applied following 
significant findings. Ten km TT performance was also analysed using a repeated measures 
two-way ANCOVA, with time and treatment as within participant factors and trial order as a 
covariate. Cohen’s d ESs are included to supplement important findings. An ES of 0.2 was 
considered small, 0.5 moderate and 0.8 large (Cohen, 1992). One-way ANOVAs with 
habitual caffeine intake (low, moderate, high users) as a factor were also employed. 
Nonparametric ordinal RPE data are reported as median (quartiles) and were analysed using 
Friedman and Wilcoxon tests. Statistical significance was accepted at p<0.05.  
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Figure 4.1. Schematic outline of the preloaded time trial (TT) experimental protocol. R=rest, WU=warm-up, HR=heart rate and RPE=ratings of 
perceived exertion.  
84 
 
4.4 Results 
4.4.1. Performance tests 
Caffeine significantly improved 10 km TT performance during cycling by 2.0(2.0)% 
compared to PLA (ES=0.4, p=0.033) (995(46) s and 1016(58) s, respectively). Ten (of 11) 
participants cycled faster during CAF (Figure 4.2). Participants (7 of 11) also handcycled 
1.8(3.0)% faster during CAF compared to PLA (1450(86) and 1476(67) s, respectively) 
(Figure 4.2) however, this failed to reach statistical significance (ES=0.34, p=0.153). The 
CVs were 4.6 and 5.7% for cycling, and 5.9 and 4.3% for handcycling following caffeine and 
placebo, respectively. There was no significant influence of trial order during cycling 
(p=0.164) or handcycling (p=0.298). The PO was significantly greater during CAF compared 
to PLA during cycling only (p=0.003), and this was apparent during the first and last 2 km of 
the TT (p<0.006). Participants’ followed similar pacing strategies during both modes of 
exercise; the second km was completed at the greatest PO, and the final 2 km end-spurt was 
evident (Figure 4.3). There was no influence of habitual caffeine intake on TT performance 
(p>0.470). Participant’s with a handcycling A ·EVO2E Apeak greater than the mean relative value 
(27.6 ml∙kg∙min-1) (n=7, 30.9 ml∙kg∙min-1) improved their handcycling TT performance by 
3.2% whereas those with a A ·EVO2E Apeak less than the mean (n=4, 21.9 ml∙kg∙min-1) had a 0.3% 
reduction in handcycling performance (Figure 4.2).  
A significantly lower relative A ·EVO2E Apeak was recorded during handcycling compared to 
cycling (27.6(5.1) and 42.9(7.3) ml∙kg∙min-1, p=0.001). The target relative exercise intensity 
of the 65% A ·EVO2E Apeak during the preload was matched experimentally with average A ·EVO2E Avalues 
of 64.5(2.5)% during cycling, and 59.7(4.8)% during handcycling but importantly, did not 
differ between mode-specific CAF and PLA trials (p>0.217). Average preload HR and RER 
did not differ between CAF and PLA (p>0.180).  
4.4.2. Blood lactate concentration 
There was a significant increase in [Bla] over time during all trials (p=0.001). This 
was evident between 10 and 20 min during cycling following CAF only (p=0.006), and at 
both 20 and 30 min compared to 10 min during handcycling following both CAF and PLA 
(p<0.005). The TT resulted in a significant increase in [Bla] post-TT and five min post-TT 
during all trials (p<0.017). The ingestion of CAF resulted in significantly higher [Bla] 
compared to PLA during cycling (p=0.001) and handcyling (p=0.007), but differences were 
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only evident post-TT (p<0.012) (Figure 4.4). The handcycling preload (despite a slightly 
lower relative workload) produced significantly greater [Bla] than during cycling regardless 
of trial (p=0.004 and 0.016 during PLA and CAF, respectively). However, there was no 
difference in [Bla] pre-exercise or post-TT between modalities (p>0.134). 
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Figure 4.2. Individual change in 10 km (a) cycling and (b) handcycling time trial (TT) 
performance. Negative bars indicate a reduction in time to complete the TT during caffeine 
(CAF) compared to placebo (PLA). Open/filled bars indicate participants with a A ·EVO2E Apeak 
above (30.9 ml∙kg∙min-1)/below (21.9 ml∙kg∙min-1) the mode-specific mean (27.6 
ml∙kg∙min-1). Participant data are ordered the same in a and b. 
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Figure 4.3. Mean power output (W) throughout the 10 km time trial during (a) cycling and 
(b) handcycling following the consumption of 4 mg∙kg-1 caffeine (CAF) or placebo (PLA). 
*Significantly different from placebo (PLA) (p<0.05). 
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Figure 4.4. Group mean(SD) blood lactate concentrations (mmol·L-1) throughout the 30 min 
preloaded (65% A ·EVO2 E Apeak) 10 km time trial protocol during (a) cycling and (b) handcycling  
following the consumption of 4 mg∙kg-1 caffeine (CAF) or placebo (PLA).  *Significantly 
different from placebo (PLA) (p<0.05). 
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Table 4.1. Overall, central and peripheral ratings of perceived exertion (RPE) at 10, 20 and 30 min during the preload and immediately post-time 
trial (TT).  
  Preload 10 min Preload 20 min Preload 30 min Post-TT 
Overall RPE C PLA 13 (12, 13) 13 (13, 14) † 14 (13, 14) †‡ 19 (17, 20) †‡# 
 C CAF 12 (11, 13) * 13 (12, 14) †* 13 (12, 14) †* 19 (18, 20) †‡# 
 HC PLA 13 (12, 14) 14 (12, 15) † 14 (13, 16) †‡ 19 (18, 20) †‡# 
 HC CAF 12 (11, 13) * 13 (12, 14) †* 14 (12, 15) † 19 (18, 20) †‡# 
Central RPE C PLA 12 (11, 13) 12 (11, 13) † 13 (11, 14) †‡ 18 (17, 20) †‡# 
 C CAF 12 (11, 13) 13 (12, 14) † 13 (12, 14) †‡* 19 (18, 20) †‡# 
 HC PLA 12 (11, 13) 12 (11, 13) † 13 (12, 14) †‡ 17 (16, 18) †‡# 
 HC CAF 11 (11, 12) 13 (11, 13) † 13 (11, 14) † 17 (17, 19) †‡# 
Peripheral RPE C PLA 13 (12, 13) 13 (13, 15) † 14 (13, 16) †‡ 19 (18, 20) †‡# 
 C CAF 13 (11, 13) 13 (12, 14) †* 14 (13, 15) †‡ 19 (17, 20) †‡# 
 HC PLA 14 (13, 15) 15 (13, 16) † 15 (13, 16) †‡ 19 (19, 20) †‡# 
 HC CAF 13 (11, 14) 14 (12, 15) 15 (12, 16) †* 19 (18, 20) †‡# 
Note. Data are median (quartiles). *Significantly different from placebo (PLA), † significantly different from Preload 10 min, ‡ significantly different from Preload 20 min and # significantly different from Preload 30 
min (p<0.05).  
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4.4.3. Subjective measures 
Participant’s RPE responses can be seen in Table 4.1. Only one participant, a low 
caffeine user, experienced side-effects during CAF (cycling), which were reported as feelings 
of sickness post-preload. Only two participants correctly identified the treatment in all four 
trials.  
4.5 Discussion 
This is the first study to assess the effect of caffeine on 10 km TT performance during 
both cycling and handcycling in habitual caffeine users. The main finding was that the 
ingestion of caffeine (4 mg∙kg-1) significantly improved cycling 10 km TT performance, 
whereas the same dose did not statistically improve handcycling performance. This study 
compliments the work of Black et al. (2015) by investigating the influence of caffeine on 
longer-term endurance performance during LBE (~47 vs. 40 min) and UBE (~54 vs. 40 min). 
It also supports a large body of evidence on the positive impact of caffeine on endurance 
cycling performance (Astorino et al., 2012; Black et al., 2015; Cureton et al., 2007; 
McNaughton et al., 2008). 
4.5.1. Preload 
The ingestion of CAF resulted in changes in RPE but not average RER, HR or A ·EVO2E A 
during the submaximal preload, which agrees with earlier studies (Bell & McLellan, 2003; 
Greer et al., 2000). While there was a trend for greater [Bla] during the preload following 
CAF, in contrast to previous steady state exercise data (Black et al., 2015) this did not reach 
significance.  
Recent reviews on caffeine and its ergogenic effects propose the antagonism of 
adenosine receptors as the primary mode of action leading to enhanced performance (Ganio 
et al., 2009; Graham, 2001). This mechanism of action has been shown to influence the CNS 
(Davis et al., 2002) through which perceived pain, effort and fatigue are reduced. The current 
results show caffeine to reduce RPE during constant rate LBE and UBE. During cycling, 
RPEO was lower at all preload time-points and RPEP and RPEC was lower at 20 and 30 min 
following CAF, respectively. During handcycling, RPEO was lower at 10 and 20 min and 
RPEP was lower at 30 min only following CAF. The reduction in perceived effort during the 
preload may have influenced the participant’s effort during the subsequent cycling TT yet 
appears not to have impacted the handcycling TT.  
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The higher [Bla] evident during the handcycling (5.55 and 5.14 mmol·l-1) compared 
to the cycling (3.39 and 2.98 mmol·l-1) preload following caffeine and placebo, respectively 
(Figure 4.4) is likely a consequence of lower oxidative capacity and greater carbohydrate 
utilisation (RER=1.04 vs. 0.98 for handcycling and cycling, respectively). The higher preload 
[Bla] could have influenced subsequent self-paced TT performance and hence a TT with no 
preload may have elicited a different ergogenic response to caffeine but this is unknown. 
Future studies could employ a preload at a percentage of lactate threshold rather than A ·EVO2E Apeak 
to help limit its impact. 
4.5.2. Time trial performance 
The 10 km TT provided data from which the influence of caffeine on endurance 
performance could be assessed in a sport-specific manner. The ingestion of CAF resulted in a 
significant improvement in cycling performance (2.0(2.0)%) compared to PLA, which was 
due to the increased PO during the first and last two km. On the other hand, it failed to 
significantly improve handcycling performance (1.8(3.0)%) and there was large intra-
individual variability. The small ESs (-0.4 and -0.34 for cycling and handcycling, 
respectively) reflect the large standard deviations for both sets of results. Individual responses 
to caffeine supplementation have often been attributed to differing rates of caffeine 
metabolism, which may in turn be linked to training status (Skinner et al., 2014). 
Unfortunately the rate of caffeine absorption and metabolism were not measured in the 
current study. Participant three, who produced the greatest handcycling A ·EVO2E Apeak of the group, 
improved handcycling TT performance by 8.3% following CAF, yet only improved cycling 
TT performance by 0.2%. Aside from the participant displaying a learning effect or having an 
unexplained good/bad performance, a further explanation for some of the inter-individual 
variability may therefore be an individual’s training status. Despite a non-significant finding, 
some sports practitioners would argue that if a 1.8% improvement held true for individual 
elite handcyclists, caffeine could positively impact performance and ultimately influence 
finishing positions in a sport where winning margins are small (~0.5%) (Perret, 2015).  
The ingestion of CAF resulted in higher post-TT [Bla] during both modes of exercise. 
This increase in [Bla] following the ingestion of caffeine is common in the literature during 
both LBE (Bell & McLellan, 2003) and UBE (Stadheim et al., 2013). The increase is 
understandable when seen in conjunction with improved performance such as during the 
current cycling trials, yet remains to be explained when a performance improvement is absent 
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as seen during the handcycling trials. The metabolic responses to exercise differ in arm and 
leg muscles. Arm exercise is physiologically more stressful than leg exercise at a given PO 
and can increase adrenaline concentration, which in turn is a potent stimulant for muscle 
glycogenolysis (Hooker et al., 1990). The arms also have a lower oxygen extraction capacity 
which results in an earlier onset of anaerobic metabolism (~50% and 75% A ·EVO2E Amax during arm 
and leg exercise, respectively) (Pendergast, 1989). Accumulation of [Bla] during the 
handcycling TT, which was further increased during CAF may have limited the participants’ 
ability to improve performance. 
Evidence from biopsy studies suggest that the triceps muscle (an important force 
producing muscle during synchronous handcycling) exhibits a greater proportion of type II 
muscle fibres than the legs (vastus lateralis) (Mizuno et al., 1990; Mygind, 1995). This may 
partly explain a lack of performance improvement during the endurance handcycling TT (~24 
min) during which type I fibres would dominate. Furthermore, type II fibres have been shown 
(in vitro) to be less sensitive to caffeine compared to type I fibres (Mitsumoto et al., 1990). 
Hence performance gains may be less likely following the ingestion of caffeine during 
exercise which relies on the arms (with a lower proportion of type I fibres). Endurance 
training can improve the oxidative capacity of muscle fibres (Gollnick et al., 1972) and hence 
may help to explain the observed handcycling TT improvements following caffeine in those 
that had an above average mode-specific A ·EVO2E Apeak (Figure 4.2). 
Previous research suggests caffeine increases muscular strength (maximal voluntary 
contraction) and motor unit recruitment in the knee extensors but not in the elbow flexors 
(Black et al., 2015; Warren et al., 2010). More and larger muscles are recruited during LBE 
compared to UBE and hence caffeine’s influence on muscle contractility may enhance LBE 
performance to a greater extent.  This potential mechanism is supported by the improvement 
in cycling but not handcycling TT performance in the current study. 
Although RPE was not reduced following the cycling TT, PO was higher during CAF 
suggesting that participants were able to cycle at a higher PO with no change in RPE. This is 
in line with previous literature that has shown caffeine to increase PO for a given RPE during 
a TT (Astorino et al., 2012; Santos et al., 2014).  It has previously been suggested that the 
limitation to maximal UBE is likely due to localised fatigue rather than central circulatory 
factors (Price & Campbell, 1997). At the end of the handcycling preload (30 min) RPEP was 
reduced by CAF but this reduction in perceived arm and shoulder effort did not translate to 
improvements in TT performance. It has been suggested that caffeine is unable to have a 
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hypoalgesic effect during heavy-severe fixed intensity exercise (Black et al., 2015), and the 
same study reported no change in RPE during a 10 min asynchronous UBE performance trial. 
The current study adds further evidence that the reduced RPE and hypoalgesic effects seen 
during submaximal synchronous UBE do not translate to improved performance during a 
maximal performance trial. It is likely that the nociceptive stimuli contributing to the 
peripheral muscle pain during handcycling may be too great for the antagonism of adenosine 
receptors to reduce RPE and pain, and hence are unlikely to translate to improved 
performance. 
The A ·EVO2E Apeak achieved during handcycling was 64% of that achieved during cycling 
(range: 52-83%), which is similar to previous reports (~70%) (Sawka & Pandolf, 1991). The 
lower handcycling A ·EVO2E Apeak is due to the training status of the current participants who were 
not specifically UBE  trained. The use of recreationally trained participants helped to limit 
the potential difference in performance between the cycling modalities and yet meant that 
participants were unfamiliar with the pacing strategies required, especially during 
handcycling. This was evident in that participant’s adopted a similar pacing strategy for both 
modes of cycling (Figure 4.3). Given the smaller muscle mass involved during handcycling 
and the lower UBE training status of the participants, a negative pacing strategy whereby 
speed gradually increases throughout the TT may have been advantageous to prevent early 
RPEp. It is worth noting that those with a relative handcycling A ·EVO2E Apeak above the mean 
improved their handcycling TT performance by 3.2%, which is much closer to the 
handcycling group CVs of 5.9 and 4.3% for caffeine and placebo, respectively. Hence the 
performance improvement seen in these individuals is less likely due to chance. 
Unfortunately further specific repeatability testing would be required to indicate smallest 
worthwhile change for future interventions. Whereas participants with a handcycling A ·EVO2E Apeak 
below the mean had a 0.3% reduction in performance (Figure 4.2). An individual’s training 
status may increase the amount of recruitable muscle mass during maximal exercise and it 
appears to affect how they respond to caffeine during UBE. This theory is supported by 
improvements in swimming velocity (during which a large proportion of the force is 
generated by the upper-body) following the ingestion of caffeine by trained but not untrained 
participants (Collomp et al., 1992). The authors suggested that the intra and/or extracellular 
adaptations resulting from specific training such as improved buffering capacity are 
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necessary to benefit from caffeine during sprint performance (Collomp et al., 1992). The 
current results suggest that this holds true for endurance UBE performance also. 
It has been suggested that one familiarisation session is sufficient for reproducible 
results in recreationally active individuals (cycling A ·EVO2E Apeak = 3.9 compared to 3.6 L·min-1 in 
the current study) completing a preloaded cycling TT (Sewell & McGregor, 2008) but it is 
unknown whether this is also the case for handcycling. That said, there was no statistical 
evidence of a trial order effect on cycling or handcycling performance, which suggests that 
the results cannot be solely attributed to a learning effect. 
4.6 Conclusion 
Pre-exercise ingestion of caffeine (4 mg∙kg-1) significantly improved preloaded 
cycling 10 km TT performance but there was no statistical improvement in handcycling in 
habitual caffeine users. The positive effects of caffeine on cycling performance may be 
related to reductions in RPE during the preload. The lack of a statistical improvement during 
handcycling is possibly due to elevated [Bla] owing to both the mode of exercise and the 
ingestion of CAF. Furthermore, participants’ training status appears to influence the ability of 
caffeine to improve UBE performance.  
4.7 Practical applications 
The results of the current study confirm caffeine’s ergogenic benefits during cycling 
endurance performance in recreationally active AB participants, and moderate doses of the 
supplement can therefore continue to be recommended during this type of event. The use of 
caffeine prior to endurance handcycling on the other hand should be considered further. The 
results suggest that it may be advantageous in more UBE trained individuals (e.g. kayak, 
canoe or wheelchair athletes) but the evidence is still insufficient. Hence, the authors would 
recommend an ‘n=1’ approach whereby a practitioner would investigate the effects of 
caffeine on an individual athlete’s performance quantitatively and qualitatively, as seen in 
Chapter seven. 
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Study 3: Improvement of sprint performance in 
wheelchair sportsmen with caffeine 
  
 
 
 
This chapter has been published in a slightly modified form in International Journal of Sport 
Physiology and Performance: 
 
Graham-Paulson, T.S., Perret, C., Watson, P. & Goosey-Tolfrey, V.L. (2015). Improvement 
of sprint performance in wheelchair sportsmen with caffeine supplementation. 
International Journal of Sport Physiology and Performance, 11(2), 214-220. 
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5.1. Abstract 
Caffeine can be beneficial during endurance and repeated sprint exercise in AB 
individuals performing leg or whole-body exercise. However, little evidence exists regarding 
its effects during UBE. This study therefore aimed to investigate the effects of caffeine on 
sprint and 4 min maximal push (PUSH) performance in wheelchair sportsmen. Using a 
double-blind, placebo-controlled, crossover design, 12 male wheelchair rugby players (age 
30.0(7.7) y, body mass 69.6(15.3) kg, training hours 11.1(3.5) h·wk-1) completed two 
exercise trials, separated by 7-14 d, 70 min after ingestion of 4 mg∙kg-1 caffeine (CAF) or 
dextrose placebo (PLA). Each trial consisted of four 4-min PUSH and three sets of 3x20 m 
sprints (SPR), each separated by 4 min rest. Participants reported Felt arousal (a measure of 
perceived arousal), Feeling (a measure of the affective dimension of pleasure-displeasure) 
and RPE using subjective scales. Salivary caffeine secretion rates were measured. Average 
SPR times were faster during CAF relative to PLA during SPR1 and SPR2 (p=0.037 and 
0.016). There was no influence of supplementation on PUSH2-4 (p>0.099) however, 
participants pushed significantly further during PUSH1 following CAF relative to PLA 
(mean(SD), 677(107) and 653(118) m, p=0.047). There was no influence of CAF on arousal 
or RPE scores (p>0.132). Feeling scores improved over the course of the CAF trial only 
(p=0.017) but did not significantly differ between trials (p>0.167). Pre-warm-up (45 min 
post-ingestion) salivary caffeine secretion rates were 1.05(0.94) and 0.08(0.05) µg·min-1 for 
CAF and PLA, respectively. Acute caffeine supplementation can improve both 20 m sprint 
performance and a one-off bout of short-term high intensity performance in wheelchair 
sportsmen. 
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5.2. Introduction 
Since its removal from the WADA list of prohibited substances in 2004, there has 
been substantial research into the effects of caffeine on exercise performance. Low-moderate 
doses of caffeine (3-6 mg∙kg-1; 210-420 mg for a 70 kg individual) typically ingested 60 min 
before exercise have been shown to have a beneficial effect on both short-term, high intensity 
(Astorino et al., 2010) and endurance (Burke, 2008; Ganio et al., 2009) performance. The 
available evidence on repeated sprint (running) performance also appears to support the use 
of caffeine (Carr & Dawson, 2008; Glaister et al., 2008).  
Caffeine’s effects are wide ranging but a possible mechanism for its ergogenic effect 
relates to its influence on the CNS. Caffeine is a lipid soluble molecule which can pass 
through cell membranes and importantly cross the blood-brain barrier. Caffeine is structurally 
similar to adenosine and can therefore act as an adenosine (most likely A1 and A2A) receptor 
antagonist (Fredholm et al., 1999) thereby reducing the influence of adenosine and producing 
motor-activating and arousing effects. Adenosine receptor antagonism may also act by 
increasing the turnover of some neurotransmitters (e.g. adrenaline and noradrenaline) 
resulting in the central stimulatory effects seen following the ingestion of caffeine (Fredholm 
et al., 1999). The exact mechanisms explaining caffeine’s beneficial effects in humans remain 
unknown however, non-selective adenosine antagonism has received much support in recent 
years. It has been suggested that certain participant/athlete characteristics such as genetics 
(Cornelis et al., 2007), training status (Collomp et al., 1992), impairment (Flueck et al., 2014) 
and an individual’s habitual intake (Bell & McLellan, 2002) may affect how they respond to 
caffeine. An individual’s response will also depend on the duration, intensity and time of 
caffeine ingestion, and the mode of exercise.  
The majority of the aforementioned studies have employed running or cycling 
exercise modalities in which the leg musculature provides the speed-generating force. The 
physiological responses to these modes of exercise differ to those of UBE (Pendergast, 1989) 
which is largely due to the smaller skeletal muscle mass used. The response to UBE in 
individuals with an impairment such as a SCI also differs to AB individuals due to the 
amount of active muscle mass available, (Maggioni et al., 2003) the distribution of muscle 
fibre types (Schantz et al., 1997) and the potential issue of prolonged GI transit times 
(Williams et al., 2012). Consequently, it may not be possible to directly transfer the findings 
from AB running/cycling exercise modalities to individuals with a physical impairment 
performing UBE. However, given that the potential mechanism of action for performance 
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enhancement following caffeine ingestion is the same in individuals with an impairment, a 
similar ergogenic benefit could be expected during UBE. Use of NS is common among 
athletes with an impairment (Chapter three) and yet data investigating their efficacy in this 
population is scarce (Table 2.3 and 2.4). Aside from an uncertainty whether caffeine is 
beneficial in this population, a lack of evidence raises concern given the potential for, or 
more acute sensitivity to side-effects in some sportspeople with a physical impairment (Van 
de Vliet et al., 2011).   
The influence of caffeine on subjective feelings and mood has also been investigated 
in AB participants whereby low to moderate doses of caffeine appear to improve mood and 
increase arousal (Smit & Rogers, 2000). A meta-analysis also revealed that caffeine can 
reduce RPE during exercise (Doherty & Smith, 2005). These factors, in part, contribute to the 
performance-enhancing effects seen during various exercise modalities but have not been 
investigated during UBE in a physically impaired population. For this reason, the current 
study employed both the Feeling (Hardy & Rejeski, 1989) and Felt arousal (Svebak & 
Murgatroyd, 1985) scales to assess the influence of caffeine on feelings of 
pleasure/displeasure and perceived arousal pre-, during and post-exercise. Both scales were 
validated using student populations and have since been regularly used in the caffeine and 
exercise literature (Ali et al., 2016; Richardson & Clarke, 2016). 
Given the dearth of evidence in the area of caffeine and UBE, this study aimed to 
determine the effects of caffeine supplementation on aspects of wheelchair sports 
performance. Wheelchair sports such as rugby, basketball and tennis are intermittent in nature 
and require short bursts of high intensity movements superimposed on a background of 
aerobic activity. The current study employed previously used wheelchair sport field tests 
(West et al., 2014; Yilla & Sherril, 1998) to assess both sprint and short-term, high intensity 
exercise performance.  
5.3 Methods 
5.3.1. Participants  
Twelve male wheelchair rugby players (mean(SD)): age 30.0(7.7) y, body mass 
69.6(15.3) kg, wheelchair rugby experience 6.7(6.0) y, and training hours 11.1(3.5) h·wk-1, 
volunteered to participate in this study. Participants impairments were cervical level SCI 
(n=7), cerebral palsy (n=2), osteogenesis imperfecta (n=1), distal weakness of limbs (n=1) 
and vanishing white matter disease (n=1). The participant’s wheelchair rugby classifications 
ranged from 0.5-3. A health screening questionnaire was completed by all participants to 
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ensure they were free from any injury or illness which may have prevented them from safely 
completing the protocol. Average daily caffeine intake was assessed using a standardised 
caffeine consumption questionnaire (Landrum, 1992). All procedures were approved by the 
local Ethical Advisory Committee and performed following the Declaration of Helsinki. 
Informed consent was obtained from all participants included in the study.  
5.3.2. Experimental design  
A double-blind, placebo-controlled, randomised, cross-over design was employed. 
Participants performed two experimental trials separated by 7-14 d. All data collection 
occurred at the wheelchair sportsmen’s training venues, which was standardised within 
participants. 
5.3.3. Preliminary testing  
During the familiarisation session participants’ body mass was measured to the 
nearest 0.1 kg, using wheelchair beam scales (Marsden MPWS-300, Henley-on-Thames, 
UK).  Participants were familiarised to the experimental testing procedures by completing: 
three 20 m sprint tests (SPR), at least two 4-min maximal pushes (PUSH) and a 3-min saliva 
sample collection. Participants were also familiarised with the Feeling (Hardy & Rejeski, 
1989), Felt arousal (Svebak & Murgatroyd, 1985) and Borg 6-20 RPE scales (Borg, 1998). 
5.3.4. Experimental trials  
Participants were asked to refrain from caffeine consumption in the 48 h, and from 
exercise and alcohol consumption in the 24 h preceding each trial. Participants were asked to 
complete a 24 h food diary prior to the first experimental trial and to replicate this prior to the 
second. Participants were asked to consume only water in the hour preceding each trial to 
help reduce the influence of eating on the saliva sampling procedure. 
Upon arrival at the testing venue participants responded to the Feeling and Felt arousal 
scales. Participants provided a pre-capsule 3-min saliva sample via the passive dribble 
method (Leicht et al., 2012) prior to ingesting placebo (PLA) (4 mg∙kg-1 dextrose) or caffeine 
(CAF) (4 mg∙kg-1) (My Protein, Northwich, UK).  Both CAF and PLA were consumed in 
powder form in cellulose capsules (G & G Food Supplies Ltd, West Sussex, UK).  
Participants then rested and prepared for exercise (wheelchair set-up, gloves, 
standardisation of wheel tyre pressure, clothing, bladder voiding etc) for 45 min prior to 
repeating the two perceptual scales and 3-min saliva collection pre-warm-up. A standardised 
20-min warm-up was started at 50 min and completed prior to the performance tests: three 
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SPR sets and four PUSH (alternate anti-clockwise and clockwise), each with a 4-min rest in-
between (Figure 5.1). The two perceptual scales and saliva collection were repeated 
immediately post-exercise. Participants were also asked whether they had experienced any 
side-effects during the protocol and to indicate which trial they believed they were on. 
Participants were permitted to consume only water ad libitum throughout each trial. 
Environmental conditions across the two training venues were: temperature 20.9(2.4°C, 
humidity 45(8)% and pressure 999(110) hPa.  
The SPR performance test was adapted from West et al. (2014). From a stationary 
position participants were asked to sprint through 20 m. Times to complete the SPR were 
recorded using wireless timing gates (Brower, Utah, USA) at 0 and 20 m. Participants were 
given ~30 s to recover in-between each SPR. One SPR set was composed of three single 
SPR. 
For the PUSH test, markers were placed every 2 m (1.5 m at the corners) to produce a 
rectangle with rounded corners and to enable the total distance covered to be recorded (One 
lap=72 m). Participants self-selected their speed with the goal of covering the greatest 
distance possible in 4 min. Communication between participants was encouraged to ensure 
overtaking was completed efficiently. Verbal encouragement was provided throughout all 
experimental trials by the same investigators, all of whom were blind to which trial the 
participants were completing. Participants were blinded to their results. 
Subjective feelings were assessed using the Feeling scale (Hardy & Rejeski, 1989) and the 
Felt Arousal scale (Svebak & Murgatroyd, 1985). The Feeling scale assessed the participant’s 
mood on a scale of +5 (Very good) to -5 (Very bad). The Felt arousal scale was used to 
assess how aroused a participant was on a scale of 1 (Low arousal) to 6 (High arousal). The 
Borg 6-20 (Borg, 1998) category scale was used to attain participants’ overall RPE scores 
following each PUSH and SPR set.  
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Figure 5.1. Schematic of the experimental trial protocol. 
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5.3.5. Saliva collection and analyses 
For analysis, samples were weighed to the nearest 10 mg. Saliva volume was 
estimated assuming saliva density to be 1.00 g·ml-1, and saliva flow rate was calculated from 
saliva volume and collection time. Saliva samples were transferred into Eppendorfs and 
centrifuged at 12,000 rpm for 3 min in a high speed microcentrifuge. Salivary caffeine 
concentration was determined using a commercially available kit (Emit Caffeine Assay, 
Dade-Behring, Milton Keynes, UK) and a microplate reader (Opsys MR, Dynex 
Technologies, Chantilly, USA) (see Appendix B). The intra-assay coefficient of variation for 
salivary caffeine concentration was 3.5%. Salivary caffeine secretion rates were subsequently 
calculated by multiplying caffeine concentration by saliva flow rate due to the high 
variability in saliva flow in this population (Leicht et al., 2012).  
5.3.6. Statistical analyses 
The Statistical Package for the Social Sciences version 20 software (SPSS Inc., Chicago, 
IL) was used to analyse the data. Distance per PUSH and total PUSH distance (sum of all 
four PUSH) were calculated. Total SPR time (all 9 sprints) and average SPR time for each set 
was calculated. Normal distribution of the outcome variables was confirmed by the Shapiro-
Wilk test for PUSH and therefore data are reported as mean(SD). Subsequently, a repeated 
measures 2 x 4 (trial x time) ANOVA was used to analyse all PUSH data. To assess the effect 
of caffeine on each individual PUSH and total PUSH, paired samples t-tests were employed. 
Non-normally distributed SPR data and ordinal Felt arousal, Feeling and RPE scales are 
reported as median (quartiles) and were analysed using Friedman and Wilcoxon tests. 
Statistical significance was accepted at p<0.05. 
5.4 Results 
5.4.1. Performance tests 
Average 20 m SPR times were significantly faster during CAF compared to PLA 
during SPR1 and SPR2 (p=0.037 and 0.016, respectively) (Figure 5.2). Total SPR time was 
significantly faster during CAF compared to PLA (61.2 (58.5, 68.6) and 62.5 (58.5, 69.7) s, 
respectively) (p=0.006). Ten (of 12) participants produced faster total SPR times. Times did 
not significantly change between SPR sets during CAF or PLA (p=0.254 and 0.212).  
There was no significant difference in PUSH distance between CAF and PLA (p=0.111), nor 
did it differ over the course of the protocol in either trial (PUSH1, 2, 3 and 4) (p=0.864). 
However, participants did cover more distance during PUSH1 during CAF (677(107) m) 
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compared to PLA (653(118) m) (p=0.047) (Figure 5.3). Total PUSH distance was not 
significantly different between supplementation (2686(416) m) and PLA (2634(392) m) 
(p=0.111). Overall, seven participants covered a greater total PUSH distance during CAF 
compared to PLA.   
5.4.2. Subjective feelings 
Felt arousal (p=0.001 and 0.006 for CAF and PLA, respectively), SPR RPE scores 
(p=0.002 and <0.001 for CAF and PLA, respectively) and PUSH RPE scores (p<0.001 and 
0.015 for CAF and PLA, respectively) increased progressively over the course of each trial 
but there was no significant effect of CAF (p>0.132) (Table 5.1 and 5.2). Feeling scores 
improved significantly over the course of the CAF trial (p=0.017), but not during PLA 
(p=0.197), and this occurred pre-capsule (0 (0, 3)) to post-exercise (3 (2, 3)) (p=0.041) (Table 
5.1). Side-effects during CAF including increased spasticity, struggling with decision 
making, headaches (also experienced during PLA) and nausea were reported by five 
participants. Trial order was correctly identified by seven participants. Mean(SD) daily 
caffeine intake was 211(201) mg/d. No participant reported experiencing a prior adverse 
reaction to caffeine. Three participants reported the regular use of caffeine supplementation 
(80-220 mg) in capsule format prior to training or competition (supplementation was not 
included in daily intake data). 
5.4.3. Salivary caffeine 
Salivary caffeine analysis revealed that participants followed the 48 h caffeine withdrawal 
procedure prior to both PLA (0.06(0.06) µg·min-1) and CAF (0.13(0.17) µg·min-1) (Figure 
5.4) and these did not differ (p=0.201). The consumption of CAF caused an increase in 
salivary caffeine secretion rates pre-warm-up (1.05(0.94) µg·min-1) (p=0.009) and post-
exercise (1.34(1.09) µg·min-1) (p=0.003).  
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Figure 5.2. The effects of caffeine supplementation (CAF) on 20 m sprint performance (3 
sprints per set). All data are median (quartiles). *Significantly different from placebo (PLA) 
(p<0.05). 
 
 
 
 
 
 
Figure 5.3. The effects of caffeine supplementation (CAF) on 4-min maximal push (PUSH) 
distance. Data are mean(SD). *Significantly different from placebo (PLA) (p<0.05). 
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Table 5.1. Felt arousal and Feeling scale responses pre-capsule, pre-warm-up and post-
exercise (n=12). 
  PLA CAF 
Felt arousal scale      Pre-capsule 2.5 (2.0, 3.0) 2.0 (1.5, 3.0) 
      Pre-warm-up 3.0 (2.5, 4.0) † 3.5 (3.0, 4.0) † 
      Post-exercise 4.0 (3.5, 4.0) † 4.0 (3.0, 5) † 
Feeling scale      Pre-capsule 2.0 (0.0, 3.0) 0.0 (0.0, 2.5) 
      Pre-warm-up 2.0 (1.0, 3.0) 3.0 (1.0, 3.0)  
      Post-exercise 3.0 (1.0, 4.0) 3.0 (2.5, 3.0) † 
Note. Data are median (quartiles) to the nearest 0.5. †Significantly different from pre-capsule (p≤0.05).  
 
 
 
 
Table 5.2. Ratings of Perceived Exertion (RPE) immediately post each sprint set (SPR) and 
4-min maximal push (PUSH) (n=12). 
 PLA CAF 
SPR1 12 (9,14) 12 (11,13) 
SPR 2 13 (10,15) † 14 (12,14) † 
SPR3 14 (11,16) †‡ 14 (10,15) † 
PUSH1 16 (13,19) 15 (15,17) 
PUSH2 17 (15,18) † 18 (15,19) † 
PUSH3 17 (16,17) † 17 (16,18) † 
PUSH4 18 (16,19) †* 18 (17,19) †‡* 
Note. Data are median (quartiles). †Significantly different from (set) 1, ‡Significantly different from SPR2 and *significantly different from 
SPR3 (p≤0.05).  
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Figure 5.4. Individual participants’ salivary caffeine secretion rates pre-capsule (0 min), pre-
warm-up (45 min) and post-exercise (2 h) (n=12) following (a) placebo and (b)                      
4 mg∙kg-1caffeine. Dotted/full lines indicate participants with/without a spinal cord injury. 
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5.5 Discussion 
The current study demonstrates that the consumption of 4 mg∙kg-1 caffeine can improve 
wheelchair sprint performance. On the other hand, caffeine did not significantly influence 
PUSH performance in wheelchair sportsmen. The following paragraphs will discuss the 
potential reasons behind these results. 
5.5.1. Sprint performance 
Caffeine improved repeated sprint performance in athletes with a physical 
impairment, which was apparent in the first and second SPR sets but not the third (Figure 
5.2). This corroborates previous research in AB individuals that has shown initial 
improvements in performance following caffeine ingestion with a subsequent null or negative 
influence on latter bouts (Glaister et al., 2008; Greer et al., 1998; Santos et al., 2014). Faster 
30 m sprint times in the first three (of 12) sprints following 5 mg∙kg-1 caffeine 
supplementation has previously been reported (Glaister et al., 2008). The authors 
hypothesised that the mechanism responsible for this initial improvement was a CNS effect 
mediated by antagonism of adenosine receptors. A CNS effect may also be responsible for 
the current study results in which participants produced faster average and total SPR times. 
These improvements are small yet meaningful for individuals competing in intermittent 
sports as they may allow a player to lead their opponent in a sprint situation and therefore 
meet the ball, player or line faster. 
The effects of caffeine (5 mg∙kg-1) on performance in simulated-contest taekwondo 
has been investigated, whereby athletes performed two combats (3 x 2 min rounds with 1 min 
rest periods) separated by 20 min (Santos et al., 2014). The ingestion of caffeine i) improved 
reaction times before the first combat, ii) increased the intensity of round one, and iii) 
maintained the intensity observed in the first combat in the second (Santos et al., 2014). 
These findings provide support for the initial performance improvements seen during SPR1 
and SPR2 in the current study. Participants were able to push faster in the first two SPR sets 
which potentially led to the development of fatigue, and contributed to a lack of subsequent 
performance improvement. Caffeine may therefore result in a performance improvement 
initially yet lead to a lack of improvement or decrement in successive exercise bouts.  
5.5.2. PUSH performance 
Interestingly, the same initial performance improvement was also observed in the 
PUSH results (Figure 5.3) despite no overall significant effect of supplementation. 
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Participants benefited from caffeine for a one-off performance, covering a greater distance 
during PUSH1, yet failed to show improvements in PUSH2, 3 or 4 compared to PLA.  
Previous research investigated the use of caffeine prior to two 200 m freestyle TTs (~2 min 
duration) separated by 30 min rest (Pruscino et al., 2008). The authors revealed that caffeine 
improved performance in TT1 (p=0.027) but participants swam 0.9(1.1)% slower in TT2 
following caffeine compared to placebo and the conclusion was that the initial effort during 
TT1 may have hindered performance in TT2 (Pruscino et al., 2008). This may also be true for 
the current PUSH results. However, another study reported opposing findings whereby 
caffeine improved 100 m swim times in trained participants and prevented a drop in 
performance during a second 100 m swim (20 min passive recovery) (Collomp et al., 1992). 
The race distance (200 vs. 100 m), caffeine dose (~6.2 vs. ~4.3 mg∙kg-1) and recovery time 
(30 vs. 20 min) may help explain the differing results in these aforementioned studies. 
5.5.3. Gastrointestinal issues 
Gastrointestinal emptying and transit times can be delayed in individuals with a SCI 
(Williams et al., 2012) and this may be more prominent in those with a high lesion level (Kao 
et al., 1999) such as those in the current study (7 of 12 participants with tetraplegia). The pre-
warm-up (45 min post-ingestion) saliva results suggest that 45 min may be inadequate time to 
develop sufficient caffeine concentrations in some participants with a physical impairment 
(Figure 5.4). However, the participants then prepared for exercise and performed a 20 min 
warm-up prior to the performance tests. The early performance improvements in SPR1 and 2, 
and PUSH1 indicate that the supplement was absorbed prior to the start of these tests (70 min 
post-ingestion). The only current study to investigate caffeine use in wheelchair athletes, 
showed no improvement in 1500 m performance (~3 min duration) following the ingestion of 
6 mg∙kg-1 caffeine, 60 min prior to exercise (Flueck et al., 2014). The authors did not measure 
caffeine concentration and therefore could not use this measure to help explain their results 
(Flueck et al., 2014). The promising finding however was that 4 (of 9) participants produced 
their fastest times in the caffeine trial compared to three other conditions (placebo, sodium 
citrate and a combination of both). Furthermore, the current results suggest that the 60 min 
absorption time employed by Flueck et al. (2015) may have been sufficient for their athletes 
with paraplegia and spina bifida to produce these individual results. In support of this, Van 
Soeren et al. (1996) suggested that the time to Cmax (6 mg∙kg-1) in individuals with tetraplegia 
did not differ to those of AB individuals. Given the large inter-individuality highlighted by 
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the salivary caffeine results, the time course for caffeine absorption in individuals with a SCI, 
especially those with tetraplegia should be further explored. 
5.5.4. Subjective feelings 
The side-effects reported by five participants were similar to those reported in AB 
participants, which include muscle trembling and shakiness/jitters but were described as 
‘increased spasticity’ by those with a SCI or cerebral palsy. These side-effects occurred 
despite a relatively moderate dose of 4 mg∙kg-1 caffeine administered in this study compared 
to often larger doses of 5-10 mg∙kg-1 in the AB literature. Interestingly, the reported side-
effects occurred in two of the three participants who reported the use of caffeine 
supplementation prior to training/competition. The dose of 4 mg∙kg-1 was greater (1.5-2 times 
more) than their usual intake, which may explain the incidence of side-effects in these 
individuals. This highlights the need to consider caffeine dose on an individual basis. It is 
likely that experiencing such issues during exercise could limit performance however; there 
was no link between those that experienced side-effects and those that did/did not improve.  
Despite the reported side-effects during CAF, Feeling scores improved over the 
course of the trial following ingestion of the supplement. The psychostimulatory effect of 
caffeine is common (Smit & Rogers, 2000) and may have contributed to the improved SPR 
performance. Other common findings include increased arousal and an altered perceptual 
response following the ingestion of caffeine (Doherty & Smith, 2005), neither of which were 
apparent in the current study. However, an absence of significant changes in RPE were seen 
in conjunction with a greater distance covered during PUSH1 and faster SPR times during 
CAF, which may suggest that the supplement influenced perceptual responses to some extent.  
The ability to successfully determine CAF or PLA is common in the caffeine literature due to 
familiar side-effects (e.g. jitteriness and energetic sensations). In the current study only seven 
participants correctly identified both trials, which increased the authors’ confidence that the 
NS is responsible for the reported performance improvements.  
5.5.5. Limitations 
A relatively small sample size was used and participants had a variety of physical 
impairments, hence the findings can only be generalised to the sport not to a specific 
impairment. As with all on court testing, a combination of factors associated with the 
participant, the wheelchair and the interfacing between the two may also have influenced 
performance, especially during cornering in the PUSH during which a high element of skill 
was required. Given the nature of field study protocols, the participants also performed in the 
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presence of external interference (e.g., participant’s, coaches and researchers) which may 
have influenced performance. An attempt to minimise this influence was employed; 
participants performed the PUSH protocol with the same fellow participants where possible, 
participants were motivated by the same investigators, and they were blind to their results. 
5.6 Conclusion 
This study supports the beneficial effects of caffeine on sprint performance and on a one-
off bout of short-term high intensity exercise in wheelchair sportsmen. The findings provide 
some support for the psychostimulatory effect of caffeine seen as improved Feeling scores 
and yet the supplement did not improve participant’s RPE or arousal scores. The combination 
of side-effects and potentially delayed caffeine absorption highlights that its use in persons 
with a physical impairment is highly individual. 
5.7 Practical applications 
The study protocol utilised moderately trained (club level) wheelchair rugby players 
performing in their own sports wheelchairs, and reflected real-life pre-training/competition 
nutrition and hydration practices. Athletes taking part in, and coaches working with similar 
intermittent wheelchair sports now have some evidence to show that caffeine 
supplementation can be beneficial during wheelchair sprinting. The measurement of salivary 
caffeine concentrations highlighted considerations for the timing of caffeine supplementation 
in individuals with a physical impairment. Caffeine should therefore be trialled on an 
individual basis by wheelchair sportsmen (especially individuals with a SCI) and should 
initially utilise low doses of 1-3 mg∙kg-1 at least 60-70 min prior to exercise. 
111 
 
6  
Study 4: Does caffeine absorption differ in 
individuals with a spinal cord injury? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published in a slightly modified form in Medicine and Science in 
Sports and Exercise: 
Graham-Paulson, T.S., Paulson, T.A.W., Perret, C., Tolfrey, K., Cordery, P. & Goosey-
Tolfrey, V.L. (2016). Spinal cord injury level influences acute plasma caffeine 
responses. Medicine and Science in Sports and Exercise Science, epub ahead of print. 
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6.1. Abstract 
Delayed GI transit times and therefore the time required to reach a therapeutic dose 
following the oral ingestion of some drugs has been reported in individuals with a SCI. Large 
inter-individual variability in the effects of caffeine on performance in individuals with a SCI 
may be linked to this delayed absorption. Therefore, this study aimed to investigate whether 
the absorption curve and acute effects of caffeine at rest varies in individuals with different 
SCI lesion levels. With institutional ethics approval 24 healthy males (8 AB, 8 individuals 
with paraplegia (PARA) and 8 with tetraplegia (TETRA)) consumed 3 mg∙kg-1 caffeine 
(CAF) in a fasted state. The [CAF], glucose, lactate, free-fatty acid [FFA] and catecholamine 
concentrations were measured during a 150 min rest period. A greater Cmax was apparent in 
TETRA (21.5 µM) compared to AB (12.2 µM) and PARA (15.1 µM), and mean time to Cmax 
occurred at 70, 80 and 80 min, respectively. Moderate and large ESs were revealed for 
TETRA compared to PARA (0.55) and AB (1.14) for the total area under the [CAF] versus 
time curve. Large inter-individual responses were apparent within both SCI groups. The 
change in plasma catecholamine concentrations following CAF did not reach significance 
(p>0.05) however both adrenaline and noradrenaline concentrations were lowest in TETRA. 
Significant increases in [FFA] were seen over time (p<0.0005) but there was no significant 
influence of SCI level. Participants’ [Bla] reduced over time (p=0.022) whereas [GLU] did 
not change (p=0.695), and no difference between groups was apparent (p>0.05). The results 
suggest that SCI level does influence the pattern of the caffeine absorption curve, and there 
was large inter-individual variation within and between groups. Individual curves should be 
considered when using caffeine as an ergogenic aid. Low doses should be trialled in training 
by TETRA, and PARA may consider consuming caffeine greater than 60 min prior to 
exercise performance. The study also supports caffeine’s direct effect on adipose tissue, 
which is not secondary to catecholamine release. 
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6.2. Introduction 
Supplementation with caffeine (3-6 mg∙kg-1) can improve long and short-term 
endurance performance (Ganio et al., 2009; Graham, 2001) in AB participants. However, 
there is a paucity of research on the effects of caffeine on exercise performance in physically 
impaired populations (Table 2.3 and 2.4). While current evidence is equivocal, an 
inconsistent beneficial effect of caffeine (4-6 mg∙kg-1 in capsule form) on short-term 
wheelchair propulsion performance has been reported (Flueck et al., 2014; Chapter five). 
These studies highlighted that there was great inter-individual variability in wheelchair 
performance responses during a 1500 m TT, 4 min maximal push and repeated sprints, 
especially in individuals with a SCI. The authors highlighted the potential for slower caffeine 
absorption due to delayed GI transit times and prolonged GE, especially in those with a 
cervical lesion level (Kao et al., 1999). Understanding an individual’s time to Cmax has been 
shown to have little impact on prolonged AB endurance cycling performance (Skinner et al., 
2013) but is likely to be important prior to short-term exercise, and may require further 
consideration in persons with a SCI. 
Both metabolic and physiological functions are altered in individuals with a SCI, and 
the level and completeness of injury has been shown to influence drug pharmacokinetics 
(Halstead et al., 1985; Mestre et al., 2011). A review of the literature by Mestre et al. (2011) 
indicated that the delayed absorption seen in some individuals with a SCI increased the time 
to achieve the required therapeutic dose. One drug reportedly affected by delayed GE and 
decreased GI motility is theophylline (Segal et al., 1986), which can be used by individuals 
with a SCI to help treat bradycardia. Diminished bioavailability could result in 
underestimating the load and maintenance dose of theophylline in individuals with tetraplegia 
(Segal et al., 1986). As a methylxanthine drug, theophylline has similar pharmacodynamic 
actions to caffeine (Raguso et al., 1996) and it has also been linked to improved endurance 
performance (Greer et al., 2000; Marsh et al., 1993). There is therefore reason to believe that 
caffeine absorption may also be delayed in persons with a SCI. In disagreement however, 
Van Soeren et al. (1996) suggested that the time to Cmax (6 mg∙kg-1) in individuals with 
tetraplegia (~47 µM at 40 min (n=6)) did not differ to those of AB individuals. The authors 
however could not assess the influence of SCI lesion level on caffeine absorption because 
there was no direct control group and only two individuals with paraplegia. They also did not 
report individual participant data, which may help to explain inter-individual performance 
responses. Flueck et al. (2015) measured median [CAF] at 60 min only following 6 mg∙kg-1 
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caffeine in AB individuals (45.1 µmol∙L-1) and individuals with paraplegia (~54.0 µmol∙L-1) 
and tetraplegia (66.1 µmol∙L-1). With only a single measurement of [CAF] it remains difficult 
to determine whether the time course of caffeine absorption differs based on an individual’s 
SCI lesion level but it is evident that the absolute [CAF] differs. 
Numerous mechanisms of action have been proposed to explain the beneficial effects 
of an acute dose of caffeine on exercise performance. Current research suggests the main 
mechanism at physiological caffeine doses is the blockade of central nervous system (CNS) 
adenosine receptors, which indirectly affects neurotransmitter release (Keisler & Armsey, 
2006) to increase arousal, alertness and attention. Individuals with tetraplegia are therefore an 
interesting study population given the reduced sympathetic activity caudal to the lesion level 
and associated impaired catecholamine response (Paulson et al., 2013b; Table 2.5). The study 
of this population has lent support to the hypothesis that caffeine can have a direct effect on 
tissues following reports of adrenaline-independent FFA mobilisation (see Table 2.5). No 
study has directly investigated the acute effects of caffeine in a group of individuals with 
paraplegia and tetraplegia, as well as a non-SCI control group. Hence, the current study 
aimed to explore the time course of caffeine absorption and its effects at rest in these three 
groups, with the aim of providing safe and accurate recommendations for its use as an 
ergogenic aid by individuals with a SCI.  
6.3. Methods 
6.3.1. Participants 
Twenty-four recreationally active males (8 AB controls, 8 individuals with paraplegia 
(PARA) and 8 with tetraplegia (TETRA)) provided informed consent to participate in the 
current study. Participants were classified using the American Spinal Injury Association 
(ASIA) impairment scale (Kirschblaum et al., 2011). A health screening questionnaire was 
completed by all participants and individuals were excluded if any of their medication had 
known interactions with caffeine. Average daily caffeine intake was assessed using a 
modified version of the caffeine consumption questionnaire (Landrum, 1992). All procedures 
were approved by the University Ethical Advisory Committee and performed following the 
Declaration of Helsinki. Participants’ characteristics are shown in Table 6.1.  
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6.3.2. Experimental design 
The study followed a cross-sectional, repeated measures design whereby participants 
were naturally placed into groups based on their SCI lesion level. Participants visited the 
laboratory only once and were aware of the caffeine dose being consumed. 
6.3.3. Experimental trials 
In the days prior to visiting the laboratory, participants maintained their normal 
dietary and activity patterns (light-moderate exercise only) and their individual medication 
regimes. Participants were provided with a list of caffeine containing foods and drinks, and 
were asked to abstain from consumption in the 36 h preceding their laboratory visit. 
Participants were also asked to refrain from alcohol consumption for 24 h prior to their visit. 
Participants arrived at the laboratory between 08:00-10.00 following an overnight fast (no 
food intake after 21:00). Water consumption was encouraged to help ensure the participant 
arrived euhydrated. On arrival participants were asked to void their bladder, if necessary, 
prior to lying in a semi-supine position on a laboratory bed. Participants were asked to report 
any side-effects to the investigators immediately at any point during the trial. A cannula 
(Venflon, Becton Dickinson, Helsingborg, Sweden) was inserted into an antecubital vein for 
subsequent venous sampling. The cannula was kept patent using 5-10 ml sodium chloride 
(0.9%) after each blood sample.  
After a minimum of 15 min rest, a baseline venous blood sample was taken. 
Participants then consumed cellulose capsules (Bulk Powders, Colchester, UK) containing 3 
mg∙kg-1 caffeine (My Protein, Northwich, UK).  Participants remained rested for 150 min 
during which a further 9 blood samples were taken. The blood sampling schedule can be seen 
in Figure 6.1. After the final blood sample, participants were asked once more whether they 
experienced any side-effects during the experimental trial. 
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Table 6.1. Participants’ characteristics 
 AB 
(n=8) 
PARA 
(n=8) 
TETRA 
(n=8) 
Age (y) 25(4) 38(10) † 33(9) 
Body mass (kg) 83.2(9.8) 74.5(12.9) 73.2(9.8) 
Lesion level  n/a T4-L1 C5-7 
ASIA A/B n/a 3/5 2/6 
Time since injury (y) n/a 4.3(4.3) 12.2(0.3) ‡ 
Habitual caffeine intake (mg·d-1) 
Low/moderate/high group 
218(157) 
2/2/4 
220(145) 
1/4/3 
224(140) 
1/4/3 
Use of caffeine as a performance aid 1 1 4 
Notes: Data presented as mean(SD). AB=Able-bodied, ASIA=American spinal injury association impairment 
scale, C=cervical, L=lumbar, PARA=individuals with paraplegia, TETRA= individuals with tetraplegia, S= 
sacral and T=thoracic. Low <50 mg·d-1, moderate 50-250 mg·d-1 and high >250 mg·d-1. †Significantly different 
from AB, ‡significantly different from PARA (p<0.05). 
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Figure 6.1. Schematic of the experimental protocol 
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6.3.4. Blood analysis 
At every sampling time-point 5 ml blood was added to an EDTA K2 vacutainer for 
subsequent [CAF] analysis. A 20 µl blood sample was removed and analysed in duplicate for 
[Bla] and glucose ([GLU]) concentrations using an automatic analyser (Biosen C-Line, EKF 
Diagnostic GmbH, Barleben, Germany).  For catecholamine and FFA analysis (baseline, 60, 
90 and 150 min), a further 10 ml of blood was dispensed into two lithium-heparin tubes 
containing 37.5 µl of EGTA-Glutathione for the subsequent analysis of plasma adrenaline 
([A]), noradrenaline ([NA]) and FFA ([FFA]) concentrations. In addition, 25 µl of 3 mg∙ml-1 
tetrahydrolipstatin (THL) was added to the tube for [FFA] analysis. All tubes were 
centrifuged at 1000g for 10 min at 4ºC. Plasma samples were aliquoted into Eppendorfs and 
stored at -80ºC until analysis. 
Analysis of [CAF] was performed using reverse-phase high-performance liquid 
chromatography (HPLC) as described by Holland et al. (1991) with the following minor 
modifications; prior to injection onto the HPLC column each sample was individually filtered 
(Mini-UniPrep syringeless filters, Fisher Scientific, UK) and no guard column was used (see 
Appendix C). The method produced a coefficient of variation (CV) of 1.06% (range 0.24-
1.45%).  
Plasma [A] and [NA] were also determined using HPLC as previously described by 
Forster & Macdonald, (1999). A plasma volume of 500 µl was used for analysis. The method 
produced CVs of 0.31 and 0.17% for [A] and [NA] respectively. Plasma was analysed 
enzymatically for [FFA] using an in vitro enzymatic colorimetric method (Wako Instrument 
kit) and a Pentra 400 analyser (Horiba Medical, California, USA). The method produced an 
intra-assay CV of 1.68 and 1.28% for high and low FFA quality controls (QC) (4 repeats of 
the QC samples at intervals during the analysis). Plasma [A], [NA] and [FFA] analysis was 
performed by qualified personnel at the University of Nottingham Medical School, UK. 
6.3.5. Statistical analysis 
Data were analysed using the Statistics Software Package for the Social Sciences 
(SPSS) version 22 (SPSS Inc., Chicago, IL). The trapezium rule was used to calculate the 
total area under the variable versus time curve for [CAF] (TAUC-CAF), [FFA] (TAUC-
FFA), [A] (TAUC-A) and [NA] (TAUC-NA). The incremental area under the plasma 
concentration versus time curve for [FFA] (iAUC-FFA), [A] (iAUC-A) and [NA] (iAUC-
NA) was also calculated using the same method after adjusting for baseline concentrations.  
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Normal distribution was checked using Shapiro-Wilk tests and the data are presented 
as mean(SD). Data for [FFA] were not normally distributed and were log transformed prior to 
analysis. These data are presented as geometric mean (95% confidence intervals (CI)) and 
analysis is based on the ratios of geometric means and 95% CI for ratios. Homegeneity of 
variances was confirmed by Mauchly’s test of sphericity, and where the sphericity 
assumption was violated, the Greenhouse Geisser correction was applied to the degrees of 
freedom. 
Repeated measures ANOVAs for group and time were used to examine differences 
between [FFA], [A], [NA], [Bla] and [GLU]. Where a significant interaction was evident, 
post-hoc one-way ANOVAs explored the effects of group and time with a Bonferroni 
adjustment for repeated comparisons.  
An analysis of covariance (ANCOVA) was used to examine differences between 
[CAF], with daily caffeine consumption (low <50 mg·d-1, moderate 50-250 mg·d-1 and high 
>250 mg·d-1) as a covariate. One-way repeated measures ANOVAs were used to analyse 
TAUC and iAUC data. Planned simple and difference contrasts were applied to explain any 
significant results.  
Statistical significance was accepted at p≤0.05 and absolute standardised ESs are 
included to supplement important findings. An ES of 0.2 was considered small, 0.5 moderate 
and 0.8 large according to Cohen (1992). Due to incomplete data sets (e.g. insufficient blood 
flow or a cannula change) the number of participants included in each analysis differs. Data 
sets were A (7/6/7), NA (7/7/8), FFA (7/7/7), Bla (5/5/6) and GLU (8/6/8) for AB, PARA and 
TETRA groups, respectively. 
Power analysis was performed using the [CAF] observed in 3 groups of participants 
with no SCI, paraplegia and tetraplegia 60 min post-ingestion of 6 mg∙kg-1 caffeine 
(46.4(6.8), 55.3(19.8) and 64.1(6.9) µM, respectively) (Flueck et al., 2015). The a priori 
analysis, conducted in G*Power 3.1, revealed that six participants would be required in each 
group to detect a similar change in [CAF] with ES of 0.59, 0.66 and 2.74, 90% power, and an 
α of 5%. Given the novel nature of this investigation and the heterogeneity of the population, 
an additional two participants per group were recruited to increase statistical power (n=8). 
6.4. Results 
6.4.1. Plasma caffeine 
At baseline, [CAF] was either undetectable or very low, which indicates that all 
participants adhered to the withdrawal guidelines. Differences over time and across groups 
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were revealed (main effect time p<0.0005; main effect group p=0.026; time by group 
interaction p=0.019) (Figure 6.2). Planned simple contrasts revealed these group differences 
occurred between AB and TETRA (p=0.017), whereas no difference was observed between 
AB and PARA (p=0.913). The Cmax for AB, PARA and TETRA were 12.2(2.3), 15.1(8.1) 
21.5(7.0) µM, respectively. The Cmax in TETRA was significantly greater than AB (p=0.008) 
yet non-significantly (p=0.058), but meaningfully (ES=0.9) greater than PARA. Time to Cmax 
varied greatly between individuals but group mean (range) was 80 (45-90), 80 (45-150) and 
70 (30-90) min for AB, PARA and TETRA, respectively. There was no influence of habitual 
caffeine use on [CAF] (p=0.943). 
No significant difference in TAUC-CAF was observed between groups (p=0.135; AB 
19.8(5.0) µM, PARA 22.6(16.1) µM, and TETRA 31.3(11.1) µM). However, small (AB vs. 
PARA, ES=0.38), moderate (PARA vs. TETRA, ES=0.55) and large (AB vs. TETRA, 
ES=1.14) ES were apparent. 
Seven participants (3 AB/2 PARA/2 TETRA) reported adverse effects prior to/during 
the first 30 min of testing (headache/light-headed (2)) and during testing (struggling with 
quick decision making (1), tingling arm (1), a twitching eye (1)). Five participants also 
reported feeling more alert. 
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Figure 6.2. (a) Mean(SD) plasma caffeine concentrations following the consumption of 3 mg·kg-1 caffeine (CAF), (b) individual data from able-
bodied participants (AB), (c) participants with paraplegia (PARA), and (d) participants with tetraplegia (TETRA). Dotted/bold lines in c and d 
represent participants with an ASIA A/B classification. 
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6.4.2. Plasma catecholamines 
All catecholamine analysis excluded the participant with a T4 lesion level due to a 
missed sample and hence statistical analysis for PARA was calculated based on injuries at or 
below T6/7. The change in [A] over the course of the resting protocol did not reach statistical 
significance but did differ between groups (main effect of time p=0.088; main effect of group 
p=0.027; time by SCI level p = 0.618) (Figure 6.3). Planned difference contrasts revealed 
these group differences occurred between PARA and TETRA (p=0.019) only. There was no 
significant difference in TAUC-A (p=0.075) between groups (AB 0.43(0.17) nmol·L-1, 
PARA 0.57(0.22) nmol·L-1, and TETRA 0.22(0.10) nmol·L-1) though ES were large for both 
AB (ES=2.02) and PARA (ES=1.04) compared to TETRA. There was no difference in 
iAUC-A (p=0.733) (Figure 6.3). 
The [NA] did not change significantly during the 150 min protocol (p=0.423) but did 
differ between groups (p=0.003), and no interaction was evident (p = 0.772). Planned 
difference contrasts revealed these group differences occurred between AB and TETRA 
(p=0.001), and PARA and TETRA (p=0.006), but no significant difference was observed 
between AB and PARA (p=0.505). There was a significant difference in TAUC-NA 
(p=0.003) between groups (AB 4.04(0.92) nmol·L-1, PARA 3.68(1.01) nmol·L-1, and TETRA 
2.01(1.21) nmol·L-1). Small (AB vs. PARA, ES=0.38) and large (AB vs. TETRA, ES=1.89, 
and PARA vs. TETRA, ES=1.50) ES were revealed. However, no significant difference in 
iAUC-NA was observed (p=0.827). 
6.4.3. Plasma FFA, lactate and glucose 
Differences in [FFA] were observed over time and between groups, however the latter 
failed to reach significance (main effect time p<0.0005; main effect group p=0.054; time by 
group interaction p=0.035). Geometric mean [FFA] was 51% (95% CI 31 to 73%), 64% 
(95% CI 44 to 88%) and 84% (95% CI 58 to 116%) higher than baseline at 60, 90 and 150 
min. Geometric mean [FFA] was 26% lower and 9% higher than AB in PARA (95% CI -46 
to 2%) and TETRA (95% CI -21 to 50%), respectively. Mean [FFA] results were 47% higher 
in TETRA compared to PARA (95% CI 6 to 103%).  
No significant difference in TAUC-FFA was observed (p=0.072) yet moderate (AB 
vs. PARA, ES=0.47, AB vs. TETRA, ES=0.85) and large (PARA vs. TETRA, ES=1.16) ES 
were revealed. No significant difference in iAUC-FFA was observed (p=0.357). 
Differences in [Bla] were observed over time but not between groups (main effect time 
p=0.022; main effect group p=0.463; time by group interaction p=0.065) (Figure 6.3d). 
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Planned difference contrasts revealed a significant decrease in [Bla] between baseline and 60 
min (p=0.049), and between 90 and 150 min (p<0.0005). No significant difference in [GLU] 
was seen over the course of the 150 min protocol (p=0.695) or between groups (p=0.983) 
(Figure 6.3e). 
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Figure 6.3. (a) Plasma adrenaline (b) noradrenaline, (c) free fatty acid, (d) lactate  and (e) 
glucose concentrations following the consumption of 3 mg·kg-1 caffeine in able-bodied (AB) 
participants and participants with paraplegia (PARA) and tetraplegia (TETRA). *Significant 
main effect for group . †Significant time-group interaction effect. 
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6.5. Discussion 
The current study is the first to report inter-individual differences in the caffeine 
absorption curve within and between groups when separated for level of SCI (AB, PARA and 
TETRA). Consequently, dosage and timing recommendations provided to individuals with a 
SCI may need to be adapted from the AB literature. In addition, the pattern of caffeine 
absorption differs in TETRA compared to AB and PARA (Figure 6.2). There were small 
differences in [A], [NA] and [FFA] between the AB and SCI groups, which were non-
significant when baseline values were accounted for using the incremental area under the 
curve. No differences in [Bla] and [GLU] were seen between groups.  
6.5.1. Plasma caffeine 
Participant’s [CAF] increased in all three groups following the ingestion of 3 mg∙kg-1 
caffeine. The [CAF] in AB at 60 min (10.8(3.1) µM) is in line with that reported 60 min post-
ingestion of 2, 3 and 4 mg∙kg-1 caffeine (5.7, ~15.0 and 14.6 µM, respectively) (Graham & 
Spriet, 1995; Skinner et al., 2010). This study is the first to investigate the caffeine absorption 
curve in a group of participants with paraplegia. The AB results did not differ from the 
PARA responses at 60 min (11.1(7.9) µM), and both groups reached mean Cmax at 80 min 
(12.2(2.3) and 15.1(8.1) µM). Individual time to Cmax differed greatly however as AB 
participant peaks occurred between 45 and 90 min, and PARA peaks occurred between 45 
and 150 min. The TETRA responses were significantly greater than AB and the mean Cmax 
(21.5(7.0) µM) was reached 10 min earlier (70 min), with an individual range from 30 to 90 
min. Flueck et al. (2015) also reported a greater [CAF] 60 min post-ingestion of ~6 mg∙kg-1 
caffeine in individuals with tetraplegia compared to those with paraplegia (66.1 and 45.1 µM, 
respectively). Interestingly, Van Soeren et al. (1996) also reported a high Cmax of 46.7(5.0) 
µM in individuals with tetraplegia (n=6) yet this was reached after only 40 min post-ingestion 
of 6 mg∙kg-1 caffeine. The current study therefore adds further support to reports of higher 
[CAF] in TETRA compared to individuals with lower lesion levels and no SCI. Furthermore, 
these findings also highlight the variability that exists within each group. Based on the 
current study there does not appear to be an influence of habitual caffeine use on the 
participants’ [CAF] in response to a single dose, as seen previously (Bell & McLellan, 2002). 
Seven participants reported adverse effects which were likely a result of withdrawal 
(headache), fasting (light headed) and CAF (tingling arm, twitching eye and struggling to 
make quick decisions). All symptoms were mild, only lasted for a short duration and occurred 
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in participants across all three groups. The 3 mg∙kg-1 caffeine dose is therefore deemed safe 
in this population. 
An interaction effect occurred due to the sharp increase in [CAF] in TETRA while 
both AB and PARA groups [CAF] increased gradually followed by a plateau. The rapid 
increase in [CAF] displayed by the majority of TETRA participants indicates that these 
individuals did not display signs of slowed absorption. The sharp rise may be due to a 
number of factors. Firstly, individuals with tetraplegia have a smaller blood volume 
compared to AB individuals due to atrophy of the musculature and vessels of the lower limbs 
(Houtman et al., 2000). This reduced blood volume may result in a falsely large [CAF] in 
TETRA following the administration of a standardised dose per kilogram body mass. 
Secondly, following a cervical or thoracic SCI sympathetic outflow to the liver is also 
disrupted, which in turn can lead to hepatic pathology (Sauerbeck et al., 2015). The liver is 
innervated by both sympathetic and parasympathetic nerves, and the sympathetic splanchnic 
nerves originate from neurons which are located between T7-T12 (Yi et al., 2010). Acute 
changes to the liver occur due to the complete (cervical level) and partial (thoracic level) 
disruption to the descending control of sympathetic neurons innervating the organ (Sauerbeck 
et al., 2015). It has been suggested previously that abnormal liver function may affect the 
metabolism and bioavailability of drugs (Mestre et al., 2011; Sauerbeck et al., 2015). The 
half-life of many drugs can be prolonged in individuals with a SCI who display suboptimal 
liver function and slow renal clearance (Mestre et al., 2011; Sauerbeck et al., 2015). Serum 
caffeine half-life has also been shown to be severely prolonged in individuals with 
compromised liver function e.g. those with alcoholic hepatic liver disease (Statland & 
Demas, 1980). The half-life of caffeine in healthy individuals is ~4-6 h (Bell & McLellan, 
2002). This may help explain the sharp rise to Cmax in TETRA (slowed metabolism) which 
remains higher than AB and PARA (slowed renal clearance). This TETRA response indicates 
that individuals with a cervical SCI may consider using a lower dose of caffeine to produce 
similar [CAF] as AB and PARA while avoiding any potential side-effects that are reported 
anecdotally and in Chapter five. Further investigation would be required to determine if a 
lower dose was as effective as higher doses and/or whether the higher [CAF] potentially 
results in an ergogenic benefit for longer in these individuals. It also suggests that individuals 
with a cervical level SCI may need to consider reducing the frequency of caffeine intake to 
prevent the potential negative effects of high doses of caffeine e.g. nervousness, jitters, 
restlessness, sleeplessness and irritability.  
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It has previously been suggested that the pharmacokinetics of caffeine may be 
modified by an individual’s FM (Abernethy et al., 1985; Kamimori et al., 1987). Caffeine is 
highly lipophilic and therefore can be transported into various tissues throughout the body. 
The increased distribution of caffeine with no change in clearance resulted in a non-
significantly longer elimination half-life in obese individuals (Abernethy et al., 1985). 
Kamimori et al. (1987) also reported than three obese individuals had lower elimination rate 
constants and longer serum caffeine half-lives compared to three lean individuals. Given the 
sample size in the 1987 study (n=3) and the non-significant trend in the 1985 study, this is 
purely speculative but the increased FM in individuals with a SCI cannot be discounted as a 
potential influencing factor on the pharmacokinetics of caffeine (Spungen et al., 2003). 
The TAUC-CAF did not statistically differ between groups yet a large ES of 1.14 was 
evident between AB and TETRA. Large inter-individual responses were seen in both SCI 
groups evidenced by large standard deviations of 16.1 and 11.1 µM in PARA and TETRA, 
respectively (Figure 6.2), likely due to the heterogeneous nature of this population. The 
equivocal findings regarding the beneficial effects of caffeine during short-term exercise 
performance (Flueck et al., 2015) may be partly explained by these inter-individual 
differences, highlighted by the current PARA and TETRA responses. Examination of 
individual data within PARA reveals some interesting findings. Participant nine (L1 lesion; 
ASIA B) produced a similar curve to the AB participants, with a Cmax (albeit larger at 29.0 
µM) at 45 min followed by a steady decline. However, caffeine did not appear in the 
bloodstream of participant 10 (T7 lesion; ASIA B) until 70 min and continued to rise for the 
remaining 80 min. Hence, participant 10 did not reach a Cmax during the 150 min resting 
protocol. The implementation of a standard caffeine protocol whereby caffeine is 
administered 60 min prior to short-term exercise performance would result in participant 10 
exhibiting a [CAF] associated with a placebo dose at the commencement of exercise. For 
short-term exercise performance it is therefore recommended that athletes with a SCI 
determine their individual absorption curve to produce individualised dose and timing 
recommendations. If this is impractical it is recommended that caffeine prior to short-term 
exercise performance is provided earlier to ensure it appears in the bloodstream prior to 
commencement. Research into the use of caffeine gum or mouth rinse is emerging yet the 
evidence of a consistent positive effect is currently limited (Paton et al., 2015; Ryan et al., 
2012). Consuming caffeine in this format allows direct absorption into the bloodstream 
through the buccal mucosa and may eliminate any potential issues regarding caffeine 
absorption in individuals with a SCI.  
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The groups’ body mass and habitual caffeine intakes were similar between all three 
groups. There was however, a significant difference between the mean age (AB vs. PARA) 
and TSI (PARA vs. TETRA) which cannot be discounted as influencing factors on [CAF] 
responses. Previous research has however suggested that age was not associated with peak, 
total or time to peak [CAF] following caffeine ingestion (p>0.612) (Skinner et al., 2014). Age 
and TSI have also been reported not to affect gastric emptying (Kao et al., 1999). 
6.5.2. Plasma catecholamines 
Resting plasma catecholamine concentrations did not significantly increase over the 
course of the 150 min protocol in any group (Figure 6.3a/b). In contrast, Flueck et al. (2015) 
and Van Soeren et al. (1996) reported increases in [A] in both AB individuals and individuals 
with paraplegia (Table 2.5), which may in part be due to the larger 6 mg∙kg-1 dose 
administered in these studies. In line with previous findings, baseline catecholamine 
concentrations were lower in TETRA compared to AB and PARA due to the impaired 
sympathetic activation of the adrenal medulla (Paulson et al., 2013b; Schmid et al., 1998). 
6.5.3. Plasma FFA, lactate and glucose 
Mean resting [FFA] increased over time from 0.36(0.19) mmol∙L-1 at baseline to 
0.61(0.25) at 150 min (Figure 6.3c), in agreement with previous research in an AB and a SCI 
population (Graham et al., 2000; Van Soeren et al., 1996; Table 2.5). In the absence of a 
catecholamine response, the current results lend further support for a direct effect of caffeine 
on human tissue, specifically adipocytes at rest. The majority of research suggests that FFA 
availability does not result in greater FFA oxidation and therefore does not alter substrate use 
at rest or during exercise (Desbrow et al., 2009; Graham & Spriet, 1991; Mohr et al., 1998). It 
is also unlikely to aid performance during short-term UBE where participants/athletes 
predominantly work anaerobically, and therefore utilise carbohydrate as the primary 
substrate. Unfortunately no body composition or RER data were collected to enable a greater 
understanding of the [FFA] responses and whether substrate use was influenced at rest. 
However, previous research would suggest this does not occur (Graham & Spriet, 1991; Van 
Soeren et al., 1996). 
Baseline [FFA] was higher in TETRA than AB or PARA (Figure 6.3c). The lack of 
muscle innervation of paralysed lower limbs in individuals with a SCI leads to rapid muscle 
atrophy and a reduction in resting metabolic rate (Monroe et al., 1998). Alongside potentially 
poor nutritional choices (Perret & Stoffel-Kurt, 2011) and a disruption in the secretion of 
anabolic hormones, these changes can result in an increase in fat mass (Spungen et al., 2003). 
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An expanding fat mass which releases more FFA and a potential reduction in FFA clearance 
leads to increased plasma [FFA] (Bjorntorp et al., 1969). The [FFA] were significantly 
greater in TETRA compared to PARA only. One possible explanation for this could be the 
difference in the group’s time since injury (PARA 4.3(4.3) y and TETRA 12.2(6.3) y) which 
has been positively associated with loss of lean tissue and increased fat mass (Spungen et al., 
2003).  
The current data show [Bla] decreased slightly over the course of the 150 min 
protocol, which is in line with previous resting data (Van Soeren et al., 1996). The [GLU] 
also decreased modestly (non-significantly) during the current protocol, as previously 
reported (Mohr et al., 1998) and is unlikely a result of caffeine ingestion. Neither [Bla] nor 
[GLU] was influenced by CAF. 
6.6. Conclusion 
The current study demonstrates that there is large inter-individual variability in the 
pattern of caffeine absorption in individuals with a SCI and that this should be assessed prior 
to making specific recommendations for its use. Individuals with tetraplegia may consider 
using a lower dose and individuals may consider consuming supplementary caffeine earlier 
than the 60 min recommended prior to short-term exercise performance.  
6.7. Practical applications 
Where possible, if an athlete is using caffeine prior to short-term, high intensity 
exercise performance it is recommended that the individual athlete’s absorption curve is 
determined. Where this is not possible, the current data would suggest that both AB and 
TETRA should allow 70 min between ingestion and performance. Whereas, PARA should 
ingest caffeine (in capsule form) 80 min prior to exercise to ensure caffeine is present in the 
bloodstream during short-term exercise. Caffeine can be consumed closer to the start of 
endurance events given their longer total duration.  
The results also suggest that an athlete with tetraplegia should trial a low dose of 
caffeine   (1-2 mg∙kg-1) in the first instance. If they do not experience any side-effects then a 
larger dose can be trialled, ideally in conjunction with controlled performance tests to assess 
whether it is ergogenic for the individual athlete. They may also need to be cautious of the 
frequency of caffeine intake to help prevent the possibility of any adverse effects due to high 
[CAF]. 
The influence of caffeine on catecholamine release in AB individuals is not replicated 
in TETRA due to their impaired sympathetic activity. Any mechanism of action reliant on 
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circulating catecholamines is unlikely to work in individuals with impaired autonomic 
function. The increase in [FFA] occurs in individuals with or without a SCI despite no 
significant change in catecholamine concentrations. However, the increase in [FFA] 
following caffeine ingestion will not necessarily lead to increased lipolysis. Practitioners 
should investigate the effects of caffeine on an individual’s performance where possible to 
determine whether it works for the n=1 of an elite athlete. 
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7 
Study 5: Caffeine improves 20 km handcycling time 
trial performance in an elite Paralympic triathlete: 
A case study 
 
Photo courtesy of Phil Wilson. 
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7.1. Abstract 
Chapter four suggests that caffeine’s ability to influence UBE endurance performance 
may be related to an individual’s training status. This case study therefore aimed to 
investigate the ergogenic effects of caffeine on 20 km TT performance of an elite male 
Paralympic triathlete with paraplegia (T7, ASIA A) who competes in the PT1 (wheelchair 
user) category. At the time of testing he was aged 46 y, with a body mass of 76.9 kg and a 
handcycling A ·EVO2E Apeak of 3.45 l∙min-1. Preliminary testing determined the athlete’s individual 
caffeine absorption curve at rest which resulted in a peak 45 min post-ingestion, which was 
adopted in the subsequent TT’s. The study followed a single-blind, randomised, placebo-
controlled, repeated measures design. The athlete completed four 20 km TT’s on a Cyclus II 
ergometer under laboratory controlled conditions following the ingestion of 2, 4 and 6 mg·kg-
1 caffeine (CAF) or placebo (PLA). [GLU], [Bla], PO, Felt arousal and Borg 6-20 RPE were 
recorded. Ingestion of 2, 4 and 6 mg·kg-1 CAF resulted in 20 km TT performance times of 
36:56, 37:06 and 36:39 min:sec which were 2, 1.5 and 2.7% faster than PLA (37:40 min:sec). 
There was no significant change in [GLU] during any trial. The participant’s [Bla] increased 
throughout all trials and was greater during CAF compared to PLA. There were no apparent 
differences in RPE between trials. Baseline Felt arousal responses differed between PLA and 
4 mg·kg-1 (‘1-low’), and 2 and 6 mg·kg-1 (‘3-moderate’). Arousal increased at each time-point 
following the ingestion of 4 and 6 mg·kg-1 CAF. The largest CAF dose resulted in a positive 
pacing strategy, which when combined with an end spurt resulted in the fastest TT. The 
increased PO at the start of the TT was likely linked to the higher arousal scores reported. 
Different baseline arousal responses may help explain the lack of a dose response following 
CAF. The athlete experienced spasticity during two trials but attributed this to the maximal 
effort delivered, not the ingestion of CAF. Caffeine (2, 4 and 6 mg·kg-1) improved 20 km TT 
performance of an elite male Paralympic PT1 category triathlete, which appears to be related 
to greater arousal and an increased PO for a given RPE. 
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7.2. Introduction 
It was shown in chapter three that caffeine is commonly used by athletes with a 
physical impairment and yet very few studies have been conducted using elite (Flueck et al., 
2014) and trained (Flueck et al., 2015) participants. Evidence of caffeine’s ergogenic effects 
during UBE remains equivocal. Findings in Chapters three, four and five suggest that 
caffeine may be more advantageous during short-term, explosive UBE compared to 
endurance UBE. This supports previous research (Black et al., 2015; Flueck et al., 2015; 
2014). Black et al. (2015) reported improvements in cycling but not arm cranking 10 min all-
out performance following 5 mg·kg-1 and a 30 min preload at 60% A ·EVO2E Apeak. In chapter four, 4 
mg·kg-1 caffeine improved cycling 10 km TT performance but failed to statistically improve 
handcycling performance following a 30 min preload at 65% A ·EVO2E Apeak. The participants’ used 
in Chapter four and by Black et al. (2015) were recreationally active males with no previous 
knowledge or experience of pacing their handcycling/arm cranking performance. However, 
participants with a handcycling A ·EVO2E Apeak above and below the mean in Chapter four improved 
their handcycling TT performance by 3.2% and -0.3%, respectively (see earlier Figure 4.2). 
This indicates that there may be some influence of training status on caffeine’s ability to 
influence performance. This theory is also supported by improvements in swimming velocity 
(during which a large proportion of force is generated by the upper-body) by trained but not 
untrained participants following the ingestion of a moderate dose of caffeine (250 mg) 
(Collomp et al., 1992). Collomp and colleagues (1992) suggested that the intra and/or 
extracellular adaptations (e.g. enhanced buffering capacity) resulting from specific training 
are necessary to benefit from the NS. Training status has also been suggested as a possible 
explanation for the equivocal data regarding caffeine’s ability to alter high-intensity exercise 
(Astorino & Roberson, 2009). Well-trained/elite athletes are also likely to have greater 
motivation to perform maximal exercise (Burke, 2008). It is understandable given the 
practicalities involved that there are limited studies utilising elite athletes. However, in this 
instance the author was provided with a unique opportunity to investigate the ergogenic 
effects of caffeine in an elite male PT1  category (wheelchair user) Paralympic athlete. 
At the London 2012 Paralympic Games the medal winning times for handcycling and 
wheelchair racing were within a 0.3-0.6% time frame (Perret, 2015). In Paralympic sport, 
winning margins are small and every second/goal/metre advantage counts. Paralympic 
triathlon is a new sport in the Rio 2016 Games in which male wheelchair athletes can 
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compete in the PT1 category. The sport involves three separate disciplines and is comprised 
of a 750 m swim, 20 km bike and 5 km run. Athletes in the PT1 category complete the latter 
two disciplines in a handcycle followed by a racing wheelchair over a total race duration of 
approximately one hour. Previous AB cycling research suggests that caffeine 
supplementation would be advantageous during 1 h TT events where ~6% improvement in 
performance has been reported (Kovacs et al., 1998 (3-4 mg∙kg-1); McNaughton et al., 2008 
(6 mg∙kg-1)). However, there is currently limited evidence to support its use during UBE and 
by athletes with a physical impairment.  
As part of the nutritional support package for a Paralympic triathlete who competes in 
the PT1 category, the author was asked to explore the potential for caffeine use by this 
triathlete. In elite sport, the ‘n=1’ research is important and can mean the difference between 
a podium finish or not. The handcycle section of a Paralympic triathlon event comprises more 
than half the competition time (~00:36 in a ~01:02 h:min performance) and hence this section 
was chosen as part of the laboratory controlled exercise protocol. The aim of the current case 
study was therefore to investigate the effects of caffeine supplementation (2, 4 and 6 mg·kg-1) 
on 20 km handcycling TT performance. 
7.3. Methods 
7.3.1. Participants 
One male Paralympic triathlete with paraplegia (T7, ASIA A) (age 46 y, body mass 
76.9 kg, body fat 25.4%, handcycling A ·EVO2E Apeak 3.45 l∙min-1 and habitual caffeine intake 160 
mg·d-1) provided written informed consent to take part in the current case study. All 
medication was checked to ensure there were no known interactions with caffeine. All 
procedures were approved by the University’s Ethical Advisory Committee and performed in 
accordance with the Declaration of Helsinki.  
As part of the athlete’s sport science support the authors were provided with the 
results from a A ·EVO2E Apeak test (3 weeks prior to visit 1) and a DXA (Lunar iDXA, GE 
Healthcare, Buckinghamshire, UK) (during the study) to enable greater understanding of the 
athlete and their training status. The athlete’s physiology support package also includes the 
completion of 20 km handcycling TTs in the same laboratory every three months and 
consequently the athlete was familiar with the testing procedures and the RPE scale (Borg, 
1998). The participant was familiarised with the Felt Arousal scale (Svebak & Murgatroyd, 
1985) during visit 1.  
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7.3.2. Experimental design 
The athlete visited the laboratory on five separate occasions. Preliminary testing (visit 
1) was a resting trial in which the athlete’s rate of caffeine absorption was determined. Visits 
2-5 were experimental trials in which the participant performed four 20 km handcycling TTs 
following the consumption of placebo (PLA), 2, 4 or 6 mg·kg-1 caffeine (CAF). The 
experimental trials followed a single-blind, placebo controlled, randomised, repeated 
measures design and were separated by at least five days. Trials were conducted at the same 
time of day (10:15am) to avoid any influence of circadian rhythm (Drust et al., 2005).   
7.3.3. Equipment 
The athlete performed the TTs in their own handcycle so the configuration and set-up 
matched that used in daily training and competition. This was standardised across trials. The 
handcycle was mounted on a Cyclus II ergometer (Avantronic Richter, Leipzig, Germany) for 
all exercise trials as in Chapter four (Figure 2.5 shows the Cyclus II handcycle set-up). 
7.3.4. Preliminary trials 
The athlete arrived at the laboratory 1.5 h post-ingestion of a self-selected 
standardised meal (1891 kJ: 64% carbohydrate, 18% protein, 18% fat) and water 
consumption was encouraged to help ensure the participant arrived euhydrated. The athlete 
was asked to void his bladder, if necessary prior to lying in a semi-supine position on a 
laboratory bed. A cannula (Venflon, Becton Dickinson, Helsinborg, Sweden) was inserted 
into an antecubital vein for subsequent venous sampling. The cannula was kept patent using 
5-10 ml sodium chloride (0.9%) after each blood sample.  
After a minimum of 15 min rest, a baseline venous blood sample was taken. The 
athlete then consumed cellulose capsules (Bulk Powders, Colchester, UK) containing 4 
mg∙kg-1 caffeine (MyProtein, Northwich, UK). The 4 mg∙kg-1 caffeine dose was selected for 
the preliminary trial because it was the median experimental dose (2, 4 and 6 mg∙kg-1 
caffeine). Absolute [CAF] may differ between doses (Desbrow et al., 2009) but they will 
provide the author with an indication of the time-course of caffeine absorption across all three 
caffeine trials as this is not affected to the same extent (Graham & Spriet, 1995). The athlete 
remained rested for 120 min during which a further 8 blood samples were taken (15, 30, 45, 
60, 70, 80, 90 and 120 min).  
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7.3.4. Experimental trials 
Prior to visiting the laboratory, the athlete maintained normal dietary and activity 
patterns, and their individual medication regime. These were standardised across trials using 
a 24 h food (5319 kJ: 55% carbohydrate, 34% protein, 11% fat) and training log which was 
replicated prior to each trial. The same standardised meal as above (7.3.4.) was consumed 1.5 
h prior to arrival at the laboratory. The athlete was provided with a list of caffeine containing 
foods and drinks, and was asked to abstain from consumption in the 24 h preceding all 
laboratory visits.  
The exercise trials involved the consumption of either 2, 4 or 6 mg∙kg-1 CAF, or 
dextrose PLA  in cellulose capsules (Bulk Powders, Colchester, UK) 45 min prior to 
commencement of the TT. The timing recommendation was based on preliminary trial 
results.  As in Chapter four the athlete was instructed to complete the 20 km TT in the 
shortest time possible, during which the gear could be changed at any time. In line with the 
usual competition environment, motivation was provided during the TT but was standardised 
and provided upon the completion of each kilometre and throughout the final 3 km. To avoid 
test-retest influence the only in-test feedback provided was cumulative distance covered. 
[GLU] and [Bla] were determined using a Biosen C-Line (EKF Diagnostic GmbH, Barleben, 
Germany) via earlobe capillary blood samples pre-warm-up, pre-TT, and upon completion of 
5, 10, 15 and 20 km during the TT. Heart rate was monitored continuously (Polar RS400, 
Polar, Kempele, Finland). Exercise trial environmental conditions were mean(SD) 
temperature 19.4(0.6)°C and humidity 51(5)%. 
The 6-20 RPE scale (Borg, 1998) was used as a measure of perceived exertion during 
the TT upon completion of 5, 10, 15 and 20 km. As in Chapter four the athlete was asked for 
three RPE scores: RPEP, RPEC and RPEO. The athlete was asked to rate their arousal on the 
Felt Arousal scale pre-capsule, pre-warm-up, pre-exercise and post-exercise as in Chapter 
five. See Figure 7.1 for the schematic of the exercise protocol. 
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Figure 7.1. Schematic of the 20 km time trial protocol. PLA=placebo, RPE=rating of perceived exertion, TT=time trial 
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7.3.5. Blood sampling and analysis 
All blood sampling and analysis procedures to assess [CAF] at rest were performed as 
described in Chapter six (see section 6.3.4) and Appendix C. 
7.4. Results 
The participant’s [CAF] peaked 45 min post-ingestion (43.2 µM) followed by a 
gradual decline. Ingestion of 2, 4 and 6 mg·kg-1 CAF resulted in 20 km TT performance 
times of 36:56, 37:06 and 36:39 min:sec, which were 2, 1.5 and 2.7% faster than PLA (37:40 
min). The athlete reported symptoms of spasticity during the 2 and 4 mg·kg-1 CAF trials but 
they did not believe this affected their performance. Average PO was 162, 171, 169 and 175 
W following the ingestion of PLA, 2, 4 and 6 mg·kg-1 CAF, respectively (Figure 7.2c). 
The [Bla] increased throughout all trials and was greater during CAF compared to PLA 
(Figure 7.2a) but there was no change in [GLU] during any trial (Figure 7.2b). The athlete’s 
HR was slightly increased in all three CAF trials compared to PLA but this difference was 
eliminated immediately post-TT.  
There was no difference in RPE between trials (Table 7.1). Baseline Felt arousal 
responses differed between PLA and 4 mg·kg-1 (‘1-low’), and 2 and 6 mg·kg-1 (‘3-moderate’). 
Arousal increased at each time-point following the ingestion of 4 and 6 mg·kg-1 CAF (Figure 
7.3). The athlete was not accurate in predicting which dose had been consumed during each 
trial. Subjectively the athlete reported feeling more ‘focused’, with an improved ability to 
‘refocus’ following the consumption of 2 and 6 mg·kg-1 CAF. 
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Figure 7.2. (a) Blood glucose and (b) lactate concentrations, and (c) average power output 
during the 20 km time trial following the consumption of placebo (PLA), 2, 4 and 6 mg∙kg-1 
caffeine. 
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Table 7.1. Differentiated (local, central and overall) ratings of perceived exertion (RPE) 
during the 20 km time trial (TT) following the consumption of placebo (PLA), 2, 4 and 6 
mg∙kg-1 caffeine. 
  5 km 10 km 15 km Post-TT 
Overall RPE PLA 15 16 16 20 
 2 mg∙kg-1 15 15 15 19 
 4 mg∙kg-1 15 17 17 19 
 6 mg∙kg-1 15 16 17 20 
Central RPE PLA 16 16 16 19 
 2 mg∙kg-1 16 14 15 19 
 4 mg∙kg-1 16 17 16 19 
 6 mg∙kg-1 16 17 16 20 
Peripheral RPE PLA 15 16 17 20 
 2 mg∙kg-1 16 15 17 20 
 4 mg∙kg-1 16 16 17 19 
 6 mg∙kg-1 16 16 17 20 
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Figure 7.3. Felt arousal responses following the consumption of placebo (PLA), 2, 4 and 6 
mg∙kg-1 caffeine. TT=time trial. 
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7.5. Discussion 
This case study contributes to the literature exploring the ergogenic effects of caffeine 
during UBE performance. It is unique in its investigation of an elite male Paralympic 
triathlete with paraplegia (T7, ASIA A) during endurance TT performance. All three doses 
(2, 4 and 6 .mg∙kg-1) improved 20 km TT performance compared to PLA and were likely 
linked to increased arousal and PO at a given RPE. 
7.5.1. Time trial performance 
Caffeine improved 20 km TT performance in an elite male Paralympic PT1 triathlete 
compared to PLA. There was no clear dose response with performance improvements of 2, 
1.5 and 2.7% following the ingestion of 2, 4 and 6 mg∙kg-1 CAF, respectively. 
During the first 5 km section average PO was 164, 172, 173 and 184 W, and during the last 5 
km section PO was 165, 175, 170 and 170 W following the ingestion of PLA, 2, 4 and 6 
mg∙kg-1 caffeine, respectively. This indicates a distinctly different pacing strategy employed 
following the ingestion of 2 and 6 mg∙kg-1 caffeine (two fastest TT times). Following 2 
mg∙kg-1 caffeine the athlete produced a steady PO throughout the TT followed by an end 
spurt (Figure 7.2c). Whereas, the ingestion of 6 mg∙kg-1 caffeine resulted in a higher initial 
PO, a gradual decline and a similar end spurt. The larger caffeine dose increased arousal at 
each time-point (3, 4, 5), which appears to have resulted in the athlete starting at a higher 
intensity than in the other trials.  This positive pacing strategy must be considered in relation 
to the triathlon event as a whole but previous research suggests that such a strategy 
(decreasing from 92 to 73% maximal 750 m swim TT time) earlier during the swim section is 
not detrimental to performance compared to both even and negative pacing strategies (Wu et 
al., 2016). These results support those in Chapter four where 4 mg∙kg-1 CAF resulted in a 
greater PO during the first and last 2 km sections of a 10 km TT compared to PLA.  
The current triathlete’s DXA results (25.4%) are also similar to those reported for 
British male wheelchair athletes (25.0%; (Goosey-Tolfrey et al., 2016) and International male 
athletes with a SCI (20.6-25.5%; Inukai, et al., 2006; Mojtahedi et al., 2009). His 20 km TT 
time (~36-37 min) was relatively faster than those reported for a 22 km TT by trained 
handcyclists with a SCI (T2-8) (~45 min) (Fischer et al., 2015). In conjunction with 
a      A ·EVO2E Apeak of 3.45 l·min-1 this reinforces his highly trained or elite status. Chapter four 
suggested that an individual’s training status may be linked to caffeine’s ability to impact 
upon TT performance. The current study supports this notion and may be related to changes 
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in muscle fibre type and oxidative capacity as a consequence of the daily endurance training 
this triathlete completes (Schantz et al., 1997). It has been suggested that type I fibres are 
more sensitive to caffeine (Mitsumoto et al., 1990) and hence with potentially more of these 
available for recruitment compared to lesser trained participants, the caffeine may have been 
able to influence performance to a greater degree.  
It has been noted previously that trained athletes’ muscle and other tissues such as 
adipocytes and the brain may be more responsive to caffeine (Collomp et al., 1992; Graham, 
2001). This has been supported by LeBlanc et al. (1985) who reported caffeine ingestion at 
rest increased adrenaline, FFAs and resting metabolism to a greater extent in trained than 
untrained participants. This area of research is currently limited and warrants further 
investigation. Highly trained athletes may also have the mental discipline to work longer 
and/or harder to benefit from the stimulus of caffeine (Burke, 2008).  
The athlete reported symptoms of spasticity during two experimental trials following 
CAF. Such symptoms were reported in Chapter five and have been anecdotally reported by 
athletes with a SCI. The triathlete has a complete SCI but this does not necessarily abolish all 
neural function below the lesion level. A complete lesion interrupts all signals coming from 
or going to higher levels of the nervous system, but spinal reflexes can be preserved below 
the lesion level if spinal nerves remain undamaged (Jacobs & Nash, 2004). Therefore, a 
sensory stimulus, such as pain in this instance may have led to muscle spasms. The athlete 
has experienced similar episodes of spasticity during his normal training sessions and it is 
apparent that the symptoms are often linked to periods of maximal effort such as during the 
current TT performances. Interestingly, the spasticity was not experienced during the largest 
dose of 6 mg∙kg-1 CAF and importantly the athlete did not believe that it affected 
performance. Physiological doses of caffeine such as those used in the current study would be 
insufficient to cause a direct effect on the muscle resulting in spasticity via mechanisms such 
as increased calcium release from the sarcoplasmic reticulum to reduce the threshold for 
potentiation (Magkos & Kavouras, 2005).  
7.5.2. Blood lactate and glucose 
Pre-WU [GLU] ranged between 4.3 and 5.3 mmol·L-1 and [GLU] remained steady or 
slightly declined during the TT to a minimum of 3.5 mmol·L-1 during PLA (Figure 7.2a). The 
athlete was not permitted to ingest anything except water and electrolytes during the TT. The 
decline appears to be smallest following the ingestion of 6 mg·kg-1 CAF which has been seen 
previously following the same dose at rest and during exercise (Graham et al., 2000). 
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Adenosine usually contributes to the stimulation of glucose uptake (Raguso et al., 1996) and 
hence if caffeine acts as a non-selective adenosine receptor antagonist, the rate of 
disappearance of glucose may be reduced following its ingestion.  
The participant’s [Bla] increased throughout each 20 km TT but was greater at 10, 15 
and 20 km following the ingestion of 6 mg·kg-1 CAF (Figure 7.2b). This has been reported 
previously in the literature (Bell & McLellan, 2002; Graham et al., 2000; Greer et al., 2000) 
and in Chapter four, and is understandable given this trial resulted in the greatest PO and 
fastest TT performance.  
7.5.3. Subjective feelings 
Different baseline Felt arousal responses may explain the lack of a dose response to 
caffeine. The athlete arrived at the laboratory with arousal responses of ‘3-moderate’ at 
baseline prior to the ingestion of 2 and 6 mg·kg-1 CAF which resulted in faster 20 km TT 
times than PLA or 4 mg·kg-1 caffeine. The greater arousal responses pre- and post-TT 
following 2 and 6 mg·kg-1 caffeine may help explain the greater PO during the first (172 and 
184 W) and last 5 km (175 and 170 W) sections which ultimately led to faster TT times. The 
athlete’s RPE responses did not appear to differ between trials but when viewed in 
conjunction with improved TT times and increased PO, this may indicate an increased PO for 
a given RPE, which has been reported previously (Astorino et al., 2012) and in Chapter four. 
Astorino et al. (2012) reported similar RPE, pain and arousal scores following the ingestion 
of 5 mg·kg-1 caffeine despite improvements in cycling 10 km TT performance. 
7.6. Conclusion 
Caffeine improved 20 km TT performance in an elite male Paralympic triathlete with 
paraplegia, which appears to be related to increased arousal and an increased PO for a given 
RPE. The case study results therefore suggest the athlete could utilise caffeine as an 
ergogenic aid prior to race performances.  
7.7. Practical applications 
The triathlete practiced using caffeine during training and race simulations, and 
following this has now introduced caffeine into his pre-race nutrition strategy. The 20 km TT 
is the middle discipline of Paralympic triathlon and comprises the largest amount of time on 
the course (~35-40 min). It follows a 750 m swim (~11-12 min) and precedes a 5 km 
wheelchair race (13-14 min). Having taken the athlete’s warm-up time into account the 
athlete now consumes caffeine 20-30 min prior to the race start time. Anecdotally the athlete 
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has reported feeling focused during races, even when things have not gone to plan e.g. 
transition errors not under his control. He plans to continue using caffeine in capsule form 
and is currently trialling a caffeinated isotonic sports drink to help tailor his plan further. 
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8  
General discussion 
8.1. Overview of experimental chapters 
Given the dearth of evidence regarding NS use by athletes with an impairment and the 
effectiveness of NS such as caffeine as ergogenic aids in this population, the objectives of the 
current thesis were: 
• To determine the NS habits and perceptions of athletes with a physical or visual 
impairment, and to establish whether caffeine is a popular NS in this population 
(Chapter three) 
• To examine the influence of caffeine on upper-body i) sprint, ii) short-term, high-
intensity and iii) endurance performance (Chapters four, five and seven) 
• To explore the acute effects of caffeine in individuals with a SCI to help determine the 
appropriate dose and timing recommendations for its use as an ergogenic aid (Chapter 
six) 
 
The main findings from the five experimental chapters of the current thesis are summarised in 
Table 8.1.  
 
Chapter three provided important evidence that NSs were being used by 58% of 
athletes with a physical and visual impairment, and that 41% of these athletes followed AB 
recommendations for dosage and timing. This adherence to AB guidelines may be linked to 
the 9% that reported negative side-effects as a result of using NS. Athletes with an 
impairment appear to use similar NS to AB athletes (protein, carbohydrate–electrolyte sports 
drinks, multivitamins and carbohydrate supplements), for similar reasons (recovery, 
immunity and energy). As may have been expected, elite athletes were more likely to use NS 
than those at lower levels of their sport, which may be related to longer training hours and/or 
access to a  
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Table 8.1. Summary of experimental protocols and main findings from experimental chapters 
Chapter Modality Caffeine dose Population Performance test Main finding 
3 n/a 
(questionnaire) 
n/a Athletes with a 
physical or visual 
impairment  
(295 males & 104 
females) 
n/a • 58% athletes used NS 
• Most used: protein, carbohydrate–electrolyte sports 
drinks, multivitamins & carbohydrate 
• 5% used caffeine 
• 9% experienced negative side-effects 
• 52% requested more information/education on NS 
4 Cycling & 
Handcycling 
4 mg∙kg-1 Recreational AB 
(11 males) 
30 min at 65% 
 A ·EVO2E Apeak & 10 km TT 
Caffeine resulted in: 
• Improved cycling performance (2.1%) 
• No sig. change in handcycling performance (1.8%) 
• Increased [Bla] post-TT 
• Improved PO for a given RPE  
5 Wheelchair 
propulsion 
4 mg∙kg-1 Club-level 
wheelchair 
sportsmen  
(12 males) 
20 m sprint 
4 min maximal push 
Caffeine resulted in: 
• Improved sprint performance 
• Improved one-off bout of 4 min maximal push 
• No change in arousal or RPE 
6 n/a (resting) 3 mg∙kg-1 AB individuals (8), 
individuals with 
PARA (8) & TETRA 
(8) (males) 
n/a Caffeine resulted in: 
• Different patterns of absorption in AB, PARA & 
TETRA 
• Greater Cmax in TETRA 
• Large inter-individuality in absorption 
• Increased plasma FFA 
• No change in plasma catecholamine concentrations 
7 Handcycling 2, 4 & 6 mg∙kg-1 Paralympic PT1 
triathlete (1 male) 
20 km TT Caffeine resulted in: 
• Improved TT performance following all 3 doses 
• Increased [Bla] 
• Increased arousal  
• Improved PO for a given RPE  
Note: AB=able-bodied, Cmax=peak plasma caffeine concentration, FFA=free fatty acids, NS=nutritional supplements, PARA=individuals with paraplegia, PO=power output, RPE=ratings of perceived exertion, 
TETRA=individuals with tetraplegia and TT=time trial  
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nutritionist/dietitian, who was reported as the most used and trusted source for NS advice. 
Beyond any macronutrient providing NS, caffeine was the most popular NS used by athletes 
with a physical impairment and hence this was chosen as a focus for further research. 
There is a large body of literature which suggests that caffeine is beneficial during endurance 
performance in AB individuals and yet the evidence for UBE was equivocal. Chapter four 
aimed to address the question ‘If caffeine is ergogenic during cycling in AB individuals, is it 
also ergogenic in the same individuals during handcycling?’ Subsequently, the study 
employed 11 recreationally active participants to complete a preloaded 10 km cycling and 
handcycling TT following the ingestion of caffeine (4 mg∙kg-1) or placebo. Caffeine 
consumption significantly improved cycling but not handcycling performance. Lower RPE 
were reported during the preload but not post-TT, and higher [Bla] were seen following 
caffeine compared to placebo. The important finding in Chapter four is that the impact of 
caffeine on endurance UBE may be related to the participants’ training status. Participants 
with a handcycling A ·EVO2E Apeak above the mean improved their handcycling TT performance by 
3.2%, whereas those below the mean had a 0.3% reduction. This may be linked to differences 
between UBE trained and untrained participants’ muscle fibre type distribution, intra and/or 
extracellular adaptations to UBE, or their ability to perform optimally during maximal 
testing. Further research regarding the relationship between the ergogenic effects of caffeine 
and training status is warranted (see section 8.3.2). 
Previous research into the effects of caffeine on short-term, high-intensity UBE 
performance was also varied but Flueck et al. (2014; 2015) reported positive individual 
responses in wheelchair athletes and individuals with paraplegia. Chapter five therefore 
employed club level wheelchair sportsmen to investigate caffeine’s effects on short-term, 
high intensity exercise and 20 m sprint performance. Caffeine (4 mg∙kg-1) improved 20 m 
sprint and a one-off bout of 4 min maximal push performance. The NS did however fail to 
improve repeated bouts of 4 min maximal push.  Salivary caffeine concentrations pre-warm 
up (45 min) suggested that this may be inadequate time to develop sufficient caffeine 
concentrations in some participants with a physical impairment (Figure 5.4). Interestingly, 
delayed drug pharmacokinetics had previously been noted in individuals with a SCI (Halstead 
et al., 1985; Mestre et al., 2001) and hence the pattern of caffeine absorption in this 
population required further investigation. 
In contrast, Chapter six observed that Cmax (3 mg∙kg-1) occurred at 70 min in 
participants with tetraplegia compared to 80 min in AB participants and participants with 
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paraplegia. Hence there was no apparent delay in absorption. The Cmax in individuals with 
tetraplegia was significantly higher than the other groups, which may be linked to suboptimal 
liver function, slow renal clearance (Mestre et al., 2011; Sauerbeck et al., 2015), reduced 
blood volume and/or increased FM (Abernethy et al., 1985; Kamimori et al., 1987; Skinner et 
al., 2014). Chapter six also highlighted that the pattern of caffeine absorption differed based 
on the SCI lesion level and that large inter-individual variation was apparent within and 
between groups. It was therefore concluded that where possible, an individual’s absorption 
curve should be assessed prior to making specific dosage and timing recommendations. 
Where this is not possible, individuals with tetraplegia might consider using a lower dose and 
all individuals might consider consuming supplementary caffeine earlier than the 60 min 
recommended prior to short-term exercise performance.  
Finally, Chapter seven expanded on the findings of Chapter four that suggested a 
greater training status may be linked to caffeine’s ability to improve performance during 
UBE. Chapter seven therefore investigated the influence of caffeine (2, 4 and 6 mg∙kg-1) on 
20 km TT performance by an elite Paralympic triathlete (PT1 ITU category). The case study 
supported the findings of Chapter four because all three doses of caffeine improved 
performance in this elite athlete. Improvements may have been linked to increased arousal 
scores and an improved PO for a given RPE. 
8.2. Contribution to scientific understanding and application of findings 
Given the lack of evidence in the area of caffeine and UBE, and more specifically in 
individuals with a physical impairment, this thesis has greatly contributed to scientific 
understanding. Importantly, the findings are also applicable to the sports nutrition practitioner 
and athlete. 
8.2.1. Nutritional supplement use in individuals with a physical impairment 
Prior to the findings of Chapter three there was insufficient evidence regarding the 
use of NS by athletes with a physical and visual impairment compared to the abundance of 
AB research in the same area. Only one study had previously investigated the use of food 
supplements by Paralympic athletes (Tsitsimpikou et al., 2009). Tsitsimpikou and colleagues 
(2009) collected data from Paralympic athletes at the 2004 Athens Games and hence 
provided an indication of supplement use at the elite level. The study reported that 27% of 
athletes declared the use of one or more food supplements (Tsitsimpikou et al., 2009), which 
was less than the 58% reported in Chapter three. The higher reported NS use may reflect an 
increase in i) NS use over the previous decade, ii) the popularity and availability of NS, 
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and/or iii) the training load/demand and pressure placed on modern day athletes with a 
physical impairment. Chapter three was able to contribute to the understanding of NS use at 
levels below the elite stage of the Paralympics whereby elite athletes were 1.6 times more 
likely to use NS than those who competed at a club level. This may be explained by the 
significantly greater training hours and access to sports nutritionists/dietitians. An important 
finding was that athletes with a physical impairment wanted more information and education 
regarding NS and topics such as anti-doping issues, effective NS and what their relative 
needs are compared to AB athletes. The findings from Chapter three have therefore provided 
a rationale for further research exploring the effectiveness of popular NS in this population. It 
has also highlighted the need for more education on both NS and anti-doping issues. The 
former should be included/mandatory on coaching education courses and any impairment-
specific advice should be made available on easily accessed websites such as WADA, IPC 
and National Governing Bodies of sports. The latter should be easily accessed on the WADA 
website and should be covered in athlete education sessions at an elite level. Chapter three 
has greatly enhanced the understanding of the use of NS by athletes with a physical and 
visual impairment. 
8.2.2. Factors influencing caffeine’s ergogenic effects 
There are many factors that may influence the ergogenic effects of caffeine during 
UBE such as genetics, training status, habitual caffeine intake, physical impairment, timing 
and dose of caffeine, and route of administration. This thesis has contributed greatly to two 
main factors: i) training status and ii) physical impairment. The combined findings of 
Chapters four and seven indicate that training status may influence caffeine’s ability to 
improve performance during UBE due to the UBE-specific training adaptations that occur 
(see section 8.2.3 and 8.2.4). The results from Chapter six also indicate that individuals with 
a SCI may need to consider their dosage and timing of caffeine intake more carefully than 
AB individuals due to high Cmax values and slow elimination and clearance rates (see section 
8.2.5). 
The combined findings of Black et al., (2015) in naive caffeine users, and Chapter 
four indicate that habitual caffeine intake may not be a large influencing factor on caffeine’s 
ergogenic ability. No performance improvement was seen in either during UBE and both 
reported improvements during LBE despite the participants being naive (Black et al., 2015) 
and habitual (Chapter four) caffeine users. It has also contributed to our understanding of the 
importance of protocol characteristics. The impact of the preload during both Chapter four 
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and Black et al., (2015) on peripheral fatigue may have been too great to see performance 
improvements in recreationally active participants. Exploration of the impact of caffeine on 
sprint (improvement), short-term endurance (one-off improvement) and endurance TT (no 
improvement in club level athletes/improvement in elite athlete) performance indicates 
changes in caffeine’s ability to influence performance depending on the exercise protocol and 
the participant characteristics. Future studies should consider exercise protocols and 
participant recruitment carefully and ensure they are as ecologically valid as possible. 
 
8.2.3 Caffeine and endurance UBE in AB participants 
Table 2.3 and 2.4 (pg 36-38) show the limited number of studies investigating the 
effects of caffeine supplementation on UBE, especially during endurance exercise. The 
double-poling studies contribute to the UBE literature however the findings must be 
translated to arm-only exercise performance with caution due to the involvement of the trunk 
and upper leg musculature. Black et al., (2015) was therefore the only study to have 
investigated the influence of caffeine on endurance exercise during arm-only exercise 
(asynchronous arm cranking) in the form of a preloaded 10 min performance trial. Caffeine 
ingestion (6 mg∙kg-1) by the male and female naive caffeine users improved cycling but not 
handcycling performance following a 30 min preload at 60% A ·EVO2E Apeak. Chapter four was able 
to extent the work of Black and colleagues by investigating the use of caffeine prior to a 
longer-term endurance performance test comprised of a 30 min preload at 65% A ·EVO2E Apeak and a 
10 km TT (lasting ~24 min). Chapter four utilised male, habitual caffeine users who are more 
representative of the general (Tran et al., 2016) and athletic population (Chester & Wojek, 
2008). It also employed a synchronous handcycling modality which is applicable to the sports 
of handcycling and triathlon. Caffeine (4 mg∙kg-1) once again improved cycling but not 
handcycling performance but there were clear inter-individual differences. Chapter four 
suggested that training status may influence caffeine’s ability to improve performance during 
arm-only exercise. It agrees with previous literature which has suggested well-trained 
participants may have the necessary intra and/or extracellular adaptations to training required 
to improve performance following caffeine consumption (Collomp et al., 1992). Well-trained 
athletes are also likely to exhibit the motivation to perform optimally during maximal 
exercise testing. Chapter four contributes further performance data to this field of research.  
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8.2.4. Caffeine and UBE in individuals with a SCI 
Chapters five and seven utilised UBE performance protocols and have contributed to 
the limited body of caffeine literature utilising participants with physical impairments, and 
specifically participants with a SCI (Table 2.4). Prior to the current thesis, Flueck et al. 
(2015; 2014) were the only research group to investigate the use of caffeine in this 
population. Flueck et al. (2014) reported no significant improvements in 1500 m wheelchair 
TT in athletes with paraplegia and spina bifida following the ingestion of caffeine. 
Interestingly, there were 4 out of 9 participants who produced their fastest TT following 
caffeine. The authors speculated that the elite status of the athletes and therefore the small 
variance in performance times may have led to a lack of performance improvement and 
suggested that less trained individuals may benefit more. This is in contrast to Chapters four 
and seven that suggest a greater training status may increase the likelihood of caffeine’s 
ability to improve UBE endurance performance in AB participants and an elite athlete with 
paraplegia. This difference may be related to muscle fibre type distribution. Untrained AB 
individuals have a greater proportion of type IIb muscle fibres (41%) in the deltoid (a key 
muscle during handcycling and wheelchair propulsion) compared to trained and untrained 
individuals with paraplegia (11-15%) (Schantz et al., 1997). Type I fibres appear to dominate 
the deltoid muscle in individuals with paraplegia (55-59%) (Schantz et al., 1997) and hence 
there may be a greater likelihood of caffeine improving endurance performance, specifically 
in well-trained individuals. Chapter seven provided a novel insight into the positive effects of 
caffeine in an elite athlete with paraplegia during endurance UBE performance. With the 
suggestion that type I muscle fibres may also be more sensitive to caffeine than type II fibres 
it might be expected to see more consistent findings in the endurance exercise literature in 
trained individuals and individuals with a SCI. Further research is required to elucidate why 
the current body of literature is equivocal. 
The beneficial effects of caffeine have also been observed during short-term, maximal 
exercise in individuals with a physical impairment (Chapter five) and a SCI (Flueck et al., 
2015). Flueck and colleagues (2015) also investigated the influence of caffeine on 3 min 
maximal arm crank performance in AB participants, and participants with paraplegia and 
tetraplegia. Performance improvements were seen in participants with paraplegia only 
(Flueck et al., 2015), which may be related to lower type IIa and b muscle fibres in trained 
individuals with tetraplegia (13 and 4% compared to 32 and 11% in trained individuals with 
paraplegia, and 17 and 41% in AB) (Schantz et al., 1997). This explanation unfortunately 
does not hold true for the findings in Chapter five that reported improvements in both 20 m 
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sprint and a one-off bout of 4 min maximal push performance. The participant group 
contained seven participants with tetraplegia and five non-SCI participants, and hence a 
greater variability in muscle fibre type distribution may have been present. Flueck et al. 
(2015) were surprised not to observe an improvement in the AB participants because a 
number of UBE performance studies have shown improvements following the ingestion of 
caffeine (Anderson et al., 2000; Bruce et al., 2000; Skinner et al., 2010). These studies 
however, employed rowing as the mode of exercise which also involves lower limb and trunk 
musculature. Furthermore, the aforementioned studies all utilised well-trained competitive 
oarsmen and women in contrast to the AB participants investigated by Flueck et al. (2015). 
Hence, as with endurance UBE there may also be an effect of training status and SCI lesion 
level on caffeine’s influence on short-term, high-intensity UBE performance. 
8.2.5. Caffeine absorption in individuals with a SCI: effect of lesion level 
Halstead et al. (1985) suggested that ingestion of passively absorbed drugs may be 
delayed in individuals with a SCI, observed as an increase in the time to peak and lag time, 
and a decrease in the maximum plasma concentrations achieved. The physiological functions 
that are altered in individuals with a SCI (e.g. delayed GI transit times) mean that 
assumptions of pharmacokinetics cannot be directly transferred from non-SCI individuals 
(Mestre et al., 2011). Van Soeren et al. (1996) previously explored caffeine (6 mg∙kg-1) 
absorption in a small number of participants with tetraplegia (n=6) and paraplegia (n=2) at 
rest. The mean Cmax in individuals with tetraplegia was 46.7(5.0) µM after 40 min at rest, 
which then gradually declined to 25.6(1.4) µM at 180 min without plateauing. The two 
participants with paraplegia reached Cmax of 43.3 and 56.5 µM at 40 min also. The authors 
therefore concluded that the pattern of caffeine absorption did not differ to that observed in 
AB individuals. Mohr et al. (1998) reported similar responses in individuals with a SCI in 
which [CAF] reached 57.3(7.4) µM following 60 min rest. Van Soeren et al. (1996) and 
Mohr et al. (1998) both investigated caffeine responses in very high caffeine users (1368 and 
898 mg/d, respectively), and 4/6 participants were smokers in the former study. Habitual 
caffeine intake may accelerate caffeine metabolism (Bell & McLellan, 2002; Van Soeren et 
al., 1993) and it is known to also be accelerated in smokers (Arnaud et al., 1999). Chapter six 
therefore contributed to the literature by employing a larger sample of individuals with both 
paraplegia (n=8) and tetraplegia (n=8), and a direct control group (n=8). The participants 
were low-moderate caffeine users (~220 mg·d-1) and non-smokers to eliminate potential 
confounding factors. Chapter six presented individual caffeine responses to 3 mg∙kg-1 caffeine 
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at regular time-points to allow further exploration of the pattern of caffeine absorption in 
individuals with a SCI. Chapter six observed a greater Cmax in individuals with tetraplegia 
(21.5 µM) compared to AB (12.2 µM) and individuals with paraplegia (15.1 µM), and mean 
Cmax occurred at 70, 80 and 80 min, respectively. The large Cmax reported in individuals with 
tetraplegia has been seen previously but has occurred earlier at 40 (Van Soeren et al., 1996) 
and 60 min (Mohr et al., 1998) compared to 70 min in Chapter six. The longer time to Cmax in 
Chapter six may reflect the removal of any potential influence of high habitual caffeine use 
and smoking on caffeine metabolism. Flueck et al. (2015) also reported a significantly greater 
[CAF] in individuals with tetraplegia 60 min post-ingestion (64.1(6.9) µM). An individual’s 
caffeine absorption pattern should therefore be considered when using caffeine as an 
ergogenic aid, especially for short-term exercise. Individuals with tetraplegia may consider 
using a lower caffeine dose and individuals may consider consuming caffeine earlier than the 
60 min recommended prior to short-term exercise performance.  
8.3. Future directions 
The current thesis has explored the influence of caffeine on UBE performance in 
recreationally active AB participants and, trained and elite participants with a physical 
impairment. The findings are therefore applicable to AB sports that involve UBE such as 
rowing and canoeing, and disability/Paralympic sports such as the wheelchair court sports 
(rugby, tennis and basketball), wheelchair racing, handcycling, paracanoeing and para-
rowing. The evidence of caffeine’s effects is inconclusive in either population, and the 
ergogenic benefit may depend on a number of factors such as SCI lesion level, training status, 
and intensity and duration of exercise performance. The current thesis has substantially 
contributed to the field of study however a number of further research questions have arisen 
that require attention. These will be outlined below. 
8.3.1. Caffeine and UBE 
The current thesis has proposed a number of factors that may impact upon caffeine’s 
potential influence on UBE performance such as muscle fibre type distribution, body 
composition, caffeine absorption and training status. To help explore the magnitude of their 
influence where feasible, future studies should aim to do the following: 
• Measure [CAF] prior to caffeine consumption and prior to exercise testing of 
participants with a SCI. Any additional time-points would provide greater detail and 
help to further understand the pattern of the caffeine absorption curve. This data 
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would also help to exclude impaired absorption/delayed gastrointestinal transit times 
as a reason for caffeine failing to improve UBE performance.  
• Quantify muscle fibre type distribution in the arm musculature of UBE trained 
individuals with and without a physical impairment. There is currently very little data 
regarding muscle fibre type distribution and yet it appears it may be an important 
factor when exploring an individual’s ability to perform UBE with/without caffeine 
supplementation. Muscle biopsy procedures are invasive for the participant and 
expensive to conduct however; less invasive procedures such as the measurement of 
muscle carnosine content via proton magnetic resonance spectroscopy are emerging 
(Baguet et al., 2011). A larger database would be useful to help explain UBE study 
findings. 
• Report training status, body mass and body composition. Additional participant 
characteristics would help explore the reasons behind caffeine’s ability to/not to 
improve UBE performance in individuals with a physical impairment. Level of 
competition, weekly training hours and fitness markers would help describe training 
status. A DXA scan would be gold standard to measure body composition in this 
population (Goosey-Tolfrey et al., 2016; Willems et al., 2016) however, other more 
accessible and cheaper anthropometric measurements would also be better than 
providing no data at all. 
8.3.2. Caffeine and endurance UBE performance: influence of training status 
Previous studies exploring the effects of caffeine on endurance UBE performance 
have produced varying results and have been observed as an improvement (Chapter seven; 
Stadheim et al., 2014; 2013) or no significant change (Black et al., 2015; Chapter four). The 
studies that observed improvements used well-trained athletes, and those that did not used 
recreationally active participants. Chapter four specifically suggests that training status may 
be related to caffeine’s ability to improve performance. With only five studies investigating 
endurance UBE performance and none specifically exploring the impact of training status, 
further investigation is required.  
Handcycling, wheelchair racing or ACE endurance performance protocols should be 
performed in a laboratory setting to assess caffeine’s impact on performance of UBE in 
trained individuals with a physical impairment. An extension of the case study in Chapter 
seven using handcycling and Paralympic triathlon athletes would extend our understanding. 
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An additional group of recreational handcyclists would increase our understanding further 
regarding the impact of training status on caffeine’s ability to effect UBE performance. 
 An alternative method of assessing the impact of training status would be to perform a 
training study whereby novice participants are tested at baseline and following a period of 
UBE training (3-4 sessions/wk) following the ingestion of caffeine and placebo. This would 
require long-term commitment from participants but would provide vital data on the 
influence of training status on caffeine’s ergogenic properties. Following these findings 
future studies should explore the influence of caffeine in more practically relevant 
environments e.g. on the track, road or in the water, because the demands of exercise on an 
ergometer or treadmill may not adequately replicate those experienced in normal training and 
competition environments. 
8.3.3. Caffeine and UBE performance: influence of SCI lesion level 
There appears to be an influence of SCI lesion level on whether caffeine has a 
beneficial effect on performance. Flueck et al. (2015) reported improvements in 3 min 
maximal arm crank performance in participants with paraplegia but not AB participants or 
participants with tetraplegia. Future studies should therefore explore the impact of SCI lesion 
level during various UBE protocols (sprint, short-term and endurance). Where possible a 
homogenous group of caffeine responders with complete paraplegia and tetraplegia should 
initially be tested to assess the influence of SCI lesion level.  
The use of a SCI population in research exploring the ergogenic benefits of caffeine 
would also allow further exploration of its mechanisms of action. Adenosine receptor 
antagonism increases circulating levels of catecholamines in AB individuals to produce 
motor-activating and arousing effects (Davis et al., 2003). This influence of caffeine on 
catecholamine release is not replicated in individuals with tetraplegia or high-level paraplegia 
due to impaired sympathetic activity. Hence any mechanism of action reliant on circulating 
catecholamines is unlikely to be responsible for any performance improvements reported in 
individuals with impaired autonomic function. This may explain the contrasting responses of 
participants with paraplegia and tetraplegia during the 3 min all-out arm crank test following 
caffeine (Flueck et al., 2015). However, improvements in short-term, high-intensity UBE 
performance were seen in Chapter five in individuals with tetraplegia and therefore another 
mechanism may be responsible. The increase in [FFA] which occurs in individuals with a 
SCI despite no significant change in catecholamine concentrations (chapter six) indicates a 
direct effect of caffeine on adipocytes and hence, a potential direct effect on other tissues. 
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Caffeine is likely to have multiple mechanisms of action and participants with a complete, 
high-level SCI remain an appealing group to help differentiate between some of these effects 
due to their impaired autonomic function (Krassioukov & West, 2014).  
8.3.4. Caffeine and cognitive/skill performance 
Performance outcomes in the wheelchair court sports such as basketball, rugby and 
tennis are not solely based on physiological parameters. These intermittent sports are partially 
dependent on motor control, decision making, cognitive function and skill performance 
(Morgulec-Adamowicz et al., 2011; Vanlandewijck et al., 1999). Skills such as passing, 
shooting, serving and dribbling are key performance indicators in these sports. Hence the 
impact of caffeine must be assessed based on its influence on sports performance as a whole, 
not on individual elements. Caffeine has been shown to improve cognitive function and sport-
specific skill performance in AB participants, especially in scenarios where physical or 
mental fatigue are prominent (Baker at al., 2014). The performance impact of caffeine on 
cognitive and skill performance must be investigated in UBE-specific sports prior to 
recommending caffeine to wheelchair sportspersons. 
8.3.5. Route of caffeine administration 
Given the inter-individual variation in caffeine absorption in individuals with a SCI, 
further exploration of routes of administration other than capsules is required. Caffeine is 
available to athletes in many forms such as coffee, sports drinks, gels, capsules and chewing 
gum. Caffeine in the form of a chewing gum has been shown to deliver the supplement faster 
than capsules and may indicate absorption via the buccal mucosa (Kamimori et al., 2002). 
The evidence is currently limited and equivocal on the effects of caffeine gum on exercise 
performance (Oberlin-Brown et al., 2016 (no improvement in preloaded cycling 20 km TT 
performance); Paton et al., 2015 (improved mean and sprint performance in a 30 km cycling 
TT); Ryan et al., 2012 (no improvement in cycling time to exhaustion)) however; given the 
potential to eliminate the influence of delayed gastrointestinal transit times it warrants further 
investigation in a population of individuals with a SCI.  
8.3.6. Ergogenic effects of other nutritional supplements 
The current thesis has shown that the ergogenic benefit of caffeine during various 
types of exercise in AB individuals may not be directly transferred to individuals with a SCI. 
The mechanism of action via the CNS should not be altered in individuals with a SCI and yet 
caffeine does not appear to consistently improve performance in this group. It is reasonable 
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therefore to assume that other NS may also vary in their ergogenic nature during whole or 
LBE and UBE performance. Table 2.1 (pp. 27) highlights the limited research in this area 
with only two studies exploring the use of creatine, one investigating sodium citrate and one 
assessing the impact of carbohydrate drinks in participants with physical impairments. 
8.4. Practitioner reflections 
 
As an applied practitioner’s thesis, the aim was to influence the practice of disability 
support staff, especially nutritionists/dietitians. The main learning from this thesis is that 
every athlete must be considered as an individual. As with AB athletes, a practitioner must 
consider numerous athlete (age, gender, body mass, genetics, training status etc) and sport 
characteristics (duration and intensity of training and competition, performance indicators for 
success, the contribution of skill, environmental conditions etc). In disability sport, a 
practitioner must also consider the impact of the athlete’s physical impairment. The impact of 
level and completeness of SCI on neurological and physical function is wide-ranging and 
well-researched. This thesis has shown that something as simple as the caffeine absorption 
curve displayed by an athlete may also be influenced by level of SCI. Hence a practitioner 
may need to adjust the dosage, timing and frequency of caffeine consumption in these 
individuals. Use of available SCI-specific evidence such as in this thesis is important and can 
be extremely useful however, a practitioner must also understand that the heterogeneity of 
SCI means that caffeine, and all other NS, should be trialled on an individual basis. The 
health and well-being of an athlete should always be considered first i.e. does the athlete 
experience any side-effects from caffeine consumption via food products such as coffee and 
tea, and is the NS batch-tested? Secondly, is there evidence or a viable mechanism of action 
for the athlete’s use of caffeine during training or competition? Finally, caffeine should be 
trialled in a controlled and safe environment alongside quantitative and qualitative data 
collection to decide whether it should be investigated further as a viable NS to enhance 
sporting performance. 
This thesis has clearly shown that the positive effects of caffeine reported during LBE 
cannot be directly translated to similar UBE protocols (Chapters four and five). This is likely 
related to numerous factors including an individual’s UBE-specific training status, whereby 
those who are highly trained are more likely to see the positive impact of caffeine due to the 
specific training adaptations acquired and the motivation to perform. A practitioner should 
therefore consider each athlete and situation separately and not rely on LBE and caffeine 
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research. This method of practice should also extend to other NS such as creatine and 
buffering agents given a lack of impairment-specific research. 
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Appendix A: Nutritional supplement questionnaire example 
 
Nutritional Supplement Habits and Perceptions of Athletes with a Disability. 
 
Thank you for choosing to complete this questionnaire, it should only take approximately 15-20 
minutes. Please remember that your answers are confidential and we therefore ask you to be as honest 
as possible. 
 
The following section refers to details about you and your sport. 
  
1. What is your age?  
 
18-24 ☐ 25-30 ☐ 31-35 ☐ 36-40 ☐  41-45 ☐ 46+ ☐ 
 
2. What is your gender? 
Male   ☐ 
 Female  ☐ 
 
3. What is your nationality? 
 
 
 
4. What is your ethnic origin?  
 White  ☐ 
 Black   ☐ 
 Asian  ☐ 
 Hispanic ☐ 
 Other  ☐ Please state in the box below 
 
 
 
5. How much do you weigh? (Please provide units of measurement such as kg, lbs) 
                     ☐ Actual (measured in the last 3 months) 
                     ☐ Estimated 
 
6. What is your height? (Please provide units of measurement such as feet, metres) 
               ☐ Actual (measured in the last 3 months) 
               ☐ Estimated 
 
7. What is your current sport/discipline/event? (Please give as much detail as possible) 
 
 
 
 
8. How many years have you been competing in your current sport? 
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9. What is the highest level you currently represent in your sport? 
Club  ☐ 
Regional ☐ 
National ☐If checked, please state which country in the box below. 
 
 
  
10. On average, how many hours per week do you train in total? (Please check 1 box) 
 
  0-5 ☐ 6-10 ☐ 11-15 ☐ 16-20 ☐ 21-25 ☐ 26+ ☐ 
      
11. What is your disability? (Please give as much detail as possible) 
 
 
 
 
 
12. What is your sport-specific classification?  
 
 
 
 
 
The following section refers to your nutritional supplement habits. The term ‘supplements’ refers to 
any product intended to supplement the diet, provide nutrients and/ or enhance performance such as 
vitamins, minerals, carbohydrate sports drinks/ bars, amino acids, herbal remedies, creatine and 
caffeine etc.  
 
13. How important do you think good nutrition is to sports performance? 
 Very important  ☐ 
 Important   ☐ 
 Moderately important ☐ 
 Of little importance ☐ 
 Unimportant  ☐ 
 
14. Do you monitor your hydration status?  
Yes  ☐ Please go to Question 14A 
No ☐ Please go to Question 14B  
  
14A. Which of the following methods do you use? (Please check all that apply)  
I use thirst as an indicator of hydration      ☐ 
I check my urine colour/ compare it to a urine/ pee chart   ☐ 
I weigh myself before and after exercise      ☐ 
A sport scientist/nutritionist/coach measures my hydration status using 
a machine to measure urine specific gravity or serum osmolality  ☐ 
Other (Please state in the box below)      ☐  
 
 
 
14B. Please indicate if there is a reason why you can’t/ don’t use any of these methods. 
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The following section asks about your use of nutritional supplements in the last 6 months. The term 
‘supplements’ refers to any product intended to supplement the diet, provide nutrients and/or enhance 
performance such as vitamins, minerals, carbohydrate sports drinks/ bars, amino acids, herbal 
remedies, creatine and caffeine etc.  
 
15. Have you used any nutritional supplements in the last 6 months? 
Yes  ☐ Please go to Question 15A, B and C 
No  ☐ Please go to Question 15D 
 
15A. For each sport-specific/ performance-enhancing supplement that you have used in the 
last 6 months please complete a row in the table below.  
Examples of sport-specific/ performance-enhancing supplements include sports drinks, gels, bars, 
drinks powders, creatine, beta-alanine, caffeine, beetroot juice…  
 
*Do not enter health supplements here; these will be entered in Question 15B 
If you have any doubt whether a product is classified as a nutritional supplement then please write 
it down. 
 
Supplement type and 
brand 
 
How do you take this supplement? 
We are looking for as much detail as 
possible For example, 
• How often? Daily, once a 
week… 
• When? During a cold/ in the 
off-season… Or Only on 
training or rest days 
• Only for some training? 
Strength, endurance or skills 
sessions 
• Timing? Before, during or 
after a session 
• How much? Do you know the 
dose/ how many grams or pills 
a day? 
Reason for taking the 
supplement? 
(Please check all that apply) 
Example: 
Powerade ION4 isotonic 
sports drink  
Example: 
Sip during a cardio session lasting 
more than 60 min or if I have not 
eaten in the 3-4 hours before training. 
Example: 
Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☒ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other-Hydration/ tastes better than 
water  
Supplement 1    
 
Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
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Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
 
Supplement 2   Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
 
Supplement 3   Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
 
Supplement 4   Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
 
Supplement 5   Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
 
Supplement 6   
 
 
 
Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
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 To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
 
Supplement 7   Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
 
 
15B. For each health supplement that you have used in the last 6 months please complete a 
row in the table below.  
Examples of health supplements include vitamins, minerals, herbal remedies, probiotics, omega 3, 
cranberry extract…  
If you have any doubt whether a product is classified as a nutritional supplement then please write 
it down. 
 
Supplement type and 
brand  
How do you take this supplement? 
We are looking for as much detail as 
possible  
• How often? Daily, once a 
week… 
• When? During a cold/ in the 
off-season… Or Only on 
training or rest days 
• Only for some training? 
Strength, endurance or skills 
sessions 
• Timing? Before, during or 
after a session 
• How much? Do you know the 
dose/ how many grams or pills 
a day? 
Reason for taking the 
supplement? 
(Please check all that apply) 
Supplement 1  
 
 Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
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Supplement 2  
 
 Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
 
Supplement 3 
 
 Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
 
Supplement 4 
 
 Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
 
Supplement 5 
 
 Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
 
Supplement 6 
 
 Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
188 
 
 
Supplement 7 
 
 Medical need/ deficiency      ☐ 
Due to an inadequate diet    ☐ 
Support immune system      ☐ 
To provide energy               ☐ 
Increase strength/power      ☐ 
To aid recovery                   ☐ 
Because everyone else does ☐ 
Because I am told to            ☐ 
Other (Please state) 
 
 
15C. Where did you obtain/ buy your supplements? (Please check all that apply) 
 Provided by a team sponsor    ☐ 
 Provided by a sports nutritionist/ dietitian  ☐ 
 From a supermarket     ☐ 
 From a health food/ sports shop    ☐ 
From a pharmacy     ☐ 
 I ordered them on the internet    ☐ 
Other (Please state in the box below)   ☐ 
 
 
 
15D. If you don’t use supplements, why not? (Please check all that apply) 
I do not need them     ☐ 
 They are unhealthy     ☐ 
 I don’t know enough about them   ☐ 
 I am concerned about a positive drugs test  ☐ 
 They are too expensive     ☐ 
 My sport does not allow them    ☐ 
 Taking supplements is like cheating   ☐ 
 Other (Please state in the box below)   ☐  
 
 
 
16. Have you taken any supplements by injection in the last 6 months? 
Yes  ☐ Please go to Question 16A 
No ☐ Please continue to Question 17 
 
16A. Please indicate which supplements you have had injected and why you used them in 
the box below. 
Product  Why? 
 
 
 
 
 
17. Have you EVER experienced any negative/side-effects from using a supplement? E.g 
gastrointestinal distress, rapid bowel movements, spasticity, cramps etc 
Yes  ☐ Please go to Question 17A 
No   ☐ Please continue to Question 18 
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  17A. Which product(s) did you use and what were the negative/side effects? 
Product (Please specify brand 
where possible) 
Negative/side-effects 
 
 
 
 
 
 
The following section relates to the sources of information YOU use when considering your 
nutritional supplement habits. 
 
18. Do you have access to information on anti-doping? 
Yes  ☐ 
No  ☐ 
 
19.  Have you ever attended a workshop/ presentation on nutritional supplements and/ or 
anti-doping? 
Yes  ☐ Please go to Question 19A 
No  ☐ Please go to Question 19B 
 
  19A. If yes, when did you attend it? 
 
 
 
      19B. If no, would you like to? 
Yes  ☐ 
 No  ☐ 
 
20. Would you like more information and education regarding nutritional supplements 
and anti-doping? 
  Yes  ☐ Please go to Question 20A and 20B 
  No  ☐ Please continue to Question 21 
 
20A. If yes, how would you prefer to receive this information? (Please check all that apply) 
 Workshops      ☐ 
Presentations     ☐ 
Leaflets/ booklets    ☐ 
Individual consultation    ☐ 
Internet      ☐ 
Other (please state in the box below)  ☐ 
 
 
 
20B. What type of information would be most useful for you regarding nutritional 
supplements and/ or anti-doping? For example effective supplements/ doses, doping 
concerns, the World Anti-Doping Code, how to read product labels, whether your needs are 
different to able-bodied athletes, other information. 
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21. How do you decide whether a supplement is safe to use? (Please check all that apply) 
It’s says on the label      ☐ 
I ask a sports nutritionist/ dietitian/ medical professional   ☐ 
I ask my coach/ teammates     ☐ 
I check the manufacturer’s website    ☐ 
I check a website that indicates which products have been  
tested for banned substances i.e., Informed-Sport  ☐ 
I do my own research using the internet, books, journals etc ☐ 
No supplement is safe      ☐ 
N/A (I don't use supplements)       ☐ 
Other (Please state in the box below)    ☐ 
 
 
 
22. Who/ What do you currently use to help you make a decision about your use of 
supplements? Please only rank up to 5 responses, 1=Your most used source, 2 = your 
second most used source, 5=Only used a little/ sometimes. If you only use 2, 3 or 4 
sources, only rank 1 down to 2, 3 or 4. 
E.g. if you use a physiotherapist most often for information on supplements, write a number 
1 in the box opposite and so on, up to a maximum of 5. 
Note - The numbers 1, 2, 3, 4 and 5 should only occur once in your answers and therefore 
some options will be left blank.  
Please ask for help if you are at all unsure about this question! 
 Rank 
Training partner/athlete     
Coach          
Friends/family        
Physiotherapist       
Sports nutritionist/ dietitian     
Doctor/medical professional    
Supplement/ health food store    
*Books/ magazines       
*Evidence-based/ scientific journals  
*Internet/ websites       
*Other  
 
22A. If you checked a box with an *, where possible please indicate which books, 
magazines, journals, websites or ‘other’ that you use.  
 
 
 
 
23. Do you have access to a sports nutritionist/ dietitian through your sport/ team? 
 Yes   ☐  
 No   ☐  
 
24. Have you ever seen a registered sports nutritionist/ dietitian in person for advice?  
Yes  ☐Please go to Question 24A 
 No  ☐ Please go to Question 25 
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24A. How often do you see them?  
Very frequently  ☐ 
Frequently  ☐ 
Occasionally  ☐ 
Rarely   ☐ 
Very rarely  ☐ 
 
25. In your opinion, do you need the same supplements as an able-bodied individual 
competing in a similar version of your sport? 
Yes, I need the same type of supplements    ☐ 
No, I have different nutritional requirements    ☐ 
Yes, I need the same type of supplements but different amounts  ☐ 
Other (Please state in the box below)     ☐ 
 
 
 
26. How do you decide how much of a supplement to take? (Please only check 1 box) 
I calculate it based on my body weight     ☐ 
I am told/ given it by the sports nutritionist/ dietitian   ☐ 
 I follow the instructions on the label/ manufacturers website  ☐ 
 Unsure         ☐ 
 N/A – I don’t use supplements      ☐ 
Other (Please state in the box below)     ☐ 
 
 
 
 
The following section relates to YOUR personal opinions regarding nutritional supplements and anti-
doping. 
 
27. Do you think all nutritional supplements that are commercially available on the 
market have been scientifically tested and are therefore safe to use? 
 Yes  ☐ 
 No  ☐ 
 
28. Do you think there is a health risk associated with taking supplements? 
 Yes, all supplements carry a health risk  ☐ 
 Some supplements have health risks ☐ 
 No, no supplements carry a health risk ☐ 
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29. Who provides the most trusted source of information on nutritional supplements? 
You do not necessarily have to use these sources but you believe they are trustworthy. 
Please only rank up to 5 responses, 1=Your most trusted source, 2 = your second most 
trusted source and so on. If you only trust 2, 3 or 4 sources, only rank 1 down to 2, 3 or 4. 
Note - The numbers 1, 2, 3, 4 and 5 should only occur once in your answers and therefore 
some options will be left blank.  
Please ask for help if you are at all unsure about this question! 
  
 Rank 
Training partner/athlete     
Coach          
Friends/family        
Physiotherapist       
Sports nutritionist/ dietitian     
Doctor/medical professional    
Supplement/ health food store    
*Books/ magazines       
*Evidence-based/ scientific journals  
*Internet/ websites       
*Other  
 
  29A. If you checked a box with an *, where possible please indicate which books,          
magazines, journals, websites or ‘other’ that you use.  
 
 
 
 
 
 
30. Do you think doping agents have the potential to improve sports performance? 
Yes  ☐ 
No  ☐ 
 
 
31. If you would definitely not be caught, would you risk your health for any performance 
gains that may come with taking doping agents?  
Yes  ☐ 
No  ☐ 
Maybe  ☐ 
 
32. Which (if any) of the prohibited substances/ methods do you believe has the greatest 
potential to improve performance in your sport?  (This is not saying you would use it, 
just that you believe it would aid performance in your sport). (Please only check 1 box). 
Stimulants e.g. amphetamines    ☐ 
Anabolic-androgenic steroids e.g. nandrolone  ☐ 
Diuretics and masking agents to prevent detection  ☐ 
Blood doping e.g. EPO, blood reinfusion   ☐   
Peptide hormones, growth factors and related substances ☐ 
Beta-2 agonists e.g. clenbuterol    ☐ 
Hormone and metabolic modulators   ☐ 
Anorectics and weight loss agents e.g. sibutramine ☐ 
Boosting       ☐ 
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Other substances/methods (Please state in the box below) ☐ 
 
 
     
   32A. How/ why do you believe this type of doping would improve your sports 
performance? 
 
 
 
 
Please indicate to what extent you agree or disagree with the following statements:  
 
33. ‘The more supplements I take, the better I will perform’. 
Strongly disagree  ☐ 
Disagree   ☐ 
Neither agree nor disagree ☐ 
Agree   ☐ 
Strongly agree  ☐ 
 
34. ‘Taking supplements gives me the competitive edge I need to win’. 
Strongly disagree  ☐ 
Disagree   ☐ 
Neither agree nor disagree ☐ 
Agree   ☐ 
Strongly agree  ☐ 
 
35. ‘I feel under pressure to use supplements’. 
Strongly disagree  ☐ 
Disagree   ☐ 
Neither agree nor disagree ☐ 
Agree   ☐ 
Strongly agree  ☐ 
36. ‘Exercise increases the need for supplements’. 
Strongly disagree  ☐ 
Disagree   ☐ 
Neither agree nor disagree ☐ 
Agree   ☐ 
Strongly agree  ☐ 
 
37. ‘There is a risk of consuming a banned substance when taking a supplement’. 
Strongly disagree  ☐ 
Disagree   ☐ 
Neither agree nor disagree ☐ 
Agree   ☐ 
Strongly agree  ☐ 
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38. ‘I feel pressured to take nutritional supplements because my competitors/ opponents 
do’ 
Strongly disagree  ☐ 
Disagree   ☐ 
Neither agree nor disagree ☐ 
Agree   ☐ 
Strongly agree  ☐ 
 
If you would like to receive feedback on the study results please write your email address in 
the box below. 
 
 
 
 
Thank you for taking the time to complete this questionnaire, we greatly appreciate your 
assistance in helping us to further understand the nutritional supplement habits of disabled 
athletes. 
 
Please don’t hesitate to contact us if you have any questions regarding the questionnaire or 
the overall study. 
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Appendix B: Caffeine Enzyme-linked immunosorbent assay (ELISA) technique for 
saliva 
 
Sample collection 
All saliva samples were collected via the passive dribble method into a sterile tube. Samples 
were weighed to the nearest 10 mg. Saliva volume was estimated assuming saliva density to 
be 1.00 g/ml, and saliva flow rate was calculated from saliva volume and collection time. 
Saliva samples were transferred into Eppendorfs and centrifuged at 12,000 rpm for 3 min in a 
high speed microcentrifuge. The supernatant was removed and frozen at -80°C until analysis. 
 
Sample analysis 
Salivary caffeine concentration was determined using a commercially available ELISA kit. 
For more detailed instructions for the assay please refer to the manufacturer’s instructions: 
Caffeine ELISA kit Cat No.: DEIA6842, Creative Diagnostics, Shirley, New York, USA. 
Briefly, the ELISA consisted of the following steps: 
• Samples were thawed completely 
• Samples were re-spun at 1300 rpm for 10 min and the supernatant was pipetted into 
an appropriately labelled Eppendorf. 
• Saliva samples and standard samples of a known concentration were pipetted into a 
96 well plate pre-coated with the specific capture antibody for antibody for the protein 
being measured. 
• During an incubation period, any protein within the saliva is bound by the 
immobilised antibody in the well. 
• The unbound substances are washed away prior to a second detection anti-body being 
added to each well, followed by a further incubation period. 
• The wash step is repeated to remove any unbound anti-body reagent, and a substrate 
and amplifier solution is added to the wells to bind to the anti-body-sample complex. 
This step initiates a reaction and causes a colour change in the sample. 
Finally, the reaction is stopped and the absorbance of each well is measured using a micro 
plate reader (Opsys MR, Dynex Technologies, Chantilly, VA). Sample concentrations are 
determined by relation to a standard curve generated by plotting the absorbance of the 
standard samples against the standard’s known concentration. 
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Appendix C: Reverse phase high-performance liquid chromatography (HPLC) 
methodology for caffeine analysis 
 
Plasma [CAF] was analysed using HPLC as described by Holland et al. (1991) with two 
minor modifications; prior to injection onto the HPLC column each sample was individually 
filtered (Mini-UniPrep syringeless filters, Fisher Scientific, UK) and no guard column was 
used. The method produced a coefficient of variation (CV) of 1.06% (range 0.24-1.45%). 
Briefly, the HPLC caffeine analysis consisted of the following steps: 
 
Caffeine sample preparation: 
• 250 μL plasma was added to 250 μL 0.8 M perchloric acid (Sigma-Aldrich, UK). 
• Sample was mixed thoroughly using a vortex (30 s). 
• Proteins were removed by centrifugation at 14000g at room temperature for 4 min. 
• 350 μL supernatant was removed and 27 μL of 4 M sodium hydroxide (Fisher, UK) 
was added to produce a sample with a pH of ~5.0. 
• Sample was mixed thoroughly using a vortex (30 s). 
• 100 μL deproteinised sample was filtered using syringeless filters (Sigma-Aldrich, 
UK) ready for direct injection onto the HPLC column. 
 
Caffeine sample analysis: 
• Sample injected by autoinjector and eluted isocratically with the elution buffer (15 
mM potassium phosphate (Sigma-Aldrich, UK) (pH 4.9)-methanol (Fisher, UK) 
(85:15, v/v) for 20 min. 
• Column flushed with acetonitrile:water (80:20, v,v) for 5 min and the reequilibrated 
with the elution buffer for 5 min. 
• Flow rate was constant at 1.75 ml/min at ambient temperatures (21-24°C). 
• Eluted peaks were detected by ultraviolet absorbance at 274 nm and peak areas were 
used for quantitation using an eight-point standard curve. 
